Adeno-associated virus-based heterologous replicon technology for detection and quantification of adeno- and herpesvirus infections by Langer, Simona
Aus dem Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie 
Lehrstuhl Virologie der Ludwig-Maximilians-Universität München  
Vorstand: Prof. Dr. med. Oliver T. Keppler 
  
   
Adeno-associated virus-based heterologous 
replicon technology for detection and 
quantification of adeno- and herpesvirus 
infections 
  
  
Dissertation 
zum Erwerb des Doktorgrades der Naturwissenschaften 
an der Medizinischen Fakultät der 
Ludwig-Maximilians-Universität zu München 
  
 
 
 
 
 
vorgelegt von 
Simona Langer, geb. Sigl 
 
aus 
Hollabrunn, Österreich 
 
2019 
  
 
 
Mit Genehmigung der Medizinischen Fakultät  
der Universität München 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Betreuerin:      Priv. Doz. Dr. Barbara Adler  
Zweitgutachter:    Prof. Dr. Reinhard Zeidler 
   
Dekan:      Prof. Dr. med. dent. Reinhard Hickel  
  
Tag der mündlichen Prüfung:   02.08.2019 
 
Eidesstattliche Versicherung 
 
Langer Simona 
 
Ich erkläre hiermit an Eides statt, dass ich die vorliegende Dissertation mit dem Thema  
  
Adeno-associated virus-based heterologous replicon technology for detection 
and quantification of adeno- and herpesvirus infections 
 
selbstständig verfasst, mich außer der angegebenen keiner weiteren Hilfsmittel bedient und 
alle Erkenntnisse, die aus dem Schrifttum ganz oder annähernd übernommen sind, als solche 
kenntlich gemacht und nach ihrer Herkunft unter Bezeichnung der Fundstellen einzeln 
nachgewiesen habe. 
 
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder in 
ähnlicher Form bei einer anderen Stelle zur Erlangung eines akademischen Grades 
eingereicht wurde. 
 
 
 
 
 
 
 
 
        München, 16.02.2019                                                               Simona Langer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This page intentionally left blank. 
 
 
  
i 
Table of contents 
Zusammenfassung .............................................................................................................................................. v 
Summary  ......................................................................................................................................................... vii 
1. Introduction ......................................................................................................................................... 1 
1.1. Microbial drug resistance .......................................................................................................................... 1 
1.1.1. Viral resistance development ............................................................................................................ 2 
1.1.2. Antiviral drug-resistant tests ............................................................................................................. 3 
1.2. Biology of large DNA viruses and their inhibitors ...................................................................................... 5 
1.2.1. Herpesviruses .................................................................................................................................... 6 
1.2.2. Herpes simplex viruses ...................................................................................................................... 7 
1.2.3. Human adenoviruses and their replication ..................................................................................... 15 
1.3. Replicon-based reporter systems in virology .......................................................................................... 22 
1.3.1. RNA virus replicon systems ............................................................................................................. 23 
1.3.2. DNA virus replicon systems ............................................................................................................. 23 
1.4. Adeno-associated virus as basis for a replicon vector ............................................................................. 24 
1.4.1. Adeno-Associated Virus and their replication ................................................................................. 24 
1.5. Objectives ................................................................................................................................................ 30 
2. Material ............................................................................................................................................... 31 
2.1. Devices ..................................................................................................................................................... 31 
2.2. Consumables ............................................................................................................................................ 31 
2.3. Reagents and biochemicals...................................................................................................................... 32 
2.4. Commercial Kits ....................................................................................................................................... 33 
2.5. Culture Media for bacteriology and cell culture ...................................................................................... 34 
2.6. Oligonucleotides ...................................................................................................................................... 35 
2.7. Enzymes for molecular biology ................................................................................................................ 36 
2.8. Plasmids ................................................................................................................................................... 36 
2.8.1. Plasmids that were constructed in this study ................................................................................. 37 
2.9. Bacterial artificial chromosomes ............................................................................................................. 38 
2.9.1. Published BACs and BACs available in the group ............................................................................ 38 
2.9.2. BAC’s cloned during this study ........................................................................................................ 38 
2.9.3. Viruses ............................................................................................................................................. 38 
2.9.4. Recombinant viral particles ............................................................................................................. 40 
3. Methods .............................................................................................................................................. 41 
3.1. Propagation of recombinant DNA in E. coli ............................................................................................. 41 
3.1.1. Culturing recombinant E. coli .......................................................................................................... 41 
3.1.2. Preparation of electro-competent bacteria .................................................................................... 41 
3.1.3. Transformation of electro-competent bacteria .............................................................................. 42 
3.1.4. Isolation of DNA from bacteria ........................................................................................................ 43 
3.2. Analysis and cloning of recombinant DNA ............................................................................................... 44 
 ii 
 
3.2.1. Determination of DNA concentration ............................................................................................. 44 
3.2.2. Ethanol precipitation ....................................................................................................................... 44 
3.2.3. Polymerase chain reaction (PCR) .................................................................................................... 44 
3.2.4. Restriction enzyme digest ............................................................................................................... 45 
3.2.5. Agarose gel electrophoresis ............................................................................................................ 45 
3.2.6. Purification of DNA from agarose gel .............................................................................................. 46 
3.2.7. Blunting of DNA ends ...................................................................................................................... 46 
3.2.8. Ligation of DNA fragments .............................................................................................................. 46 
3.2.9. DNA sequencing .............................................................................................................................. 47 
3.3. Mutagenesis of BAC DNA ......................................................................................................................... 47 
3.3.1. Homologous recombination of BACs .............................................................................................. 47 
3.3.2. Flp/FRT recombination system ........................................................................................................ 48 
3.4. Tissue culture ........................................................................................................................................... 48 
3.4.1. Cultivation of mammalian cell lines ................................................................................................ 48 
3.4.2. Cryopreservation of mammalian cell lines ...................................................................................... 49 
3.4.3. Transfection of cultured mammalian cells ...................................................................................... 50 
3.4.4. Construction of stable cell lines ...................................................................................................... 51 
3.4.5. Cryopreservation of transfected cells ............................................................................................. 51 
3.4.6. Antiviral drug treatment of cultured cells ....................................................................................... 52 
3.4.7. Extraction of genomic DNA from cultured mammalian cells .......................................................... 52 
3.4.8. Quantitative real-time PCR .............................................................................................................. 52 
3.4.9. Flow cytometry ................................................................................................................................ 53 
3.5. Virological methods ................................................................................................................................. 53 
3.5.1. Virus infection of cultured cells ....................................................................................................... 53 
3.5.2. Reconstitution of viruses from BACs ............................................................................................... 53 
3.5.3. Preparation of viral inocula ............................................................................................................. 54 
3.5.4. Preparation of high-titer virus stocks .............................................................................................. 54 
3.5.5. Endpoint dilution assay ................................................................................................................... 55 
3.5.6. Gaussia luciferase assay .................................................................................................................. 56 
4. Results .................................................................................................................................................. 57 
4.1. Construction of the AAV based replicon .................................................................................................. 57 
4.2. Characterization of the AAV replicon system .......................................................................................... 61 
4.2.1. Delivery of the AAV replicon by transient transfection and its applications ................................... 62 
4.2.2. Construction and characterization of stable cell lines carrying AAV replicons ............................... 69 
4.2.3. Induction of frozen AAV replicon vector transfected cells .............................................................. 76 
4.2.4. Induction of the AAV replicon vector packaged into recombinant AAV2 particles......................... 78 
4.3. Applications ............................................................................................................................................. 87 
4.3.1. Trans-complementation of HAd5 late protein pVI by the AAV replicon vector .............................. 87 
4.3.2. AAV replicon system for diagnostic approaches ............................................................................. 92 
4.3.3. Screening for new antivirals by the AAV replicon-based assay ..................................................... 104 
 iii 
5. Discussion ......................................................................................................................................... 111 
5.1. Advantages and disadvantages of taking AAV as basis for the AAV replicon vector ............................. 111 
5.1.1. Comparison of the AAV replicon to RNA replicon vectors ............................................................ 111 
5.1.2. Comparison of the heterologous AAV replicon to the homologous DNA virus replicon system .. 112 
5.1.3. The versatility of the AAV replicon system.................................................................................... 114 
5.1.4. Comparison to other virus-inducible reporters ............................................................................. 116 
5.2. AAV Replicon vector for testing drug resistance ................................................................................... 117 
5.2.1. Advantages and disadvantages of AAV replicon-based test compared to classical PRA .............. 117 
5.2.2. Advantages and disadvantages of AAV replicon compared to other methods ............................. 120 
5.3. AAV replicon vector for testing new inhibitors ...................................................................................... 121 
5.3.1. Why new inhibitors are needed .................................................................................................... 121 
5.3.2. Current testing systems ................................................................................................................. 122 
5.4. Concluding remarks ............................................................................................................................... 126 
References ...................................................................................................................................................... 127 
List of Figures ................................................................................................................................................. 143 
List of Tables ................................................................................................................................................... 144 
Abbreviations ................................................................................................................................................. 145 
Publications and posters ................................................................................................................................ 148 
Acknowledgement ......................................................................................................................................... 149 
 
 
 
 
 
 
 
 
  
 iv 
 
 
 
 
 
 
 
 
 
 
 
 
This page intentionally left blank. 
 
  
 v 
Zusammenfassung 
Die Entwicklung von Resistenzen gegen bestimmte Medikamente steigt bei Herpes- und 
Adenovirus Infektionen, vor allem bei Kindern und immungeschwächten Personen, stark an. 
Gegen beide Viren gibt es trotz klinischem Bedarf nur eine unzureichende Auswahl an antiviral 
wirksamen Substanzen, welche oft mit schädlichen Nebenwirkungen einhergehen. Zusätzlich 
sind phänotypische Tests zur Ermittlung von Resistenzen zeitaufwendig, schwer 
quantifizierbar und mit langen Wartezeiten bis zur Auswertung verbunden. In dieser Arbeit 
haben wir ein neues, konditionelles Replikonsystem konstruiert, welches auf dem Genom des 
Adeno-assozierten Virus (AAV) beruht. Unser Ziel war es, ein Reportersystem zu etablieren, 
um virale Resistenzen gegen zugelassene Medikamente und neue antivirale Wirkstoffe 
effektiv zu detektieren. 
 
Dabei nutzen wir die natürliche Eigenschaft des AAV, eine lytische Replikation nur in 
Abhängigkeit einer Überinfektion mit anderen Viren wie dem Herpes-simplex-Virus (HSV) oder 
dem Adenovirus (Ad) durchführen zu können. Um ein induzierbares Expressionssystem zu 
entwickeln, wurden die strukturell kodierenden Sequenzen des AAVs mit einem Reportergen 
ausgetauscht, ohne die entsprechende Promotersequenz des Virus-Genoms zu verändern. Die 
Expression dieses Reportergens wird bei diesem sogenannten AAV Replikon Vektor nur durch 
eine Infektion mit den entsprechenden Wildtyp-Viren induziert. Infektionen aller getesteten 
Ad-Serotypen, wie auch Infektionen durch HSV-1, HSV-2 und das humane Cytomegalievirus 
(HCMV) konnten das AAV Replikon Reportersignal signifikant induzieren, während bei 
fehlender Infektion ein Signal nur knapp über dem Hintergrundsignal gemessen wurde. Für 
unterschiedliche Anwendungen haben wir verschiedene Einführungs-möglichkeiten des AAV 
Replikon Vektors in entsprechende Zelllinien getestet: transiente und stabile Transfektion und 
Transduktion durch Verpackung des AAV Replikon Vektors in AAV Vektoren. Unter allen 
Versuchsbedingungen führte die Induktion des Replikon Vektors durch Infektion zu 
unterschiedlichen Reporterexpressionsniveaus. 
 
Um eine Virusinfektion zu therapieren, ist das schnelle und präzise Testen eines effektiven 
antiviralen Wirkstoffes an Patienten-Virusisolaten essentiell. Deshalb haben wir mit dem AAV 
Replikon System einen phänotypischen Wirkstoff-Resistenztest für HSV etabliert und mit 
diesem bereits 21 HSV Patientenisolate auf ihre Resistenz gegen das Referenzmedikament 
Acyclovir getestet. Dabei waren wir in der Lage, die Ergebnisse des als Standard geltenden  
5 -7 Tage dauernden Plaque-Reduktions-Tests für alle HSV-1 Isolate bereits nach 24 Stunden, 
und für HSV-2 nach 48 Stunden quantitativ zu bestätigen. 
 
Zusätzlich haben wir mit dem AAV Replikonsystem ein Wirkstofftestsystem etabliert, welches 
auch im Hochdurchsatz-Screening-Format genutzt werden kann. In einem ersten Vorversuch 
wurden 22 unbekannte und 2 bekannte Wirkstoffe auf deren Wirksamkeit gegen Ad und 
HSV-1 getestet. Das Replikonsystem konnte dabei reproduzierbar die bekannten Wirkstoffe 
detektieren und zusätzlich neue interessante Wirkstoffgruppen als direkte Inhibitoren der 
Virusreplikation in vitro identifizieren. 
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Summary 
Due to long-term chemoprevention, the risk of immune compromised patients to suffer from 
an infection of therapy-resistant herpes simplex virus (HSV) or adenovirus (Ad) is increasing. 
Therefore, fast and reliable tests for drug resistance of these viruses become more and more 
important in clinical praxis. Additionally, because of the lack of approved antivirals in case of 
human Ad and the limitation of the therapeutic target range for antiviral therapy of HSV 
infections, there is an unmet need for new antivirals improving the infectious mortality in this 
patient group. 
Here, we constructed a new conditional expression system that is based on the adeno-
associated virus (AAV) genome replication. This system provided an appropriate reporter 
system for replication of large DNA viruses, for testing their drug resistance and for screening 
of new antiviral substances. The multiplication of AAV is dependent on super-infection with 
other viruses such as herpes- or adenoviruses. The helper functions provided by these viruses 
induce the replication of the previously silent AAV turning its lytic gene expression on. We 
employed this natural switch to regulate the expression of a reporter gene, replacing the AAV 
Cap gene, depending on the infection with herpes or adenoviruses. By replacing the coding 
sequences for the structural AAV proteins with a Gaussia luciferase (GLuc) or a green 
fluorescence protein (GFP) open reading frame, we constructed a genetic element. This 
genetic element retained the extremely low basal activity in absence, and inducibility in the 
presence of helper virus infection. Instead of AAV production, reporter gene expression is 
turned on dependent on this infection. We coined this genetic element as AAV replicon in 
analogy to similar virus replication-based reporter systems, which were established for 
assessing RNA virus replication. 
After successful introduction of the AAV replicon into permissive cells the reporter gene 
expression was specifically activated upon infection with different human Ad serotypes, 
HSV-1, HSV-2, and human cytomegalovirus (HCMV). Almost no induction of the signal was 
measured without infection. In this study, we characterized the responsiveness of the AAV 
replicon system using different delivery methods and target cell lines and tested feasibility of 
different applications such as resistance testing, trans-complementation and drug screening.  
A fast diagnosis of drug resistance of patient isolates towards certain antiviral drugs is 
absolutely essential for the decision on effective therapy. Therefore, a phenotypical drug 
resistance test using the AAV replicon vector system was established for HSV. By testing 21 
clinical isolates of HSV we showed that the AAV replicon-based test can differentiate between 
acyclovir sensitive and resistant strains already after 24 hours (for HSV-1) and 48 hours (for 
HSV-2) after virus isolation, compared to the gold standard plaque reduction assay, which 
takes 5-7 days. 
Furthermore, the AAV replicon vector system was used to generate a drug susceptibility test 
system, which can be applied in a high-throughput screening format. In a first approach, 24 
kinase inhibitors were tested for their ability to inhibit Ad and HSV. The system was 
reproducibly detecting known inhibitors and could even identify new interesting compound 
groups.  
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1. Introduction 
1.1. Microbial drug resistance 
Antimicrobial resistance is a natural mechanism of pathogens to overcome treatments with 
antimicrobial drugs. It occurs due to adaptive genetic changes of the pathogen 
microorganisms under selection pressure. Especially prolonged treatment, overuse and 
misuse of antimicrobials are accelerating this process in all kind of microorganisms, such as in 
bacteria, viruses, fungi, and parasites. Emergence and spreading of antimicrobial resistance 
mechanisms occur globally and influence the ability of treating common infectious diseases 
[1] [2]. 
Antibiotic resistance of bacteria can be preserved by intrinsic or acquired mechanisms. 
Intrinsic mechanisms are obtained by naturally occurring genes like multidrug-resistant active 
efflux systems and modification of antibiotic target sites [3]. Acquired mechanisms in contrast 
include the transfer of resistance genes on plasmids, bacteriophages, transposons, and similar 
mobile genetic material [4]. Consequences for humans infected with emerged pathogens 
resistant to multiple antibiotics, are prolonged illness, disability, and death [5] [6]. Some 
nosocomial pathogens are even untreatable if they become resistant to all antimicrobials 
available [7].  
Antimicrobial susceptibility testing is important to meet the challenge of fast treatment. 
Bacterial infection, for example, currently have to be treated with broad-spectrum antibiotics 
before the antimicrobial susceptibility test result of the isolated pathogen is available. 
Preferred testing methods at the moment are broth microdilution test, agar dilution, disk 
diffusion, and gradient diffusion methods. These methods take 16–24 hours. More rapid 
results (3.5–16 hours) can be obtained by automated instrument methods, like ultra-high-
throughput bacterial growth assays, for which materials and devices are commercially 
available [8] [9]. In clinical practice, every hour can be crucial for the mortality rate of patients 
if the effective antimicrobial treatment is not started as soon as possible [10] [11]. Globally, 
the world is facing an increasing emergence of multi-drug resistances, while the average time 
span of developing a new antimicrobial treatment takes 10–12 years [7]. Future prospects 
concentrate on alternatives to antibiotics, like modulating the host immune response by 
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altering inflammation and autophagy, or on combinations of antibiotics and so-called 
antibiotic resistant breakers [12]. 
1.1.1. Viral resistance development 
Viruses have the evolutionary advantage to generate a remarkable genetic diversity by a fast 
adoption to new host and environmental changes. The necessary viral mutations in their 
genomes are dependent on multiple viral- and host-specific processes [13]. Emergence of 
resistant strains is therefore a common result of therapeutic selection pressure [14]. In this 
perspective, an antiviral drug must fulfill several requirements. The two most important 
requirements are safety and potency. Since the viral life cycle is dependent on cellular 
functions, it is important to specifically inhibit either a viral function or a cellular pathway that 
is essential for virus growth, without causing deleterious effects on the host cell functionality 
itself. Most antivirals therefore target viral enzymes such as proteases, nucleic acid 
synthesizing proteins or other viral targets essential for viral reproduction. For a potent 
antiviral drug, it is important to avoid even modest replication of the virus. Due to their fast 
adopting capacities, viruses can easily acquire resistance in presence of an inhibitor that does 
not fully block virus replication. If the drug concentration is insufficient to completely inhibit 
virus replication, the remaining virus population can expand and gain fitness due to genetic 
variation. In patients that are not treated with an alternative antiviral drug in time, the 
uncontrolled expansion of the resistant mutant virus can be fatal [15]. 
In the last two decades, potent antiviral drugs were approved for treatment of viral infections. 
Some antivirals can clear infections from the patient or persistent viruses can at least be 
controlled effectively by antivirals. Unfortunately, development of resistance has been 
documented for nearly all clinically used antivirals. The mechanisms of how viruses circumvent 
drug therapy involve either a gene mutation of the target site of the antiviral drug or a gene 
mutation of antiviral drug activators [14]. The randomly appearing frequent mutation rate and 
the fast replication of viral genomes lead to a large pool of variants called quasispecies. The 
respective fitness of the quasispecies determines whether a mutation leads to a replication-
competent and additionally resistant virus mutant. Therefore, once the replication of the virus 
is not fully repressed, the possibility of resistance development is very high [16]. This is the 
reason for resistance occurring with an increased probability especially in 
immunocompromised patients under long term low dose antiviral prophylaxis. Extensive 
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immunosuppression for example, has to be initiated in transplant patients due to the 
management of rejection in solid organ transplant recipients or hematopoietic stem cell 
transplant recipients. This is similar for the treatment of leukemia and autoimmune diseases 
[17] [18]. In the following chapter, the mechanisms behind resistance development of viruses 
as well as strategies for dealing with resistance are discussed for selected important viruses. 
1.1.2. Antiviral drug-resistant tests 
The risk for patients to suffer from drug-resistant viruses should be detected as fast and as 
accurate as possible. There are two means of determining drug resistance: either by genotypic 
or by phenotypic assays. Genotypic assays detect mutations in the viral genome pools that are 
known to cause resistances. Phenotypic assays measure the actual drug resistance of patient 
derived infectious virus. The choice which assay to use for drug resistance detection is 
dependent on the genome size of the respective virus and the ability to culture the virus in 
vitro. 
Genotypic testing has several technical advantages. However, novel or so far uncharacterized 
mutations that lead to resistance as well as the overall replication fitness of mutated viruses, 
cannot be detected with this method. Especially under long term therapy of patients, the 
choice of antiviral drugs based on genotyping can be challenging because of the increasing 
occurrence of cross resistance and multiresistance. Furthermore, the implementation of new 
antiviral drugs on the market will lead to new and complex patterns of yet unknown mutations 
[19]. Notably, genotyping of resistance is only applicable for drugs that are in longtime use 
and therefore sufficient data are available to connect resistance with specific mutations. This 
connection needs to be generated or proven by a phenotypic test. Hence, a standardized 
phenotypic testing would be necessary for each virus of interest.  
Phenotypic assays have the advantage of detecting decreased susceptibility of a viral mutant 
to a certain antiviral agent compared to a wild-type strain. The drug concentration necessary 
to inhibit wild-type viral growth by 50% is called IC50 value. For evaluation of the phenotypic 
drug resistance, the increase of the IC50 of the viral isolate strain compared to the wild-type 
strain is important. The general IC50 threshold (so called cut-off), which defines therapeutic 
resistance, is dependent on the respective assay and determined by careful assessment of 
standard strains and isolates [17]. 
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The standard clinical practice test for hepatitis B virus (HBV) antiviral susceptibility is the 
genotypic resistance test, because it is fast and convenient. Since most of HBV drugs on the 
market are nucleosid- or nucleotid analogs, the detection concentrates mainly on HBV 
polymerase gene mutations [17]. Genotypic resistance mutation tests include standard 
sequencing of polymerase chain reaction (PCR) products, real-time PCR, reverse hybridization, 
restriction fragment length polymorphism, single genome sequencing, and ultra-deep 
pyrosequencing. These assays differ up to 20% concerning the sensitivity of the minor 
subpopulation of mutant HBV viruses [20] [21]. Since the genome size of HBV is small, the 
number of mutations leading to resistance is better investigated compared to viruses with a 
larger genome size. The database for genetic resistance is based on and controlled by 
phenotypic tests. 
For HBV, the phenotypic testing method is limited in clinical use because of the absence of a 
fully permissive HBV infectious cycle in a cell culture system. Nevertheless, there are different 
methods to determine the phenotypic resistance of patient derived HBV isolates to learn more 
about drug-resistant HBV phenotypes. This includes the transient transfection method, where 
clinical isolated HBV genomes are either amplified or cloned and transfected to hepatocyte-
derived cell lines in the presence of antiviral drugs [22]. Another method is the transduction 
of recombinant baculoviruses encoding drug-resistant HBV clones. Like the transient 
transfection method, this method is very work-intense but good for cross-resistance testing 
[19]. To define and characterize the fitness of a certain HBV mutant, a stable human hepatoma 
cell line, which promotes differentiation and phenotypic stability, can be constructed for every 
isolated mutant [23] [24]. 
In the case of human immunodeficiency virus (HIV) the high rate of replication in vivo leads to 
an accumulation of innumerable genetically distinct quasispecies with a high genetic 
variability in individuals [25]. HIV drug resistance is mainly tested via sequencing-based 
genotyping methods, as they offer reduced costs and faster turnaround times compared to 
phenotypic cell-based methods. Despite the disadvantages of phenotypic assays, they are 
used for HIV-testing and are able to define antiviral resistance to any drug without prior 
knowledge of the corresponding mutations. The most advanced phenotypic tests are based 
on construction of pseudotyped viruses by homologous recombination of patient derived 
coding sequences for integrase, protease, and reverse transcriptase into a standardized virus 
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backbone. The spread of these recombinant HIV infection is measured in the presence of 
different drugs and compared to wild-type standards. Significant increase of spread reveals 
presence of coding sequences with resistance phenotype. Unfortunately, the sensitivity of this 
methodology allows a detection of resistant viruses only if they constitute more than 10% to 
20% in one patient sample [26-28]. Overall, the data of phenotypic tests provide experimental 
proof for the correlation between genome mutations and drug resistance. These 
characterizations are very important for the interpretation of genotypic data and 
improvement of performing HIV genotyping based predictions [29]. In case of assays for HIV 
susceptibility testing, the greatest sensitivity for drug resistance is reached by next-generation 
sequencing based methods. The increased sensitivity thereby is achieved by massively 
increased coverage of sequencing data, which generates three to four orders of magnitude 
more identification of mutations compared to the Sanger-sequencing based method [30] [31] 
[32]. This allows the description of the drug resistance potential for a given HIV pool more 
exactly, including the genotypes with extremely low frequency. However, one of the major 
limitations of next-generation sequencing, especially for lower volume laboratories, is the 
necessary start-up and running costs. Nevertheless, the utility of next-generation sequencing 
for human viral pathogens in general is expected to increase in the future [33]. 
In contrast to HIV and HBV, the resistance determination of larger DNA viruses like herpes 
simplex viruses (HSV) or adenoviruses (Ad) is more challenging due to their large genome size 
and therefore aggravated conditions to detect mutations leading to resistance. However, for 
HSV, a phenotypic assay is standard because patient derived viral isolates can be grown easily 
in vitro. In case of other herpesviruses, like cytomegalovirus (CMV) or varicella zoster virus 
(VZV), in vitro growth abilities are limited and therefore neither genetic nor phenotypic 
methods can be easily applied for testing drug resistance. For Ad, genotypic and phenotypic 
drug resistance testing is limited to specialized laboratories. Further information on resistance 
tests for HSV and Ad can be found in chapter 1.2.2.7 and chapter 1.2.3.5. 
1.2. Biology of large DNA viruses and their inhibitors 
Herpesviruses and adenoviruses belong to the large class of double-stranded viruses. Both 
groups of viruses are able to induce AAV replication and therefore their growth potential can 
be tested by an AAV based replicon system. 
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1.2.1. Herpesviruses 
In order to structure the relationship of herpesviruses into a taxonomical framework, the 
International Committee on Taxonomy of Viruses (ICTV) classified the order of Herpesvirales 
into three families called Alloherpesviridae, Herpesviridae and Malacoherpesviridae. This 
classification was made according to their biological characteristics, like having a linear 
double-stranded DNA genome, a capsid of about 100 nm with icosadeltahedral shape, a 
proteinaceous matrix called tegument, and an glycoprotein-containing lipid envelope [34]. 
Amongst those, the family of Herpesviridae consists of three subfamilies: Alphaherpesvirinae 
(with the genera of Iltovirus, Mardivirus, Scutavirus, Simplexvirus, and Varicellovirus), 
Betaherpesvirinae (with the genera of Cytomegalovirus, Muromegalovirus, Proboscivirus, 
Roseolovirus) and Gammaherpesvirinae (with the genera of Lymphocryptovirus, Macavirus, 
Percavirus, Rhadinovirus) [35]. 
The transmission route of Herpesviridae ranges from physical contact to aerosol spread. 
Severe symptoms after infection are often limited to immunocompromised hosts [36]. A 
characteristic observed among all herpesviruses is their ability to establish a life-long latent 
state after primary infection. Interestingly, herpesviruses show a high species specificity due 
to a long-lasting coevolution between the viruses and their hosts. This may be the reason why 
the pathology of primary herpesvirus infection is normally relatively mild. For example, in 
humans, although the average adult population is infected with 3-4 out of the 9 human 
herpesviruses, symptoms of primary herpesvirus infections are rarely observed [37].  
The nine known human herpesviruses are Human alphaherpesvirus 1 (also called herpes 
simplex virus type 1 (HSV-1)), Human alphaherpesvirus 2 (also called herpes simplex virus type 
2 (HSV-2)) and Human alphaherpesvirus 3 (also called varicella zoster virus (VZV)), which 
belong to Alphaherpesvirinae, Human betaherpesvirus 5 (also called cytomegalovirus (CMV)) 
and Human betaherpesvirus 6A, 6B, and 7, belonging to Betaherpesvirinae- and Human 
gammaherpesvirus 4 (also called Epstein-Barr virus (EBV)) and Human gammaherpesvirus 8 
(also called Kaposi’s sarcoma-associated herpesvirus (KSHV)), which belong to the 
Gammaherpesvirinae subfamily [37, 38]. The clinical outcome of infections and the tissue 
tropism in vivo and cell tropism in vitro differs amongst these herpesviruses. 
Human Alphaherpesvirinae have a restricted host specificity and are characterized by their 
short reproduction cycle and rapid spread in cell culture. During latent state, these viruses are 
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maintained in the nervous system in vivo. They may cause neurological diseases upon both 
primary infection and reactivation [38] [39] [40]. In contrast, human Betaherpesvirinae 
possess a very broad cell tropism compared to Alphaherpesvirinae subfamily. They are able to 
replicate in vitro in epithelial cells, fibroblasts, endothelial cells, and smooth muscle cells, 
whereas their replication cycle takes longer (reviewed in [41]). Viruses remain latent in bone 
marrow-derived hematopoietic or endothelial cells [42] [43]. Human Gammaherpesvirinae 
subfamily has the highest restriction of host cell tropism both in cell culture and in vivo 
amongst the human herpesviruses. EBV infects either B cells or epithelial cells by tropism 
switching after propagation in one or the other cell types [44] and latently infected cells are 
resting memory B cells used by the virus in a non-pathogenic persistence state [45].  
1.2.2. Herpes simplex viruses  
There are two known human members of the Simplexvirus genus: HSV-1 and HSV-2, common 
and endemic worldwide. In Germany, the seroprevalence of HSV-1 in the population older 
than 15 years is relatively high, being 76.3% in females and 75.2% in males, in contrast to the 
seroprevalence of HSV-2 being only 18% in women and 13.8% in men [46]. In some regions in 
developing countries, the seroprevalence of HSV-1 and HSV-2 is even up to 100%. In principle 
the prevalence of infection is strongly dependent on age, geographic regions, population 
subgroups, and pre-infections with other endemic human viruses like HIV [47] [48]. 
Usually HSV-1 is already transmitted during childhood mainly due to oral contact with body 
fluids of infected persons around the mouth (orolabial) causing oral herpes. However, a 
proportion of HSV-1 infections can as well be transmitted via the genital or anal area and cause 
genital herpes. In contrast, HSV-2 is mainly sexually transmitted also leads to genital herpes 
infections. Infections with both HSV species persists lifelong and, in most cases, asymptomatic. 
Reactivation from latency is associated with mild symptoms in about 30% of latently infected 
patients and characterized by recurrent eruptions of painful blisters or ulcers at the respective 
site. Immunocompromised patients, such as HIV infected patients, and solid or bone marrow 
transplant recipients are at high risk to develop herpes simplex keratoconjunctivitis and 
herpes simplex encephalitis, where the latter goes along with a frequency of 5 in 1 million 
people. Perinatal HSV infections of neonates lead to a life threating systemic disease. Herpes 
infections of neonates, immunocompromised patient and herpes encephalitis is associated 
with high mortality [49] [50] [51].  
Introduction 
8 
1.2.2.1. Genome organization of HSV  
The genome of HSV consists of a linear, double stranded DNA, which contains two unique 
regions named unique segment long (UL) and unique segment short (US). Both are flanked by 
an internal repeat sequence (IR) and a terminal repeat sequence (TR) (see Figure 1). HSV 
produces 4 roughly equimolar genomic isomers, which differ by inversion of the long and short 
components. Furthermore, the HSV genome has three origins of replication depicted as ORIL 
and ORIS. The latter one is present twice [52] [53]. 
 
Figure 1: The structure of HSV-1 genome. 
Genome configuration depicting IRS and TRS. (modified from [54]). 
1.2.2.2. Lytic and latent infection cycle 
Like all Herpesviridae, HSV has a biphasic life cycle consisting of a lytic and a latent state. 
During latency in neurons of sensory ganglia, gene expression is limited, and viral production 
is completely inhibited. Only microRNAs and latency-associated transcripts (LATs) are 
abundantly accumulated whereby LATs are suggested to suppress viral lytic genes as primary 
function [55-57]. Especially stress or neuronal damage can lead to periodic viral reactivation 
throughout the lifetime of a host. During a productive lytic phase, virions are retrogradely 
transported along neuronal axons resulting in a release of an infectious virus in the axonal 
termini, where it has access to permissive peripheral tissue to cause recurrent lesions [58]. 
Here, viral genes are expressed in a certain cascade manner of at least three coordinated 
kinetic classes: immediate-early (IE) genes, early (E) genes and late (L) genes [59] [60]. 
HSV virions consist of an outer envelope containing 13 distinct viral envelope glycoproteins 
for viral attachment and entry, and host-cell derived lipids and membrane proteins. A 
proteinaceous layer termed tegument links the envelope to the inner viral capsid. This inner 
icosahedral capsid of 100 nm size contains 150 hexons and 12 pentons in an icosahedral 
symmetry (T=16). The linear double-stranded DNA is comprised in the inner nucleoprotein 
core [61] [62]. The attachment of HSV-1 is upon binding of the viral glycoprotein gC to cell 
surface heparin sulfate (HS). Viral glycoprotein gB mediates fusion of the viral envelope with 
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the cell membrane [63]. In case of HSV-2, the glycoprotein gB is involved in both mechanisms 
of binding and penetration of HSV [64]. Then the viral envelope is fused to the cellular 
membrane and the tegument with the capsid is released into the cytoplasm [65] [66]. The 
microtubule-mediated transport mechanism transfers the viral nucleocapsid to the nucleus 
and naked DNA is then released at a nuclear pore [67]. The linear DNA is converted into a 
covalently closed circular form [68].  
Transcription of HSV genes is solely dependent on the host RNA polymerase II (pol II) since the 
virus does not encode its own RNA polymerase. Gene expression is conducted by the 
formation of an activator complex by the viral protein VP16 with the host cell factor (HCF) and 
the octamer-binding transcription factor-1 (Oct-1). This complex binds to IE gene promoters, 
recruits other transcriptional factors and stimulates directly the transcription of IE genes ICP0, 
ICP4, ICP22, ICP27 and ICP47 [69] [70]. Then the early phase of transcription is stimulated 
mainly by ICP4 [70] [71] and ICP22 [72]. The E genes are involved in viral genome replication 
during the viral lytic cycle. HSV encodes for its own polymerase helicase and single stranded 
DNA binding protein ICP8, which are mandatory for the viral DNA replication [73]. The final 
late phase is characterized by expression of viral structural genes after onset of the DNA 
genome replication [74]. 
1.2.2.3. Viral DNA replication 
The onset of DNA replication in HSV leads to significant reduction of E gene expression 
whereas L genes start to be expressed in very high amounts. Seven viral proteins are essential 
for viral DNA synthesis: the viral DNA polymerase complex composed of a catalytic subunit Pol 
UL30 and a processivity subunit UL42, the origin-binding protein UL9, the DNA binding proteins 
ICP8 (UL29) and the helicase/primase complex is based on UL5/UL8/UL52 (reviewed in [53]). 
Detection of nucleoprotein complexes into the nucleus leads to the recruitment and formation 
of cellular nuclear substructures called ND10 protein foci, which are disrupted by IE protein 
ICP0 [75] [76]. The initiation step at the beginning of DNA synthesis is started by UL9 and ICP8 
with distortion or destabilization at one of the three Oris. During the elongation phase, H/P 
complex is recruited to unwind duplex DNA and for synthetizing short RNA primers for 
initiation of the DNA replication step [77]. Then the two-subunit polymerase is recruited to 
the fork to catalyze leading- and lagging-strand synthesis [78]. The lagging strand is looped 
back to the fork. Leading and the lagging strands, which consists of so-called Okazaki 
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fragments, are synthesized in cycles [79] [80]. Whether DNA replication initially proceeds by 
a rolling circle amplification or by a theta type mechanism remains as one of the challenges in 
the field [81]. 
1.2.2.4. Viral assembly and egress 
After DNA replication, the viral DNA is incorporated into the accumulated and pre-assembled 
viral capsids [82, 83]. Maturated nucleocapsids then egress to the cytoplasm. First an 
envelopment takes place at the inner nuclear membrane. Then there follows a de-
envelopment of the nucleocapsid at the outer side of the nuclear membrane [84]. In this 
process the capsids acquire a transient (also called “primary”) envelope. Primary enveloped 
virions can be found only in the peri-nuclear space. After the fusion of the primary envelop to 
the outer nuclear membrane, the nucleocapsids are released to the cytosol where they 
acquire most of their tegument. Their morphogenesis is continued in the trans-Golgi derived 
membrane compartment, which is enriched in viral glycoproteins. There they acquire their 
permanent (secondary) envelop, which can be found in infectious particles. During the 
secondary envelopment the virus particles are budding to secretory vesicles and the resulting 
virions are entering the extracellular space ready to initiate a new infection cycle [85, 86]. 
1.2.2.5. Immunity against herpes simplex viruses 
Since HSV are ancient and very well adapted human pathogens, their immune evasion 
mechanisms are complex. Both, the innate and the adaptive immune response are activated 
by the virus. As a first line of defense against HSV the innate immune response is induced in 
all cells that are infected and mainly rely on the type I interferon response. This innate immune 
response against HSV also involves activity of multiple immune cell types [87]. Most 
importantly, natural killer (NK) cells respond by cytokine production and cell killing to the 
recognition of HSV infected cells. Additionally, plasmacytoid dendritic cells (pDCs) produce 
type I IFN and thereby support the cell intrinsic antiviral immune responses [88, 89]. The 
adaptive immune response shows an important role in controlling disease progression, 
latency, and limiting of viral spread. Key players in the cellular response are CD8+ T cells [90] 
[91]. In the absence of other immune effectors, CD4+ T cells as well as the humoral immunity 
have been shown to play only a minor role in protection [92]. 
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1.2.2.6. Antiviral drugs against herpes simplex virus infections 
The most commonly used drugs against HSV are nucleoside and nucleotide analogues, sharing 
a common molecular mechanism of inhibiting the viral DNA polymerase.  
Acyclovir and valacyclovir: 
Among the 25 by the US Food and Drug Administration (FDA) approved antiviral nucleoside 
analogues, Acyclovir (ACV) was the first efficient and selective antiviral agent against 
herpesvirus infections back in 1982. Still, it is a commonly used drug and the primary choice 
in treatment of HSV infections. ACV consists of a guanosine derivate with an acyclic side chain 
declared as 9-[(2-hydroxyethoxy)methyl]guanine. The specificity relies on the fact that mainly 
the viral encoded thymidine kinase (TK) performs phosphorylation of the acycloguanosine to 
a monophosphate (ACV-MP) (Figure 2). This reaction is not efficiently catalyzed by any 
nucleotide kinases belonging to the host nucleoside salvage pathway. After this initial step, 
however, the host cellular GMP kinase and the host nucleoside diphosphate kinase (NDP), 
respectively, can further phosphorylate the ACV-MP resulting in the biologically active 
intermediate of acyclovir, which is the ACV-triphosphate (ACV-TP) [93] [94]. The ACV-TP then 
serves as an alternative substrate of the natural nucleoside dGTP for the interaction with the 
viral DNA polymerase. If ACV-TP is incorporated into the DNA at its 3’ terminus, a further chain 
elongation is impossible because the nucleoside analogue lacks the hydroxyl group needed 
for this step [95] [96].  
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Figure 2: Chain termination mechanism of Acyclovir. Different viral and cellular kinase 
phosphorylation steps are needed before the ACV-triphosphate is recognized by the viral DNA 
polymerase. Figure reprinted from [97]. 
 
Furthermore, the HSV DNA polymerase-associated 3’ -> 5’-exonuclease activity is not able to 
excise the incorporated ACV-monophosphate residues [98]. In principle, ACV is very potent 
against HSV-1 but only half as potent against HSV-2. In vitro, the half inhibitory dose (IC50) 
against HSV-1 is 0.09 - 4 µM and in case of HSV-2 it is 0.1 – 9.8 µM [99]. Due to its low oral 
absorption, this drug is applied topically against labial herpes and intravenously to fight 
systemically genital and labial herpes and herpes encephalitis [100] [101]. 
The low oral uptake is the reason why the L-valyl-ester prodrug of acyclovir called valacyclovir 
was developed, which shows a better oral bioavailability (54% versus 12 – 20%) [99]  [100]. 
After oral intake, valacyclovir is first carried out by the human intestinal transporter. In the 
intestine it is then converted to ACV by ester hydrolysis. ACV and valacyclovir are both very 
well tolerated drugs [102]. 
Penciclovir and famciclovir: 
Another drug used in the clinic is penciclovir and its prodrug famciclovir, which shows 
improved oral bioavailability. Penciclovir is an acyclic guanine derivative and famciclovir is the 
inactive prodrug of penciclovir with an additional diacetyl ester. Similar to ACV, penciclovir 
leads to a limited chain elongation during viral DNA replication by virtue of the triphosphate 
hydroxyl group. The advantage of penciclovir over acyclovir is the higher stability of the active 
triphosphate as well as the longer time frame it persists inside the target cell [103] [104]. 
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Because the antiviral mechanisms of ACV and penciclovir are similar, resistance to one of these 
agents has an impact on the other drug as well [105].  
Foscarnet: 
The similarity of ACV and penciclovir is the reason why foscarnet, with the chemical name 
phosphonoformic acid (PFA), is used as a second in line drug. It inhibits the viral DNA 
polymerase by mimicking the structure of pyrophosphate and therefore blocking the 
pyrophosphate-binding site during DNA chain elongation without being incorporated. It does 
not belong to the nucleoside or nucleotide analogues. During its mode of action, it is 
independent from viral and cellular kinase activation in contrast to ACV. In addition, compared 
to host cellular enzymes foscarnet shows a 100-fold increase against viral derived enzymes 
[106]. The drug is supplied intravenously and it is associated with nephrotoxicity and 
hemoglobin disturbances [107]. 
Cidofovir: 
Another second line therapy is cidofovir, which has a very broad antiviral mechanism of action 
against several DNA viruses. It consists of an acyclic phosphonate nucleotide analogue. Here 
an initial phosphorylation of the viral kinase is not required because it has already a single 
phosphate group attached. It is sequentially phosphorylated to its active triphosphate form 
by the cellular kinases. As a consequence, cidofovir selectively inhibits the viral DNA 
polymerase due to the 25- to 50-fold greater affinity compared to the cellular one [108] [109] 
[110]. 
New drugs: 
New drugs target different sides of the virus life cycle. 1-docosanol for example is a 22-carbon-
long saturated fatty alcohol, which prevents the fusion of the viral capsid with the host cell 
membrane and is used topically against recurring labial herpes infections [111]. Another 
current approach of special novel small molecules, which are currently in development, 
belongs to the class of helicase-primase inhibitors. This class of inhibitors are based on the 
viral helicase-primase enzyme complex, which is essential and has no eukaryotic homologue. 
Thus it is a very interesting target for novel drugs against HSV [101]. The two most promising 
helicase-primase inhibitors are amenamevir and pritelivir [112] [113]. 
Since current treatments of HSV infections generally show limited efficacy, new and more 
competent antiviral drugs are needed. Especially for immunocompromised patients with a 
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higher probability of developing an acyclovir resistant HSV infection, therapies with an 
increased oral bioavailability, less toxic effects, and higher efficacy are urgently needed. 
1.2.2.7. Antiviral drug resistance of HSV 
Although drugs against HSV are widely used, the prevalence of resistance in 
immunocompetent hosts is less than 1%. In contrast, 3.5% to 14% of immunocompromised 
hosts are affected by drug-resistant HSV infections (reviewed in [17]).  
Two genes of HSV are currently targeted by approved antiviral therapy: either the UL23 gene 
encoding the 376-amino-acid (aa) HSV TK protein or the UL30 gene encoding the HSV DNA-
polymerase enzyme. Since the TK protein is dispensable, the probability of gene mutations in 
this gene is 95% in contrast to the essential UL30 gene [114] [115]. TK mutations can lead to 
different outcomes like TK-negative or -low-producer mutants, which show no or reduced TK 
activity. In the minor cases, the mutation leads to TK-altered mutants, which are able to 
circumvent phosphorylation of ACV or PCV [116] [117]. The essential sites for enzyme activity 
are the nucleoside-binding site, the ATP-binding site, one cysteine at codon 336, which is 
responsible for the structure of the active site, and six highly conserved domains [118]. The 
DNA polymerase consists of 1235 aa with eight conserved regions, whereas the regions 
associated with resistance are most likely region II and III [119] [114]. Since in general the UL23 
gene and the UL30 gene reveal a polymorphism pattern, it is not easy to differentiate between 
mutations having no influence and mutations leading to resistance [99]. Most of the resistant 
viruses show cross resistance to other nucleoside analogues and even resistance to both ACV 
and foscarnet can been found [120] [121] [122]. 
1.2.2.8. Assays for HSV drug resistance 
As described in the last chapter, in case of detecting HSV resistance in patient isolates, 
genotypic tests reveal only already characterized mutations. If treatment failure points toward 
resistance development, a phenotypic test should be performed to define a possible 
responsive drug for counselling and management of the patient. 
The “gold standard” for phenotypic determination of antiviral susceptibility of HSV-1 and 
HSV-2 isolates is definitively the plaque reduction assay (PRA). For testing the antiviral drug 
effect on HSV, the appropriate patient-derived clinical specimen has to be propagated in a 
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cultured cell line. Afterwards, the viral inoculum is grown in the presence of serial dilutions of 
the applicable drug. The time needed to make a defined statement due to viral plaque 
numbers is usually 2-3 days. For manual counting of the single plaques, the cells have to be 
fixed and stained. All in all, a final conclusion about the susceptibility of an isolated virus takes 
3-7 days [123]. The disadvantage of this method is that it is time-consuming, labor intensive, 
and due to its manual read out, the results are very subjective. 
Alternative methods are evaluating the antigen expression after virus multiplication in vitro, 
like the sandwich enzyme-linked immunosorbend assay (ELISA) or the microplate in situ ELISA 
called MISE [124] [125] [126]. Other established methods are based on DNA hybridization 
[127] or fluorescence activated cell sorting (FACS) analysis of late gene expression [128]. A 
similar method like PRA is a genetically marked Vero cell line that responds to HSV infection 
with β-Galactosidase expression [129]. The DNA reduction assay (DRA) combines pre-cultured 
clinical samples treated with antivirals and nucleic acid detection with HSV-1 specific 
quantitative real-time PCR by measuring the viral DNA concentration in the cell lysates. The 
cell count and lysis are corrected via beta-globin PCR [130]. 
1.2.3. Human adenoviruses and their replication 
Adenoviruses (Ad) were detected in human tonsils and adenoids in tissue culture in 1953 by 
Wallace Rowe and Robert Huebner when they were searching for the causative agent of 
‘common cold’ [131]. In general adenoviruses are important pathogens of human and animals. 
Furthermore, they are very interesting as vectors for gene therapy. 
According to the ICTV, the family of Adenoviridae consists of 5 genera: Atadenovirus (infecting 
a broad range of hosts like ovine and bovine), Aviadenovirus (infecting birds), Ichtadenovirus 
(the only species infecting sturgeons), Mastadenovirus (infecting mammals) and Siadenovirus 
(infecting birds and frogs). The genus of Mastadenovirus consists of 36 species infecting 
different mammals, including the 7 species of human adenovirus species, currently coined 
Human mastadenovirus A-G. The human adenovirus species consist of different serotypes. All 
in all up-to-date 71 different human adenovirus serotypes were described [132] [35]. The 
classification is based on classical serotyping via neutralization testing and hemagglutination 
patterns among other biological attributes [133] [134].  
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The transmission route of human Ad ranges from physical contact to aerosol spread. In 
general, the virus shows a high stability outside the host and can still be infectious after several 
weeks at room temperature or after one week at 36°C [135]. Human Ad are the causative 
agent of a multitude of diseases including respiratory infections, gastroenteritis and epidemic 
keratoconjunctivitis [136] [137] [138]. The different Ad serotypes and their specific tropism 
are summarized in Table 1.2.3.1. Dependent on serotype of the infecting human Ad and the 
immune status of infected individuals, the disease manifestation varies from mild localized 
lesions to life-threatening disseminated diseases. Like in the case of HSV infections, the 
frequency of diseases caused by human Ad increases in immunocompromised patients, like 
allogeneic hematopoietic stem cell recipients, solid organ transplantation recipients, or bone 
marrow recipients [139] [140]. 5–47% of immunocompromised patients were found to be 
infected with Ad and out of these, 6–70% died [141]. In immunocompromised children, the 
mortality rate is even greater than 50% [142].  
Table 1.2.3.1: Differentiation of human adenovirus types by species and tropisms. 
Species Type Tropism 
A 12, 18, 31 Enteric, respiratory 
B1 3, 7, 16, 21, 50 Respiratory, keratoconjunctivitis 
B2 14, 11, 34, 35, 55 Renal, respiratory, 
keratoconjunctivitis 
C 1, 2, 5, 6, 57 Respiratory, keratoconjunctivitis, 
hepatic, lymphoid 
D 8-10, 13, 15, 17, 19, 20, 22-30, 32, 
33, 36-39, 42-49, 51, 53, 54, 56, 70 
Keratoconjunctivitis, enteric 
E 4 Respiratory, keratoconjunctivitis 
F 40, 41 Enteric 
G 52 Enteric 
Since for human Ad it was shown that the virus is able to be excreted after acute infection for 
several months or years, it is suggested that Ad is able to establish a persistent infection [143]. 
This point is supported by the ability of adenoviruses to infect the urinary tract, lymphatic 
tissues, like tonsils and adenoids, and the gastrointestinal tract permanently [144] [145] [146]. 
1.2.3.1. The organization of the adenovirus genome 
The genome of Mastadenovirus genus consists of a linear double-stranded DNA of 34-36 kbp, 
which has two inverted terminal repeats (ITRs) on both ends of the genome as well as a 
terminal protein (TP) covalently linked to the 5’ end of the ITR at each strand [147].  
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The genomes of Ad are organized in 8 units transcribed by the RNA polymerase II, which are 
located at both DNA strands (Figure 3). The transcription units are temporally regulated and 
can be divided into: five early genes expressed before onset of DNA replication (E1A, E1B, E2, 
E3, E4); the delayed early genes expressed independent of DNA synthesis (IX and Iva2); and 
one late transcription unit expressed after replication of Ad DNA (L1-L5) [148]. Additionally, 
there are two RNA polymerase III dependent transcription units encoding virus-associated 
RNAs I and II (VAI and VAII RNAs).  
 
Figure 3: Genome organization of human adenovirus.  
Black arrows highlight early protein gene regions, blue arrows indicate delayed early genes, green 
arrows show late transcription units and red arrows denote the VA-RNA I and II. Adopted from [149]. 
 
In principle, the human Ad life cycle can be divided in an early and late phase. In the early 
phase, regulatory proteins are expressed. Regulatory proteins are responsible for activating 
transcription of other viral genes, for avoiding antiviral host mechanisms, and for altering host 
protein expression. The first transcription unit expressed shortly after cell entry is the E1A 
gene. The two major proteins encoded by E1A are transcription modulators and force the host 
cell to enter the S-phase [150] [151]. The gene products of E1B are the proteins called 19K and 
55K, which both prevent apoptosis of the host cell by inhibiting the tumor suppressor protein 
p53 as well as using p53-independent apoptosis [152] [153]. From the two early regions E2A, 
three proteins are encoded by alternative splicing: TP, which is responsible for a unique 
protein-priming mechanism, the DNA polymerase, and the ssDNA binding protein (DBP) [154] 
[155] [156]. Proteins encoded by E3 have immunomodulatory functions [157]. The gene 
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products of the E4 gene, which encodes 18 distinct mRNAs due to alternative splicing 
mechanisms, are associated with DNA replication, transcription and in the regulation of cell 
cycle signaling [158] [159]. The VA RNAs are responsible for inhibition of the interferon-
induced PKR  and for the block of cellular micro-RNA machinery [160] [161]. As soon as all 
proteins responsible for viral DNA replication are synthetized, the late phase starts with DNA 
replication on the one side and transcription of late virus genes on the other side. The late 
viral genes encode the structural proteins and the proteins that are necessary for the 
maturation of viral particles [162].  
1.2.3.2. Adenoviral DNA replication  
The DNA replication of human Ad depends on a unique mechanism among viruses. It starts 
between 5 to 8 hours after infection of the cell. The DNA replication is catalyzed by the viral 
DNA polymerase (POL) and involves other essential viral components such as the pre-terminal 
protein (pTP), which forms a heterodimer with the POL. The DBP is the viral single strand 
binding protein and essential in stabilization of replication intermediates [163] (Figure 4). The 
initiation of the process starts when a deoxycytidine monophosphate (dCMP) is covalently 
linked to the pTP serine hydroxyl group by the adenovirus polymerase [164]. The pTP has a 
high affinity for ssDNA. In presence of the two cellular factors octamer-binding transcription 
factor-1 (Oct-1) and nuclear factor-1 (NF1), it binds to the origin of DNA replication and 
functions as a primer for replication [165] [166]. The DBP most likely plays a key role for the 
unwinding of the DNA,  although the full mechanism has not yet been understood [167]. Then 
a 5’ to 3’ elongation process starts and the new growing strand displaces the old one [168]. 
Subsequently, the new dsDNA serves as template for the following replication rounds. In a 
second step, the displaced single strand, which is protected by DBPs, forms a panhandle 
structure by hybridization of the complementary sequence of the two ITRs. The strand 
synthesis is then primed by new pTP binding and takes place in the same way as the 5’ to 3’ 
strand synthesis [169] [170]. DNA replication is finalized by a viral protease cleaving pTP to TP. 
The resulting progeny DNA is finally packaged into the virion [171]. The protein priming and 
the missing lagging strands (and Okazaki fragments) clearly differentiate the human Ad 
replication machinery from the mammalian DNA replication as well as for the replication 
strategy of most DNA viruses. 
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Figure 4: Adenovirus genome replication.  
Terminal protein precursor (pTP) and viral DNA polymerase form a heterodimer. This binds to viral 
DNA and induces DNA replication by priming. During elongation process, one strand is displaced by 
new synthesized DNA and protected from degradation by binding of DNA binding Protein (DBP). 
Panhandle structure is formed by hybridization and second strand is synthesized. Figure reprinted from 
ViralZone with permission [172]. 
1.2.3.3. The adenovirus virion 
Ads consist of icosahedral particles of about 90 to 100 nm in size, which are composed of 13 
structural proteins denoted by roman numerals (II-X). The 252 capsomeres comprise the 
major structural component: the trimeric hexon proteins and 12 pentons, consisting of a 
pentamer and a penton base. There is a trimeric fibre protein at each capsid vertices 
projecting from the penton base that mediates the initial attachment to the host cells. Species 
C Ad enter the host cell via the primary coxsackie B virus and adenovirus receptor (CAR) on 
the cell membrane [173]. Although most Ad species are able to bind CAR, they primarily use 
several additional receptors: CD46 as well as the cadherin protein Desmoglein-2 (DSG-2) and 
the sialic acid-containing proteins were identified as entry receptors for different Ad species 
[174]. Subsequently, the penton base promotes interaction with cellular αv integrins, causing 
the entry of the virus via clathrin-mediated endocytosis. Other minor components of the 
capsids are IIIa, VI, VIII and IX. After internalization within the endosomes, the acidification 
leads to the release of the dismantled virus particle due to disruption of the endosomal 
membrane by protein pVI [175]. Inside the capsid, the viral double-stranded DNA genome is 
associated with five basic polypeptides: V, VII and X (also called Mu), which form the virus 
core, Iva2, responsible for genome packaging and the TP [149]. After transportation along the 
microtubules, the viral DNA is imported into the nucleus where DNA replication of the virus 
takes place [162] [176]. Since translation to proteins occurs in the cytoplasm, but the assembly 
Introduction 
20 
of progeny occurs in the nucleus, protein VI serves to shuttle the proteins over the nuclear 
pore complex back into the nucleus [177]. There, assembled virions with the packaged DNA 
must go through a maturation process by processing several viral proteins with the viral 
cysteine protease [178]. As the nucleus finally is fully packed with virions, the cytoskeleton is 
disrupted leading to rounding up of cells and in the end to cell lysis [179] [180]. 
1.2.3.4. Induction immune cascade 
Human Ad infection induces release of type I interferons (IFN) in infected cells: IFNα and IFNβ, 
which cause an antiviral state in neighboring cells [181] [182]. At the level of the host, 
however, the immune response upon symptomatic Ad infection is initiated by the release of 
proinflammatory cytokines IL-6, IL-1β and additionally the tumor necrosis factor alpha (TNF-
α) into the bloodstream. Other important innate immune mechanisms include the activation 
of cytotoxic immune cells [183]. Macrophages are attracted at first to different infected 
organs. They are trapping the invading viruses and play an important role in preventing 
viremia and systemic spread of Ad infection [184] [185] [186]. Further cytotoxic innate 
immune cells are chemo-attracted by different macrophage-derived cytokines and 
chemokines, whereby IL-1α/IL-1R1 pathway is the most important [187]. The adaptive 
immune response plays a crucial role in controlling the dissemination of adenovirus infection. 
Both humoral and cytotoxic adaptive immune mechanisms are involved in humans to contain 
adenovirus infection. It is believed that the serotype-specific antibody response is protective 
against reinfection with the same serotype. 
1.2.3.5. Antiviral drugs against adenovirus infections 
Until now, no approved drug against Ad is available and therefore only broadly active antivirals 
such as cidofovir or ribavirin are used in therapy of adenoviral diseases. Cidofovir acts as an 
Ad DNA replication inhibitor by mimicking a triphosphate nucleotide substrate for Ad DNA 
polymerases after activation by cellular kinases (see also 1.2.2.6). It is active against all species 
of human adenoviruses in vitro. Several clinical case studies have already indicated an efficient 
treatment of acute adenoviral keratoconjunctivitis as well as adenoviral infections in 
immunocompromised children and adults with cidofovir [188] [189] [190] [191] [192]. It was 
shown that the time point of treatment after infection plays a key role concerning the antiviral 
efficacy of cidofovir [193]. Additionally, combination-therapies with e.g. intravenous 
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immunoglobulin therapy (IVIG) demonstrate promising results [194]. The disadvantage using 
cidofovir for therapy of adenovirus infections is a high rate of non-responders and a limited 
oral bioavailability. This is the reason why an intravenous administration is necessary. 
Moreover, cidofovir tends to be accumulated in renal tubule cells to toxic levels and therefore 
this drug is associated with nephrotoxicity [195] [196]. 
Another broad-spectrum antiviral agent, which is used against both RNA and DNA viruses, is 
ribavirin. In vitro activity is shown mainly against Ad of species C, which is the clinically most 
relevant species in humans [197]. It is a purine nucleoside analogue, but up to now, there has 
been no consensus about the mechanism of action that would explain the major antiviral 
activity of ribavirin [198]. According to the “European guidelines” ribavirin is not an approved 
drug for the treatment of Ad infections since it failed to show consistent activity against 
various different Ad serotypes.  
A new anti-Ad therapy showed a major advantage in recent years, concerning upcoming drugs 
against Ad: Brincidofovir (3-hexadecyloxy-1-propanol-cidofovir), developed by Chimerix, 
received Fast Track designation from the FDA for the treatment of Ad, CMV and smallpox virus. 
In addition, it obtained Orphan Medicinal Product Designation from the European Commission 
for the prevention of Ad- and CMV-disease. Brincidofovir (previously named CMX001) is a 
lipid-linked derivative of cidofovir and can be orally administered because of a lipid moiety. 
The drug is cleaved only within the cells to Cidofovir and cannot exit cells readily. Since it is 
not transported by an organic anion transporter, it does not show any nephrotoxicity because 
there is not re-accumulation in renal tubules [199] [200]. 
Patients suffering from T-cell-specific diseases, such as T-cell-depleted grafts, severe 
lymphopenia, and hematopoietic stem cell transplantation, especially associated in children, 
have a high risk for fatal Ad infections [201]. Successful treatment with Ad-specific cytotoxic 
T-lymphocytes from donors (CTL) have been reported [202] [203]. 
1.2.3.6. Assays for virus resistance 
Failing to control Ad infections in risk groups with systemic Ad infection occurs frequently. A 
timely start of monitoring human Ad loads, especially in vulnerable patient groups, is 
important to prevent progression of invasive and disseminated diseases and to control the 
susceptibility of Ad in immune compromised patients [204]. The role of viral resistance 
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development in these therapy failures is unknown. Detection methods for different Ad 
serotypes include quantitative PCR (qPCR), Ad-specific viral antigen assays, and viral culture. 
Evaluation by real time PCR is a fast and easy-to-handle test. However, the current lack of 
broad knowledge concerning the drug resistance mutations in Ad does not allow genotyping 
of resistance. A reliable phenotypic resistance test is an urgent need in the field to generate 
the information pool needed for the genetic approaches. The basis of the current standard 
phenotypic tests, the culture of Ad, is work and time intense. It can take one to four weeks. 
Additionally, in some cases, the viral isolate does not grow well in cell culture [205]. 
For evaluation of new anti-Ad-targets it is important to have a cell culture model for screening 
the antiviral activity of a certain compound. The most commonly used methods for in vitro 
antiviral assays in the case of Ad are: the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT)-based method, the plaque assay, the yield reduction assay, and the real-time 
PCR. These methods can be applied at any step of the viral replication cycle [206] [207]. Also, 
several other methods can be used like non-replicative vectors with a reporter gene, as well 
as other cell-based assays that concentrate on specific steps of the Ad life cycle. Furthermore, 
biosensor method using capacitance sensor arrays, computation method and animal model 
can be used for detection of Ad [208]. 
1.3. Replicon-based reporter systems in virology 
Replicons are genetic elements that are amplified by virus infection. In general, they are 
comprised of a viral origin of replication (ORI) and a transgene. The ORI itself is the starting 
point of DNA- or RNA-replication. The dependence of the initiation of replication on certain 
viral elements, which are missing from the replicon itself, is the key factor for the specificity 
and the inducibility of replicon systems. As a consequence, the transgene is only expressed, if 
this deficiency is rescued by a co-infecting complementation proficient virus. These systems 
can provide platforms for new viral vaccines, specific detection system of infectious RNA 
viruses, drug susceptibility testing, studies on viral replication, and pathogenesis [209] [210] 
[211] [212]. 
Especially in the field of RNA virus research and diagnostics, replicon-based systems are 
already playing important roles as specific live cell-based reporter systems for detection of 
infectious particles. In contrast to traditional diagnostic tools, replicon-based reporter systems 
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have the advantage of a great sensitivity towards infectious viruses and are furthermore a 
robust, fast, cost effective, and specific technology [213]. They can easily be applied for testing 
of potential new antiviral inhibitors in a high throughput format. 
Unlike RNA viruses, replicon-based reporter vectors for DNA viruses are more difficult to 
establish due to the challenges of viral DNA delivery into the nucleus and the dependence of 
the DNA virus transcription on the host RNA polymerases. Until now, only one replicon-based 
gene expression system for a DNA virus was published [214]. 
1.3.1. RNA virus replicon systems 
RNA virus replicons have the advantage that replication and transcription of the genetic 
information are mainly confined to the cytosol. If nuclear localization was needed, the 
transgenes could not be transcribed by the host RNA polymerases. The replicons derive from 
either positive- or negative-strand RNA viruses with at least one essential gene deletion. 
Besides the viral ORIs and the transgene, the RNA virus replicons normally encode for the 
specific RNA replicase and many viral co-factors too. RNA replicons can be used for several 
approaches such as trans-complementation of essential viral genes, for tracking of viral 
infections, and for the production of recombinant viruses [211]. 
1.3.2. DNA virus replicon systems  
The only published DNA virus-based replicon vector is specific for the murine CMV (MCMV) 
replication. It is based on an episomal vector and constitutes a conditional gene expression 
system that depends on viral DNA replication. The true-late genes of herpesviruses are only 
expressed after onset of lytic DNA replication and silenced in the absence of tightly regulated 
viral factors [214]. For the construction of the MCMV based replicon vectors, an episomal 
transgene was coupled to the MCMV origin of lytic replication (oriLyt). Since the oriLyt is 
activated upon a MCMV infection, the transgene expression relies on a co-infection of the cell 
with a wild-type MCMV. While the reporter gene expression is silenced in the absence of a 
lytic MCMV infection, an active infection leads to an induction of the transgene expression by 
more than 1000-fold. Mohr et al. used this mechanism as a tool for effective complementation 
of toxic viral late genes without the need of an additional inducer. Furthermore, the MCMV 
replicon-based vector could be exploited in vitro for intracellular immunization against MCMV 
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infection. In principle, the MCMV replicon vector shows a virus dose dependent induction of 
the transgene and therefore is able to provide a quantitative reporter tool for productive 
MCMV infection [214]. The disadvantage of the MCMV replicon system is that it is dependent 
on host histone-deacetylase-induced silencing process for optimal inducibility and therefore 
specific stable cell lines have to be generated for each application. Moreover, the published 
strategy could not be applied to human CMV (Zsolt Ruzsics, personal communication). 
1.4. Adeno-associated virus as basis for a replicon vector 
The Adeno-Associated Viruses (AAV) replicate only when the host cells are infected by another 
DNA virus. This natural switch built into the AAV’s genetic system provided a promising 
platform to develop a replicon system responding to DNA virus infections. 
1.4.1. Adeno-Associated Virus and their replication 
In 1965, a small parvovirus was discovered as contamination of an Ad preparation and was 
therefore named adeno-associated virus [215]. This virus belongs to the Parvoviridae family, 
which has been isolated from many species, including humans. The genus to which the AAV is 
assigned to is named Dependovirus because it does not productively infect cells in vitro 
without a coinfection by a so-called helper virus. Viruses, known to serve as helper viruses for 
AAV are Ad, many herpesvirus strains like HSV-2 [216], HCMV [217], VZV [218] EBV, HHV6 
[219] and pseudorabies virus (PrV) [220]. Other virus families, like human papillomavirus 
(HPV) [221] or an insect virus called baculovirus [222] were also shown as inducers of AAV 
productive cycle. Vaccinia virus is known as a sub-helper for AAV replication and packaging 
but fails to activate AAV promoters [223]. 
AAVs have a non-enveloped, icosahedral capsid of about 20-26 nm in diameter. Their genome 
consists of a linear, single-stranded DNA with approximately 4.7 – 6 kb. 13 human- and 
primate- specific AAV serotypes are currently known and the seroprevalence within the 
human population is very high (about 80%) [224]. Although no disease or pathogenic 
properties could be associated to AAV infections, the virus can be readily isolated from many 
different human samples. CD3+ T lymphocytes were recently suggested as putative site of AAV 
persistence in humans [225]. 
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1.4.1.1. AAV genome organization 
The AAV particles carry a single stranded 4.8 kbp large linear DNA genome. At each end of the 
genomes, there are identical ITRs of about 150 bp, which form secondary structures by base 
pairing with one another [226]. The cis elements in the ITRs are necessary for AAV replication 
and for packaging of the AAV genome into the capsids [227]. Within the ITRs there are 3 open 
reading frames (ORFs), which encode the non-structural Rep gene, the structural Cap gene, 
and the assembly activating protein (AAP) gene [228]. Via unspliced and single-spliced forms, 
two out of four mRNAs encoding for the Rep proteins are transcribed by 2 different promoters 
and by additional alternative splicing of either transcript. All in all, the Rep gene encodes for 
four different proteins: Rep78 and Rep68, which are regulated by the promoter p5; Rep52 and 
Rep40 where transcription of both is activated by p19. Rep68 is the truncated version of Rep78 
and Rep40 the one of Rep52 [229]. The Rep gene product is important for regulation of viral 
transcription, replication, encapsidation, integration of viral genome into the host 
chromosome, rescue from the latent state, and packaging of DNA. 
The p40 promoter regulates the Cap gene that encodes the three structural proteins VP1, VP2 
and VP3, all residing in the same reading frame [225] [230]. Responsible for the activation of 
p40 are the two larger Rep proteins in the presence of essential factors provided by large DNA 
viruses (see 1.4.1.3) [231] [232]. A nested alternative ORF within the Cap gene encodes an 
assembly-activating protein (AAP). A nonconventional start site initiates its translation [228]. 
1.4.1.2. Latent infection of AAV 
In the absence of an additional helper virus, AAV establishes a latent state in its host cell. This 
is either characterized by chromosomal integration, mostly within the AAVS1 site located on 
the human chromosome 19, or by persistence in an extrachromosomal ds DNA episome [233] 
[234]. After entering the cell, the single stranded DNA is completed to a double stranded DNA 
in the host cell nucleus. Within the ITR there is a Rep-binding site (RBS) that allows binding of 
the two large Rep proteins of AAV [235]. Rep68 and Rep78 exhibit endonuclease activity, 
which is needed for unwinding the DNA and integration of a single-stranded DNA nick nearby 
a specific terminal resolution site (TRS) at the ITR [236]. In the AAVS1, a homologous DNA 
sequence to the RBS was found. This 33 bp sequence is sufficient for AAV integration and 
encompasses the RBS and the TRS element [237]. 
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1.4.1.3. Productive replication cycle of AAV 
Suitable conditions such as the infection of the same cell with a defined helper virus or, to a 
much lower extend, due to metabolic inhibitors, UV irradiation or genotoxic compounds lead 
to an initiation of a lytic replication cycle of AAV [238]. If the AAV genome is latently integrated 
into the host genome, the induced Rep gene products lead to its rescue [239]. As starting 
point, AAV p5 and p19 promoters are trans-activated by specific viral helper factors [240] 
[241]. As a consequence, the expression of the large Rep proteins lead to the replication of 
the AAV genome [242]. AAVs replicate their genome over unidirectional strand-displacement 
replication (Figure 5) [243] [244] [245]. Two motifs within the ITRs are important for 
replication: the TRS and the RBS. The ITRs have the ability for self-annealing and therefore 
build secondary structures on both ends of the genome, which provide unidirectional DNA 
synthesis due to a base-paired 3’OH group. Then, the replication of the AAV strand is done 
dependent on the infecting helper virus by either the viral or the cellular DNA polymerase with 
support by cellular proteins, which are involved in this process. As soon as the DNA template 
is copied, the terminal resolution step is initiated by binding of the Rep proteins at the RBE 
within the ITRs on both ends of the AAV genome. Their endonuclease activity is responsible 
for introducing a site-specific single stranded nick at the TRS. This leads to a free 3’-OH serving 
as a primer for new DNA synthesis [246]. The additional helicase activity provided by the REP 
proteins is another function in the replication process and is important for rendering the TRS 
site to single-stranded and therefore providing the access for introducing the nick into the TRS 
[236]. As a result, a double stranded full length AAV genome as well as a single stranded full 
length AAV displacement product is generated [247].  
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Figure 5: AAV Genome Replication.  
Model of ssDNA replication of AAV genome showing the steps that lead to generation of multiple AAV 
genome copies. Illustration taken from [246]. 
The transcription of the AAV capsid proteins is controlled by p5 dependent Rep proteins in the 
presence of helper virus. Here, the binding of the cellular factor Sp1 to the larger Rep proteins 
promotes induction of the p40 promoter. In the presence of helper virus functions and wild-
type AAV Rep proteins, there are three sequence elements essential for p40 promoter activity: 
the two Sp1 binding sites at -50 (Sp1-50) and -70 (GGT-70) bp upstream of the start of p40 and 
the TATA-box at -30. Another important element for maximal Rep mediated p40 activation is 
the CARG-like element at -140 in the p19 promoter, which cooperates with the Sp1-50 site of 
the p40 promoter [232] [231]. 
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After the expression of the capsid proteins, the AAP protein directed capsid assembly takes 
place in the nucleus and genomes with both positive and negative polarity are packaged into 
the preformed AAV particles by assistant of the small Rep proteins Rep52 and Rep40 [227]. 
1.4.1.4. Ad helper functions for productive AAV replication  
A productive AAV replication is dependent on helper functions by different helper viruses. 
Isolated adenoviral gene products that are able to induce AAV replication are E1A, E1B, E2A, 
E4ORF6, and the VA-RNA [248]. The different Ad proteins reveal different tasks: E1A is needed 
for the activation of the AAV promoters as transcription factor, for driving the host cell into S-
phase of the cell cycle and stabilization of p53, which leads to apoptosis [249] [241]. The E2A 
encoded protein DBP binds the ssDNA of AAV together with Rep gene products in the nuclear 
replication centers and serves for viral DNA replication and furthermore for viral mRNA 
processing and export [250] [251] [252]. It is also important for activating p5 transcription of 
AAV [253]. By inhibiting the interferon-inducible eIF-2 protein kinase, the Ad derived VA-RNA 
circumvents this cellular anti-viral mechanism, which would block AAV protein translation 
[254] [255]. E1B55K together with E4ORF6 prevents apoptosis and counteracts E1A by forming 
a complex with p53 that leads to degradation [256] [257]. Furthermore, the two proteins form 
a heterodimer in order to export AAV and Ad late mRNAs from the nucleus and at the same 
time to inhibit the transition of Ad early genes as well as cellular mRNAs [258]. In case of Ad 
induction, the DNA polymerase responsible for AAV replication is of cellular origin [259]. 
1.4.1.5. HSV helper functions for productive AAV replication  
Opposed to Ad, HSV-1 helper functions are directly involved in AAV genome replication. As 
helper functions for AAV, the ternary HSV-1 helicase/primase (HP) complex and the major ss 
DNA-binding protein ICP8 are sufficient for a productive AAV2 replication [260] [261]. For the 
initiation of AAV genome replication, ICP8 forms a ternary complex by co-localization with 
Rep78 and the AAV ssDNA within nuclear replication centers [262] [263]. In addition, a few 
other HSV-1 gene products enhance AAV replicative cycle. ICP0 protein was shown to activate 
Rep gene expression in latently AAV infected cells [264]. The proteins ICP4 and ICP22 act 
synergistically with ICP0 and therefore support the enhancing effect. Furthermore, the HSV-1 
DNA polymerase complex (UL30/UL42) was proven to increase the AAV DNA replication 
substantially [260]. Another HSV-1 protein, the exonuclease (UL12), has recently been shown 
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to intervene with AAV genome replication. UL12 increases the resolution of AAV replicative 
forms and in addition it is involved in AAV particle production [265]. 
The helper effect of HPV is dependent on E1, E2 and E6 genes, which are able to increase AAV 
replication in vitro. The main contributor was shown to be the helicase/ATPase domain of the 
carboxy-half of E1 [266] [221]. 
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1.5. Objectives 
The aim of this work was the construction of a novel replicon-based gene expression system 
based on the genome of the Adeno-associated virus. This system had to fulfill several criteria: 
 
1. Expression of the AAV replicon system transgene should be induced by wild-type virus 
infection without further modification of the viral genome. 
2. There should be no homology between the AAV-based replicon system and the 
inducing virus to avoid recombination events. 
3. Several delivery methods of the AAV replicon vector should be tested for different 
applications of the system. 
 
The newly generated AAV replicon-based system had to be tested for several applications: 
 
1. Trans-complementation of the toxic HAd5 late protein pVI by the AAV replicon vector 
should be tested in order to have a tool for studying essential viral genes in a 
chronological correct expression kinetic. 
2. A fast phenotypical diagnostic assay for detecting drug-resistance in patient-derived 
viral samples should be generated in order to decrease the treatment start time for 
the patient and furthermore to get the most effective therapy according to the 
sensitivity of the infecting virus. 
3. A drug susceptibility test system should be established in order to test new drugs 
against herpes- and adenoviruses in a high-throughput screening format ensuring 
reliable quantitative results for data analysis. 
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2. Material 
2.1. Devices 
BD FACSCanto™ II Biosciences, San Jose, CA, USA 
Biofuge Pico Heraeus Centrifuges, Buckinghamshire, E 
Bio-Photometer Eppendorf, Hamburg, D 
CASY® cell counter Schärfe System, Reutlingen, D 
Centrifuge 5417 R Eppendorf, D 
Centrifuge AvantiR J-26 XPI Beckman Coulter GmbH, Krefeld, D 
Centrifuge AvantiTM J-20 XP Beckman Coulter GmbH, Krefeld, D 
Fluorescence microscope DMI4000B Leica, Wetzlar, D 
Gene PulserTM Bio-Rad, D 
Incubator B5050E Haereus instruments, D 
Incubator BB16CU Haereus instruments, D 
Bakterienschüttelschrank Certomat BS1 Satorius, Göttingen, D 
Light Cycler ® 2.0 Roche, Mannheim; D 
Light microscope Axiovert 40L Zeiss Carl AG, D 
Magnetrührer RCT basic  IKA® Labortechnik, D 
Microplate Luminometer XFluor4_V4_51 Tecan, Grödig, A 
Multifuge 3 S-R Heraeus Centrifuges, Buckinghamshire, E 
Multikanalpipette, 12-Kanal (100 µL, 30-300 µL) Eppendorf, Hamburg, D 
NanoDrop™ ND-1000 Spectrophotometer Peqlab, Erlangen, D 
NanoPhotometer® P-Class P330 Implen, Westlake Village, USA 
Optima LE-80K Ultracentrifuge Beckman Coulter GmbH, Krefeld, D 
PH-Meter 430 Cornig, Miami, USA 
Photo documentation apparatus Bio-rad, München, D 
Shaking water bath GFL 1092 Burgwedel, D 
T Gradient PCR Machine Biometra, Göttingen, D 
Thermomixer 5436 Eppendorf, Hamburg, D 
Vortex-Mixer M51 IKA® Labortechnik, D 
2.2. Consumables 
96 well plate flat CC ST W/Lid Thermo Electron, Langenselbold, D 
Caesium Chloride Disposable PD 10 Desaltin Sigma-Aldrich, Deisenhofen, D 
CASYcups OLS OMNI Life Science 
Cell culture dish (20 cm2; 55 cm2; 145 cm2) Corning, Durham, USA 
Cell culture plate (6-, 12-, 24-, 48-, 96-well) Corning, Durham, USA 
Cell scrapers Costar, Bodenheim, D 
Combitips plus (5 mL, 10 mL) Eppendorf, Hamburg, D 
CryoTube™ Vials nunc, Langenselbold, D 
Electroporation cuvettes Bio-Rad, D 
epDualfilter tips (2-100 µL; 20-300 µL) Eppendorf, Hamburg, D 
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Eppendorf tubes Eppendorf, Hamburg, D 
Falcons conical tubes (15 mL, 50 mL) Becton Dickinson, Heidelberg, D 
Inoculation Loops Sarstedt, Nürnbrecht, D 
LightCycler® Capillaries (20 µL) Roche, Mannheim, D 
Mikroschraubenröhre 0.5 mL Sarstedt, Nürnbrecht, D 
Pipettes (5 ml, 10 ml, 25 ml) Kuhnle, Karlsruhe, D 
Reaction tubes (0.5 mL, 1.5 mL, 2 mL) Eppendorf, Hamburg, D 
Ultracentrifugation tubes Beckman Coulter GmbH, Krefeld, D 
2.3. Reagents and biochemicals 
Acetone Roth, Karlsruhe, D 
Acetic acid Sigma-Aldrich, Deisenhofen, D 
Acycloguanosine Sigma-Aldrich, Deisenhofen, D 
Agar BD Falcon™, D 
Agarose Thermo Fisher Scientific, MA, USA 
Alcaline Phosphatase (CIP) NEB, Frankfurt/Main, D 
Ammonium sulfate (> 99.5%, p.a.) Fluka Chemie, Buchs, CH 
Ampicillin Sigma-Aldrich, Deisenhofen, D 
Bacto™ Agar Becton Dickinson, Heidelberg, D 
Bacto™ Tryptone Roth, Karlsruhe, D 
Bacto™ Yeast Extract Becton Dickinson, Heidelberg, D 
Benzonase® Nuclease Sigma-Aldrich, Deisenhofen, D 
Boric acid Sigma-Aldrich, Deisenhofen, D 
Carboxymethyl Cellulose Sodium Medium Sigma-Aldrich, Deisenhofen, D 
Cell culture lysis reagent (5x) Promega, Madison, USA 
Cesium chloride, Optical Grade Sigma-Aldrich, Deisenhofen, D 
Chloramphenicol Sigma-Aldrich, Deisenhofen, D 
DMEM-Dulbecco’s Modified Eagle 
Medium 
Thermo Fisher Scientific, MA, USA 
DNA ladder (100 bp, 1 kbp) NEB, Frankfurt/Main, D 
dNTPs NEB, Frankfurt/Main, D 
Ethanol Roth, Karlsruhe, D 
Ethylen-Diamin-Tetra-Acetic acid (EDTA) Fluka, Karlsruhe, D 
Fetal calf serum (FCS) PAN-Biotech, Aidenbach, D 
Fomaldehyde Roth, Karlsruhe, D 
Foscarnet sodium hexahydrate Sigma-Aldrich, Deisenhofen, D 
FuGene® HD Transfection Reagent Promega, Madison, USA 
Glycerin Roth, Karlruhe, D 
Glycin Roth, Karlsruhe, D 
Hepes (1M) buffer Thermo Fisher Scientific, MA, USA 
Hygromycin B solution Sigma-Aldrich, Deisenhofen, D 
Isopropanol Merck, Darmstadt, D 
Kanamycin Sigma-Aldrich, Deisenhofen, D 
L-Arabinose Sigma-Aldrich, Deisenhofen, D 
L-Glutamin Thermo Fisher Scientific, MA, USA 
Lipofectamine2000 Thermo Fisher Scientific, MA, USA 
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L-Plus Arabinose Crystalline Sigma-Aldrich, Deisenhofen, D 
Luciferase Cell Lysis Buffer NEB, Frankfurt/Main, D 
Methanol Roth, Karlsruhe, D 
Newborne calf serum (NCS) PAN-Biotech, Aidenbach, D 
Opti-MEM™ I Reduced Serum Medium Thermo Fisher Scientific, MA, USA 
PEI "Max", MW 40.000 Polysciences, Eppelheim, D 
Penecillin/Streptomycine Thermo Fisher Scientific, MA, USA 
Phenol-Chloroform Roth, Karlsruhe, D 
Phosphate buffered saline (PBS) Thermo Fisher Scientific, MA, USA 
Proteinase K Quiagen, Hilden, D 
Q5® High-Fidelity DNA Polymerase NEB, Frankfurt/Main, D 
Restriction enzymes and buffers NEB, Frankfurt/Main, D 
Sodium acetat Merk, Darmstadt, D 
Sodium chloride Merk, Darmstadt, D 
sodium dodecyl sulfate SERVA, Heidelberg, D 
SuperFect Transfection Reagent Quiagen, Hilden, D 
Tris-HCl (pH 8.0) Sigma-Aldrich, Deisenhofen, D 
Tris Sigma-Aldrich, Deisenhofen, D 
Trypsin/EDTA Solution (TE) Thermo Fisher Scientific, MA, USA 
T4 DNA Ligase NEB, Frankfurt/Main, D 
2.4. Commercial Kits 
BioLux® Gaussia luciferase Assay Kit NEB, Frankfurt/Main, D 
DNeasy™ Blood and Tissue Kit Quiagen, Hilden, D 
Dual-Luciferase® Reporter Assay System Promega, Madison, USA 
Expand High Fidelity PCR System Roche, Mannheim, D 
illustra ™ plasmidPrep Mini Spin Kit GE Healthcare, Freiburg, D 
NucleoBond® PC100 Plasmid DNA Purification Kit Macherey-Nagel, Düren, D 
Plasmid Maxi Kit Quiagen, Hilden, D 
QIAquick PCR Purification and Gel Extraction Kit Quiagen, Hilden, D 
QuantiTect SYBR Green PCR Kit Quiagen, Hilden, D 
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2.5. Culture Media for bacteriology and cell culture 
Table 2.5.1: LB medium 
LB medium 
10 g Bacto Tryptone 
5 g Bacto yeast extract 
5 g NaCl 
add 1 L ddH2O 
 
Table 2.5.2: LB agar 
LB agar 
7.5 g Agar 
in 500 mL LB medium 
 
Table 2.5.3: TE buffer 
TE buffer 
10 mM Tris, pH 8 
1 mM EDTA 
 
Table 2.5.4: TAE buffer 
TAE buffer 
40 mM Tris-HCl 
1 mM EDTA (pH 8.0) 
20 mM acetic acid 
add 1 L ddH2O 
 
Table 2.5.5: TBE buffer 
TBE buffer 
90 mM Tris 
2.5 mM EDTA (pH 8.0) 
90 mM boric acid 
add 1 L ddH2O 
 
Table 2.5.6: Freezing medium 
Freezing medium 
10% DMSO 
60% FCS 
30% DMEM 
 
Table 2.5.7: 1 x Hepes buffer 
1 x Hepes buffer 
100 mM of HEPES 
20 mM of MgCl2 
add 100 mL ddH2O 
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2.6. Oligonucleotides 
All oligonucleotides for cloning and sequencing used were either synthesized by Metabion 
(Martinsried, D) and additionally HPLC purified if the sequence exceeded 33 nt or purchased 
from GATC for sequencing directly. 
List of oligonucleotides: 
Name Comments Sequence 5’ - 3’ 
AVfor Sequencing primer for AAV 
replicon vector 
CCGTGTCAGAATCTCAACCC 
AVrev Sequencing primer for AAV 
replicon vector 
CATGCTTTGCATACTTCTGCC 
REPfor1 Sequencing primer for AAV 
replicon vector 
AGAAGCTGCAGCGCGACTTTCTGAC 
REPrev1 Sequencing primer for AAV 
replicon vector 
GGTGATCAGATCAAAAACTTCAGCCAGGTAC
ATG 
REPfor2 Sequencing primer for AAV 
replicon vector 
GAGCTGGTCGGGTGGCTCGTGG 
REPrev2 Sequencing primer for AAV 
replicon vector 
GGTGGGCAAAGGATCACGTGG 
pBR3 GATC sequencing primer for 
AAV replicon vector 
TCCCCATCGGTGATGTC 
5ITRfor Sequencing primer for AAV 
replicon vector 
GAAGTGGCGAGCCCGATCTTCCCC 
HYGfor Forward PCR primer for 
pAV1-Hyg 
GTGTGGGCCCTGTGGTATGGCTGATTATGATC
CTC 
HYGrev Reverse PCR primer for 
pAV1-Hyg inclusive a multiple 
cloning site (MCS) 
GTGTCTCGAGGACACTCTCTCTGAGCTAGCTT
CGTACGGATATCACCGGTAACTTAAGTTGCGG
CCGCGTGTGGAAAGTCCCCAGGCTCCCC 
Bgfp-rev Sequencing primer for pAV1-
GFP-Hyg 
GGACGAGCTGTACAAGTAAAGCGGCCGCGAC 
LUCfor Forward PCR primer for 
pAV1-GLuc-Hyg 
GTGTAGATCTCGGGATCCACCGGTCGCCACCT
CCGGAGGCGGCGGCTCCGAAGACGCCAAAAA
CATAAAGAAAGG 
LUCrev Reverse PCR primer for 
pAV1-GLuc-Hyg 
CTCTGGCACAAAATCGTATTCATTA 
pEGFP_N Sequencing primer for pAV1-
GFP-Hyg 
CTGGTCGAGCTGGACGG 
M13_FP GATC sequencing primer for 
pL-MTT-P and pL-SV40L-P 
TGTAAAACGACGGCCAGT 
M13_RP GATC sequencing primer for 
pL-MTT-P and pL-SV40L-P 
CAGGAAACAGCTATGACC 
AVfor2seq Sequencing primer for pAV1-
GLuc-P40M-MTT-TPL and 
pAV1-GLuc-P40M-SV40L-TPL 
GCTGCCGATGGTTATCTTCC 
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GLucrevseq Sequencing primer for pAV1-
GLuc-P40M-MTT-TPL and 
pAV1-GLuc-P40M-SV40L-TPL 
TTGTTCTCGGTGGGCTTGGC 
AVfor3seq Sequencing primer for pAV1-
GLuc-P40M-MTT-TPL and 
pAV1-GLuc-P40M-SV40L-TPL 
ATGTGGATTTGGATGACTGC 
H3-PPVIT-
zeo2 
Forward PCR primer for 
ETPCR_DELpVI 
CTGGCGGCGACATGGACGCATACATGACACA
CATACGACACGTTAGCTATTGAACTGCTGATC
TTCAGATCCTC 
H5-PPVIT-
zeo 
Reverse PCR primer for 
ETPCR_DELpVI 
TAAAAAGTCTGGACTCTCACGCTCGCTTGGTC
CTGTAACTATTTTGTAGACGTTTACAATTTCGC
CTGATGCG 
pVI-3seq Sequencing primer for pBA5-
FRT-ΔpVI 
CTCAGGTACTCCGAGGCGTCC 
pVI_5seq Sequencing primer for pBA5-
FRT-ΔpVI-zeo 
ATCCTGCCCCTCCTTATTCC 
BAC_for Sequencing primer for pBA5-
FRT- Che-ΔpVI-zeo 
GCCGTGCCGGCACGTTAACC 
pVI_5seq Sequencing primer for pBA5-
FRT- Che-ΔpVI-zeo 
ATCCTGCCCCTCCTTATTCC 
APVIfor Forward PCR primer for 
pAV1-PVI-Hyg 
GTGTGCTAGCATGGAAGACATCAACTTTGCGT
CTC 
APVIrev Reverse PCR primer for 
pAV1-pVI-Hyg 
GGGTGCAATCCCTGAAGCGCCGACGATGCTT
CTGAGCGGCCGCACAC 
 
List of real time PCR primer: 
Name Sequence 5’ - 3’ 
QGLucfor AAGTTCATCCCAGGACGCTGCC 
QGLucrev ACACTGCACGTTGGCAAGCCCT 
GAPDHfor TGGTATCGTGGAAGGACTCA 
GAPDHrev CCAGTAGAGGCAGGGATGAT 
 
2.7. Enzymes for molecular biology 
All restriction endonucleases used during this study were purchased from New England 
Biolabs (NEB) (Frankfurt/Main, D) and applied according to the manufacturer’s instructions. 
2.8. Plasmids 
pLITMUS28 NEB, Frankfurt/Main, D 
pAV1 (REF: Laughlin et al 1983) ATCC 37215 
pTRE2Hyg Clontech, Mountain View, CA, USA 
pGluc NEB, Frankfurt/Main, D 
pEGFP-N1 Clontech 
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pB45neo-F-tet Derived from pBMGNeo [267]. The papillomavirus derived sequences 
and the MTT promoter used in this study were identical to pBMGNeo 
pSVL-mo FceRI Newly synthetized sequence by Addgene (Cambridge, MA, USA) 
pMK-T-P40M(syn) Newly synthetized by Invitrogen GeneArt Gene Synthesis; mutated 
human Ad-5 p40 promoter (Thermo Fisher Scientific, Waltham, MA 
USA) 
pMK-T-TPL(syn) Newly synthetized by Invitrogen GeneArt Gene Synthesis; 5′-
untranslated tripartite leader sequences (Thermo Fisher Scientific, 
Waltham, MA USA) 
pO6-ie-zeo GenBank AccNr: AY700022.1 [268] 
pO6-A5-CMV-
mCherry 
Sirion Biotech, Martinsried, Germany 
pCP20 Chloramphenicol and ampicillin resistant genes, temperature 
sensitive replication of yeast Flp recombinase gene [269] 
2.8.1. Plasmids that were constructed in this study 
Name (Resistance) Comments 
pAV1-Hyg Generated by inserting the amplicon PCRHyg –MCS (PCR template on 
pTRE2Hyg using primer pair HYGfor and HYGrev) replacing the Gap 
genes into pAAV1 with a hygromycin cassette and a multiple cloning 
site (MCS) with ApaI/XhoI. 
pAV1-GLuc-Hyg Generated by inserting the amplicon PCR-GLuc (PCR template on 
pGLuc using primer pair LUCfor and LUCrev) inot pAV1-Hyg after 
restriction with NheI/NotI using the sites in the cloned MCS. 
pAV1-GFP-Hyg The EGFP gene was excited from the plasmid pEGFP-N1 and inserted 
into pAV1-Hyg after treatment with NheI/NotI using the sites in the 
cloned MCS of pAV1-Hyg. 
pL-SV40L-P Generated by inserting the amplicon PCRSV40Lpro (PCR template on 
pSLV-mo using primer pair SV40LPfor (#1505) and SV40LPrev 
(#1506))  into pLitmus28 after restriction with XhoI/AgeI 
pL-P40M-SV40L The mutated p40 promoter from plasmid was excised from the 
plasmid pKM-T-P40M and inserted into pL-SV40L-P after treatment 
with XhoI/BglII. 
pL-P40M-SV40L-
TPL 
The TPL sequence was excised from the plasmid pKM-T-TPL and 
inserted into pL-P40M-SV40L after treatment with AvrII/AgeI. 
pAV1-GLuc-P40M-
SV40L-TPL 
The P40M-SV40L-TPL sequence was excised from the plasmid pL-
P40M-SV40L-TPL and inserted into pAV1-GLuc-Hyg after treatment 
with NheI/BsteII. 
pL-MT-P Generated by inserting the amplicon PCR MTTpro (PCR template on 
pB45neo-F-tet using primer pair  MTTfor (#1507) and MTTrev 
(#1508)) into pLitmus28 after restriction with XhoI/AgeI 
pL-P40M-MT The mutated p40 promoter was excised from the plasmid pKM-T-
P40M and inserted into pL-MTT-P after treatment with XhoI/BglII. 
pL-P40M-MT-TPL The TPL sequence was excised from the plasmid pKM-T-TPL and 
inserted into pL-P40M-MT after treatment with AvrII/AgeI. 
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pAV1-GLuc-P40M-
MT-TPL  
 
The P40M-MT-TPL sequence was excised from the plasmid pL-P40M-
MT-TPL and inserted into pAV1-GLuc-Hyg after treatment with NheI 
(fulcut) /BsteII (partial cut). 
pAV1-pVI-Hyg Generated by inserting the amplicon PCRAd5_ppVI (PCR template on 
pBA5-FRT using primer pair APVIfor and APVIrev) into pAV1-Hyg 
after treatment with NheI/NotI. 
2.9. Bacterial artificial chromosomes 
2.9.1. Published BACs and BACs available in the group 
Name Comments 
pBA5-FRT Derived from [270]  BAC carrying the Ad5 genome and an FRT site for 
homologous recombination; left ITR, the encapsidation signal, the E1 
and E3 region are deleted;  
2.9.2. BAC’s cloned during this study 
Name Comments 
pBA5-FRT-ΔpVI-
zeo 
Generated by homologous recombination to replace the pVI gene of 
pBA5-FRT by a zeocin resistance cassette using the amplicon 
ETPCR_DELpVI (PCR template on pO6-ie-zeo using primer pairs H5-
PPVIT-zeo and H5-PPVIT-zeo2) 
pBA5-FRT-Che Ectopic insertion of pO6-A5-CMV-mCherry into pBA5-FRT via Flp/FRT 
system. 
pBA5-FRT- Che-
ΔpVI-zeo 
Ectopic insertion of pO6-A5-CMV-mCherry into pBA5-FRT-ΔpVI-zeo 
via Flp/FRT system. 
2.9.3. Viruses 
Name Comments 
Human adenovirus 
type 5 wild-type (Ad5-
WT ) 
German reference center, Albert Heim, Hannover, D 
Ad5-Che SIRION Biotech, Martinsried, D 
Human Ad-12  Kindly provided by Prof. A. Ehrhardt, Lehrstuhl für Virologie und 
Mikrobiologie, Witten, D 
Human Ad-3  Kindly provided by Prof. A. Ehrhardt, Lehrstuhl für Virologie und 
Mikrobiologie, Witten, D 
Human Ad-11  Kindly provided by Prof. A. Ehrhardt, Lehrstuhl für Virologie und 
Mikrobiologie, Witten, D 
Human Ad-9 Kindly provided by Prof. A. Ehrhardt, Lehrstuhl für Virologie und 
Mikrobiologie, Witten, D 
Human Ad-17  Kindly provided by Prof. A. Ehrhardt, Lehrstuhl für Virologie und 
Mikrobiologie, Witten, D 
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Human Ad-4  Kindly provided by Prof. A. Ehrhardt, Lehrstuhl für Virologie und 
Mikrobiologie, Witten, D 
HSV-1 strain F Kindly provided by Dr. G. Jäger, Max von Pettenkofer-Institut, 
München, D [271] 
HSV-1 res Kindly provided by Dr. G. Jäger, Max von Pettenkofer-Institut, 
München, D Resistant control strain used in the viral diagnostic 
department of the MvP. 
ACV+ HSV-1 isolate 
# 824670 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV+ HSV-1 isolate 
# 842369 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV+ HSV-1 isolate 
# 842913 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV+ HSV-1 isolate 
# 854014 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV+ HSV-1 isolate 
# 838500 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV+ HSV-1 isolate 
# 847890 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV+ HSV-1 isolate 
# 848759 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV- HSV-1 isolate 
# 852044 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV- HSV-1 isolate 
# 846206 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV- HSV-1 isolate 
# 861747 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV- HSV-1 isolate 
# 845708 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV- HSV-1 isolate 
# 854437 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV- HSV-1 isolate 
# 860929 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV- HSV-1 isolate 
# 845531 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV+ HSV-2 isolate 
# 17-168 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV+ HSV-2 isolate 
# 17-604 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV+ HSV-2 isolate 
# 17-742 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV+ HSV-2 isolate 
# 18-650 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV- HSV-2 isolate 
# 18-161 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
ACV- HSV-2 isolate 
# 18-553 
Kindly provided by Dr. V. Kapper-Falcone, Institut für Virologie, 
Freiburg, D 
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HCMV (TB40-BAC4) Wild-type BAC derived endotheliotropic HCMV strain [272]; 
Kindly provided by PD Dr. rer. nat. Barbara Adler, Max von 
Pettenkofer-Institut, München, D 
2.9.4. Recombinant viral particles 
Name Comments 
rAAV1-CMV-GFP SIRION Biotech, Martinsried, D 
rAAV1/2-CMV-GFP SIRION Biotech, Martinsried, D 
rAAV2-CMV-GFP SIRION Biotech, Martinsried, D 
rAAV4-CMV-GFP SIRION Biotech, Martinsried, D 
rAAV5-CMV-GFP SIRION Biotech, Martinsried, D 
rAAV6-CMV-GFP SIRION Biotech, Martinsried, D 
rAAV2-REP-GLuc SIRION Biotech, Martinsried, D 
rAAV1/2-R-GLuc SIRION Biotech, Martinsried, D 
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3. Methods 
3.1. Propagation of recombinant DNA in E. coli 
3.1.1. Culturing recombinant E. coli 
For propagation of plasmid DNA or viral BAC DNA in bacteria, the respective Escherichia coli 
strains carrying the recombinant DNA were amplified. The strains for harvesting recombinant 
DNA were propagated either in liquid culture using low-salt Lucia Broth (LB) medium or, if 
isolation of single colonies was needed, on LB-agar plates in the presence of appropriate 
antibiotics. Antibiotics used were: Ampicillin (amp) at concentrations of 100 µg/mL for 
selection of high copy plasmids, and 50 µg/mL for selection of low copy plasmids and BACs, 
Chloramphenicol (cm) was used at concertation of 25 µg/mL, Kanamycin (kn) at 50 µg/mL, and 
Zeocin (zeo) at 30 µg/mL. DH10B and PIR1 cells were cultured at 37°C and SW102 were 
cultured at 32°C. For optimal aeration liquid cultures were propagated under constant shaking 
at 160 rpm. 
Glycerol stocks of the bacterial strains with the DNA of interest were long-term stored. For 
this purpose, 600 µL of the respective culture were added to 400 µL of 60 % (v/v) sterile 
glycerol and after rigorous vortexing they were stored at -80°C. To recover the strains from 
the glycerol stocks they were either plated or recovered in liquid pre-culture o.n. 
 
Table 3.1.1.1: Used bacterial strains 
E. coli strain Genotype 
DH10B F −  mcrA Δ(mrr−hsdRMS−mrcBC) Φ80lacZΔM15 ΔlacX74 recA1  
endA1 araD139 Δ(ara, leu) 7697 galU galK rpsL nupG λ −   
(Invitrogen, Karlsruhe, D) 
PIR1 F −  Δlac169 rpoS(Am) robA1 creC510 hsdR514 endA recA1  
widA(ΔmluI):pir-116 (Invitrogen, Karlsruhe, D) 
SW102 DH10B [λc1857 (cro-bioA)<>Tet] gal490 ΔgalK [273] 
  
3.1.2. Preparation of electro-competent bacteria 
For the preparation of electro-competent DH10B and PIR1 cells, 2 x 200 mL pre-warmed LB-
medium was inoculated with 2 mL of overnight pre-cultures (see chapter 3.1.1) and kept at 
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37°C constantly shaking at 160 rpm until reaching the middle logarithmic phase at OD600 of 
about 0.5. The bacterial cultures were then incubated on ice for 30 min and centrifuged to 
collect the bacteria at 6000 x g for 10 min at 4°C. All further steps were subsequently 
performed on ice with pre-cooled equipment and buffers. The received pellets were combined 
and re-suspended in 200 mL of 10 % (v/v) glycerol. The bacteria were collected again by 
centrifugation as above. This washing step was repeated two times to remove as much salt 
residuals as possible. After the last centrifugation step, the pellet was re-suspended in 1 mL 
of fresh 10 % (v/v) glycerol and aliquoted to 65 µL/tube in 1.5 ml Eppendorf tubes. The bacteria 
were either transformed directly by electroporation or snap-frozen in liquid nitrogen and 
stored at -80°C.  
For preparation of electro-competent SW102 E.coli, 100 mL of LB were inoculated with 2 mL 
of the pre-culture and grown at 32°C constantly shaking at 160 rpm until the OD600 of 0.55 to 
0.6 was reached. In case of homologous recombination, the expression of the recombinases 
was heat induced at incubating the bacterial culture 42°C for 15 min in a shaking water bath. 
The bacterial cultures were then incubated on ice for 10 min and centrifuged to collect the 
bacteria at 6000 x g for 10 min at 4°C. All further steps were subsequently performed on ice 
with pre-cooled equipment and buffers. The received pellets were combined and re-
suspended in 50 mL of pre-cooled ddH2O. The bacteria were collected again by centrifugation 
as above. This washing step was repeated two times to remove as much salt residuals as 
possible. After the last centrifugation step, the pellet was re-suspended with 250 µL of ddH2O 
and aliquoted to 65 µL/tube in 1.5 ml Eppendorf tubes. The electro-transformation in case of 
SW102 cells was always done directly after the preparation of competent cell. 
3.1.3. Transformation of electro-competent bacteria 
Aliquots of electro-competent cells were either taken directly after their preparation or were 
thawed on ice from frozen aliquots for 15 min. Then approximately 25 – 50 ng DNA was 
transferred to pre-cooled 2 mm electroporation cuvettes. The prepared electro-competent 
cells were added directly to the DNA and mixed. Bacteria cells were electro-shocked at 2.5 kV 
(25 µF/200 Ω). Right after pulsing, 1 mL of pre-warmed LB w/o antibiotics was added and 
suspension was incubated for 1 h at the appropriate temperature (32°C or 37°C) using a 
thermo-mixer. Appropriate amounts of transformed cultures were then plated on LB-agar 
plates with selective antibiotics and cultured o.n. at 32°C or 37°C respectively.   
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3.1.4. Isolation of DNA from bacteria 
3.1.4.1. Small scale isolation of plasmid DNA 
Single clones from the o.n. plate culture were picked and inoculated in 2 mL LB completed 
with the appropriate antibiotics. The cultures were incubated o.n. at 32°C or 37°C, at 160 rpm. 
Plasmid DNA was purified from saturated o.n. cultures using the illustra ™ plasmidPrep Mini 
Spin Kit according to the manufacturer's instructions. 
3.1.4.2. Large scale isolation of plasmid DNA 
For isolation of plasmid DNA in large quantities o.n. 200 mL of LB was inoculated with either 
100 µL of an o.n. culture from small scale preparations or from a scratch of a glycerol stock 
(see chapter 3.1.1) together with the appropriate antibiotics. Plasmids were purified according 
to the manufacturer’s instructions using the NucleoBond® PC100 Plasmid DNA Purification Kit 
(Macherey-Nagel). Plasmid DNA pellet was dissolved in 200 µL TE buffer at 4°C o.n. and then 
stored at -20°C. 
3.1.4.3. Small scale isolation of BAC-DNA 
A single bacterial clone was picked and cultured in 10 mL LB in the presence of the appropriate 
antibiotics for selection of the BAC DNA in SW102 or DH10B strains at 32°C or 37°C, 
respectively, with shaking at 160 rpm o.n. Bacterial cultures were centrifuged at 3500 rpm for 
15 min at RT and then pellets were re-suspended in 300 µL of resuspension buffer P1 of the 
Plasmid Maxi Kit (QIAGEN) and transferred to 2 mL Eppendorf tubes. 300 µL of lysis buffer P2 
of the Plasmid Maxi Kit (QIAGEN) was added and mixed by gentle inversion. After an 
incubation time of 5 min at RT, 300 µL of neutralization buffer P3 of the Plasmid Maxi Kit 
(QIAGEN) was added to precipitate proteins and chromosomal DNA. Samples were incubated 
for 10 min on ice before pelleting the precipitate by centrifugation at 13,000 x g for 10 min at 
4°C. Supernatants were transferred into a new 2mL tube with containing 1 mL of phenol-
chloroform for BAC DNA extraction. After inversion, another centrifugation with 13.000 x g 
for 5 min followed. The DNA containing upper aqueous phase was transferred to a new tube 
and for precipitation 900 µL of isopropanol was added and mixed by inversion a few times. 
Then the precipitates were collected by centrifugation at 13.000 x g for 20 min. The pellet was 
washed with 1 mL of 70% ethanol during centrifuged at 13.000 x g for 10 min to remove salts 
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residuals. Then supernatant was discarded, the pellet was air-dried for 10 min, and finally the 
BAC DNA was dissolved in 60 µL TE buffer o.n. at 4°C. Purified BAC DNA was stored at 4°C. 
3.1.4.4. Large scale isolation of BAC-DNA 
NucleoBond® Xtra Midi/Maxi Kit of Macherey-Nagel was used for isolation of BAC DNA in large 
scale volume as described in the manufacturer’s instructions for low copy plasmids. Then 
precipitated BAC DNA was eluted in 100 µL TE buffer o.n. at 4°C.  
3.2. Analysis and cloning of recombinant DNA 
3.2.1. Determination of DNA concentration  
Isolated nucleic acid concentrations were determined by measuring the optical density (OD) 
at 260 nm and 280 nm by using the NanoPhotometer® P-Class P330. The purity of DNA was 
measured using the ratio between OD260/OD280 that should be optimally in 1.8 for DNA 
preparations. For analyzation of the concentration in ng/µL, the OD260 value had to be 
multiplied with the factor 50 ng/µL and with the dilution factor.  
3.2.2. Ethanol precipitation 
To concentrate purified DNA or for removal of reaction components from DNA solutions, the 
DNA fragments were precipitated by addition of 1/10 volume of 3 M sodium acetate (pH 5.3) 
and three volumes of 100% ethanol. Then the mixture was incubated for 1 h on ice and 
centrifuged at 13.000 x g at 4°C for 30 min. The pellet was washed with 70% ethanol and 
centrifuged another time 13.000 x g at RT for 10 min. After air-drying of the pellet at RT, the 
DNA was dissolved in the required volume using 10 mM Tris-HCl buffer (pH 8.0). 
3.2.3. Polymerase chain reaction (PCR) 
To amplify DNA fragments for mutagenesis and cloning, a touch down PCR protocol was used 
(see Table 3.2.3.1). In this approach, the PCR cycling starts at high annealing temperatures, 
ensuring high specificity. During the run the annealing temperature is decreased gradually, 
allowing high productivity of the amplification. This approach also avoids the necessity of the 
PCR optimization for most of the primer pairs. In general, the PCR reaction was set up using 
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the manufacturer’s protocol of Expand High Fidelity PCR Kit using a reaction volume of 100 µL 
and 3-25 ng template DNA. 
Table 3.2.3.1: Program of touch down PCR: 
 step temperature time cycles 
1. initial-
denaturation 
95°C 5 min  
2. denaturation 95°C 30 sec  
3. annealing 67°C 30 sec -1°C every cycle 
4. elongation 72°C 2 min 17 x back to 2. 
5. denaturation 95°C 30 sec  
6. annealing 45°C 45 sec  
7. elongation 72°C 2 min 20 x back to 5. 
8. final-elongation 72°C 7 min  
9. end 4°C ∞  
3.2.4. Restriction enzyme digest 
DNA restriction endonucleases from NEB were used for either restriction fragment analysis or 
for the preparation of linear DNA fragments. All restriction endonucleases used were 
purchased from NEB and performed according to the manufacturer’s instructions. For 
restriction pattern analysis, 300-600 ng of plasmid DNA was digested with 10 U of the 
appropriate restriction enzyme in a total volume of 20 µL and incubated for 2 h. For 
preparative digestion for cloning of plasmid DNA, 1 µg of DNA was digested at the same 
conditions as for restriction pattern analysis for at least 3 h. 
For analysis of BACs 50 µL (1-2 µg) of BAC mini preparations (see chapter 3.1.4.3) were 
restricted in 60 µL reaction volumes using 10-50 U restriction enzyme o.n. For the digestion of 
BACs for reconstitution of viruses, BAC DNA was ethanol precipitated (see chapter 3.2.2) to a 
concentration of 10-12 µg and diluted in 10 µL. The restriction with PacI enzyme was done 
using 10 x reaction buffer and 10-50 U PacI restriction enzyme in a total volume of 40 µL to 
linearize the DNA. Incubation was done at 4°C o.n. 
3.2.5. Agarose gel electrophoresis 
To analyze the fragment lengths after restriction of plasmid or BAC DNA, the restriction 
fragments were separated by agarose gel electrophoresis. Plasmid derived fragments were 
analyzed using 1 % agarose/ TAE gels containing 1 µg/mL ethidium bromide, which were run 
in TAE buffer. DNA fragments were separated by a fast electrophoresis protocol adjusted to 
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the length and amount of expected fragments using 80-120 V and a duration of 20-60 min. 
BAC DNA, on the other hand, was separated on a 0.8% agarose/ TBE gel with ethidium 
bromide staining for visualization in TBE buffer for 16 h at 80 V. Separated bands were 
visualized under UV-light and documented by the Eagle-eye imaging system. 
3.2.6. Purification of DNA from agarose gel 
After separation of fragments by preparative restriction enzyme digestion, a selected 
fragment was excised from the gel by usage of non-mutagenic UV-transillumination. The DNA 
was then purified with the Qiaquick Gel Extraction Kit as described by the manufacturer’s 
instructions. The isolated fragments were eluted by 35 µL using 10 mM Tris-HCl buffer (pH 
8.0). 
3.2.7. Blunting of DNA ends 
For ligation of incompatible restriction sites, 5’ overhangs were filled and 3’overhangs 
removed using the DNA polymerase I, Large (Klenow) Fragment of NEB according to the 
manufacturer’s protocol. After a 15 min incubation at a temperature of 25°C of, the reaction 
was stopped. This was achieved by adding EDTA to a final concentration of 10 mM. Then the 
enzyme was heat inactivated for 20 min at 75°C. Then the blunted fragment was purified via 
QIAquick PCR Purification Kit according to the manufacturer’s instruction for further cloning 
steps.  
3.2.8. Ligation of DNA fragments 
The ligation of DNA fragments was achieved by mixed vector and insert in a molar ratio of 1:3, 
respectively, with 2 units of NEB T4 DNA ligase and the T4 DNA ligase reaction buffer using 
100 ng of linearized vector DNA in a volume of 20 µL in total. An additional control reaction, 
containing water instead of insert DNA, was also prepared. Then reaction mix was incubated 
o.n. in +4°C. 2 µL of the ligated DNA were in a further step used for transformation into 60 µL 
of electro-competent bacteria. 
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3.2.9. DNA sequencing 
For verifying the recombinant DNA constructs, 500 ng of generated DNA-plasmids were sent 
to GATC Biotech (Konstanz, D) for Sanger sequencing along with sequencing primers flanking 
the region of interest. 2000 ng of purified BAC-DNA were sent to Sequiserve (Vaterstetten, D) 
for Sanger sequencing with optimized BAC protocols along with sequencing primers flanking 
the region of interest. 
3.3. Mutagenesis of BAC DNA 
Bacterial artificial chromosomes (BACs) enable the preservation and mutagenesis of the 
genome of large DNA viruses in E.coli. Here the advanced methodology of bacterial genetics 
to the cloned viral genomes can be applied for the generation of recombinant viruses with 
virtually any mutation. The fertility factor (F-factor) constitutes the backbone of the BAC 
vector and harbors repE and repF gene products regulating the origin of replication S (oriS) to 
allow maintenance of only one BAC copy per cell, reducing unwanted recombination events  
[274].  
3.3.1. Homologous recombination of BACs 
For the deletion of the pVI gene in the adenovirus BAC DNA, the technique homologous 
recombination was used to manipulate the pBA5-FRT BAC vector coding for an E1/E3 deleted 
Ad5 genome, which can be propagated in 293 cells [270]. To do so, the pVI gene was replaced 
by the marker for zeo resistance. The zeo resistance cassette from pori6ie-zeo was amplified 
by PCR using primers that were flanked by 50 nt homologies to the sequences up- and 
downstream to the pIV coding sequences. The PCR product was column purified, DpnI 
digested and precipitated with ethanol. 
For the homologous recombination, the pBA5-FRT BAC was introduced to the E. coli strain 
SW102. In this E. coli strain cis-acting λ prophage recombineering system can be induced by 
heat shock [273]. The SW102 harboring the pBA5-FRT BAC vector were prepared for electro-
transformation as described in chapter 3.1.2 and were transformed with 0.2-0,5 µg of the 
prepared recombination fragments containing the zeo cassette and the homologies. 
Transformed cells were incubated with 1 mL LB medium w/o antibiotics for 1.5 h at 32°C. Then 
the cells were transferred to cm and zeo containing LB-plates and incubated o.n. at 32°C. 
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Single colonies were picked on the next day and incubated to perform BAC mini-preparations. 
Subsequently, BAC mini-preparations were tested by restriction fragment length 
polymorphism (RFLP) and then sequences verified. 
3.3.2. Flp/FRT recombination system 
In order to insert DNA sequences at a pre-determined site in the viral BAC DNA, recombination 
between two FRT sites was performed by the Flp recombinase to introduce a mCherry 
expression cassette as a marker gene into the Ad5 BACs. The Ad-BACs used in this study 
carried an FTR- site at the position of their deleted E1 region, the place where usually 
transgenes are inserted in first generation Ad vectors. The mCherry expression cassette was 
cloned into pO6-A5-CMV vector, which carried a conditional origin of replication (RK6) and an 
FRT site. For the replication of this RK6 phage based pO6 plasmid, the presence of the phage 
π-protein trans-complemented in the E.coli strain PIR1 is necessary [275]. In other bacterial 
strains lacking π-protein, these plasmids cannot be maintained. Therefor all cloning steps for 
pO6-A5-CMV-mCherry were performed in PIR1 cells, whereas FLP-mediated insertion was 
done using DH10B strain for propagation of the BAC DNA. 
To carry out Flp recombination DH10B cells carrying the recombinase helper plasmid pCP20 
were co-transformed with 100 ng of the pBA5-FRT constructs and the pO6-A5-CMV-mCherry 
plasmid. In order to induce Flp recombinase expression, the transformed cells plated onto LB 
plates at 43°C and selected with cm and kan o.n. to isolate the BACs with the integrated donor 
plasmids. Single colonies were picked on the next day and were analyzed by BAC mini-
preparations, which were tested for single copy insertion of the donor plasmid by RFLP and 
then correct insertions were verified by sequencing. 
3.4. Tissue culture 
3.4.1. Cultivation of mammalian cell lines 
All mammalian cells were maintained under sterile conditions in an incubator providing a 
temperature of 37°C, humidity of 95% and 5% CO2 concentration. Cells were passaged as 
indicated in Table 3.4.1.1. Adherent cells were splitted by removing the old DMEM medium, 
washing once with PBS and detaching the cells from the plate by addition of 0.25% trypsin/ 
EDTA in an accurate amount according to the size of the respective well or culture dish for 5 
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min at RT. Reaction of detaching was stopped by addition of the respective and appropriate 
amount of fully supplemented DMEM medium for resuspension of the cells. After 
centrifugation at 1200 rpm (311 x g), cell pellets were re-suspended again using appropriate 
amount of the full medium and a defined proportion of the cells were aliquoted and seeded 
on new cell culture plates with fresh DMEM medium. To ascertain a defined number of cells, 
100 µL of the aliquoted cells were analyzed by addition of 1 mL of CASYton and measurement 
using the CASYCell Counter & Analyzer. 
 
Table 3.4.1.1: Used cell lines and culture conditions. 
Cell lines Type and source Cultivation medium 
Split ratio, 
interval 
293A Human embryonic kidney cells, ATCC® 
CRL 1573TM 
DMEM 
10% FCS, P/S 
1:8 
2-3 days 
LE2D8 Stable 293A derived cell line containing 
pAV1-GLuc-Hyg; constructed in this 
study 
DMEM 
10% FCS, P/S 
1:8 
2-3 days 
U-2 OS Human osteosarcoma cell line, ATCC® 
HTB-96TM 
DMEM 
10% FCS, P/S 
1:8 
2-3 days 
911 Human embryonic retinoblast cell line, 
RRID:CVCL_1K15 
DMEM 
10% FCS, P/S 
1:6 
2-3 days 
Vero Cercopithecus aethiops kidney 
epithelial cell line, ATCC® CCL-81TM 
DMEM 
10% FCS, P/S 
1:10 
2-3 days 
A549 Human lung carcinoma cell line, ATCC® 
CCL-185TM 
DMEM 
10% FCS, P/S 
1:10 
2-3 days 
HFF Human foreskin fibroblasts, PromoCell 
NHDF-c; C-12300 
DMEM 
10% FBS, Q, P/S 
1:3 
7 days 
P/S, 1.3 % (w/v) streptomycin 0.6 % (w/v), penicillin; Q, 0.3 mg/mL L-glutamine;  
3.4.2. Cryopreservation of mammalian cell lines 
For maintaining of stock cells in liquid nitrogen permanently, cells were grown on 3 x 145 cm2 
dishes to 80-90% confluence and harvested by trypsinization. Then the cells were pelleted by 
centrifugation at 311 x g for 5 min and resuspended in 9 mL freezing medium. For freezing, 
the cell suspension was aliquoted in cryo-tubes, 1 mL each. The cell aliquots in cryo-tubes 
were kept in isopropanol filled cryo-boxes for 48 h at -80°C to allow gentle freezing of the cells. 
Then the frozen cells were long-term stored in liquid nitrogen. 
The frozen cell aliquots in the cryo-tubes were thawed at 37 °C using a water bath. Then the 
cells of each aliquot were transferred to 9 mL fresh DMEM medium and centrifuged at 311 x 
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g for 5 min. Washed cell pellets were subsequently re-suspended with 10 mL appropriate 
medium and seeded on a new 10 cm cell culture dish. 
3.4.3. Transfection of cultured mammalian cells 
Four different transfection reagents were used in the course of this study: polyethylenimine 
(PEI) (Polysciences), Lipofectamine2000 (Invitrogen), FuGene HD® (Promega) or SuperFect 
(Quiagen). For the usage of PEI and Lipofectamine2000, cells were seeded onto 10 cm dishes. 
For FuGene HD® or SuperFect the same was done onto 6-well plates. For all three transfection 
reagents, this was done one day before the experiment. On the day of transfection, the 
confluency should reach 80 %. In parallel to all transfections, an EGFP expressing control 
plasmid was co-transfected for evaluation of transfection efficacy. 
293A cells transfection with PEI was performed using a 6-well plate format for seeding on the 
day before transfection. A total of 6 µg of DNA was used per well, consisting of 1.5 µg of AAV1-
GLuc-Hyg plasmid DNA, 0.75 µg of EGFP control plasmid and for the rest Litmus28 as tracer 
DNA for increasing transfection efficacy was taken. DNA was suspended in 100 µL Opti-MEM, 
15 µL of PEI were added, vortexed and transferred to the cell culture medium after an 
incubation time of 40 min at RT. After incubation time on the cells of 3 h medium was changed 
to fresh complete medium. 
SuperFect was used as transfection reagent for the AAV replicon vector in 293A, 911 and U-2 
OS cells seeded on a 6-well plate to 60 - 80% confluency. Here cells were transfected in 
duplicates with 2 µg DNA consisting of 0.5 µg pAV1-GLuc-Hyg, 0.25 µg pO6-A5-ORI-GFP 
plasmid and 1.25 Litmus28 as stuffer DNA according to manufacturer’s instructions. After an 
incubation time of 3 h, the DNA-SuperFect mixture was removed and changed to 2 mL fresh 
complete medium. 
Transfection of 293A, 911, U-2 OS and Vero cells with FuGene HD® was performed in 
duplicates in 6-well plate format after seeding of the cells onto a 6-well plate to 60 – 80% 
confluency. In total 6 µg of DNA were transfected. For trans-complementation experiments, 
1.5 µL PacI (60 U) restricted and ethanol precipitated BAC DNA, 0.5 µg of AAV1-GLuc-Hyg DNA,  
3.85 µg of stuffer DNA and 0.15 µg of pO6-A5-ORI-GFP control plasmid were mixed, whereas 
for transfection of AAV replicon vector, and 0.75 µg of pO6-A5-ORI-GFP control plasmid were 
mixed with 100 µL of Opti-MEM and vortexed. Then 15 µl of FuGene HD® reagent was carefully 
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added and immediately vortexed bevor incubation for 30 min at RT. Then the DNA-
transfection mixture was added drop wise to the cell culture supernatant.  
Duplicate transfected cells were harvested and pooled together after 72 h and 3E+04 cells per 
well were seeded on a 96-well plate. 
3.4.4. Construction of stable cell lines 
To generate stable cell lines, 293A cells were transfected either with pAV1-GLuc-Hyg or with 
pAV1-EGFP-Hyg. Cells of one 6-well plate were transferred to a 10 cm cell culture dish and 
hygromycin (200 µg/mL) was added for selection towards the AAV replicon vector containing 
cells. Cells that did not show positive transfection of the AAV1-GLuc-Hyg usually died within 4 
- 5 days. Single cell clones were subcloned using limiting dilution by seeding the cells on day 7 
(0.5, 3 and 10 cells per well) onto a 96-well plate under Hyg selection. Single cells that started 
to proliferate were tagged and after confluency were transferred to a 24-well plate and then 
to a 6-well plate. The stable cells were frozen after 4 passages and tested for their inducibility 
after 5 passages by Ad infection with either a Luciferase assay or via FACS analysis.  
3.4.5. Cryopreservation of transfected cells 
Transfection of pAV1-GLuc-Hyg into 293A cells with FuGene HD® as transfection reagent was 
done as described in chapter 3.4.3. Then transfected cells were pooled after 48 and 72 h post 
transfection (h p.t.). Cells were pelleted by centrifugation at 1200 rpm (311 x g), supernatants 
were removed, and cells were re-suspended in freezing media (70% DMEM, 20% FBS and 10% 
DMSO) and seeded onto 96-well plates at a density of 3E+04 cells/well. Subsequently, the 
plates were sealed and then rapidly frozen in -80°C.  
For thawing of the plates 150 µL of pre-warmed growth medium was added directly to each 
well and cells were incubated for 2 hours under normal cell culture conditions. Then, the 
supernatants were removed and 100 µL of growth medium was added to each well. The 
inducibility of the introduced AAV replicon after thawing the transfected cells was tested by 
infection 4, 6, 20 and 26 h after thawing with different MOIs of Ad and HSV-1. 
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3.4.6. Antiviral drug treatment of cultured cells 
For the treatment of cells with different antiviral drugs as listed in Table 3.4.6.1, stock 
solutions were prepared in DMEM and stored in 200 µL aliquots at -20°C and used only once 
after thawing in indicated concentrations. 
 
Table 3.4.6.1: Stock solutions of antiviral drugs. 
drug abbreviation Storage concentration 
Acyclovir ACV 166.67 µg/mL 
Ganciclovir GCV 15 mg/mL 
Foscarnet PFA 300 µg/mL 
Cidofovir Hydrate CDV 15 mg/mL  
 
3.4.7. Extraction of genomic DNA from cultured mammalian cells 
DNA extraction from cultured cell lines was performed before analyzing the genomic DNA via 
quantitative real-time PCR. To do so, 2 wells of a 6-well plate were transfected with the AAV 
replicon vector and 3 days later seeded onto a 12-well plate. Then the cells were either 
infected or kept mock infected by addition of the same volume of complete medium. 
Extraction of the genomic DNA was performed with the DNeasy Blood & Tissue Kit. This was 
done according to the manufacturer’s instructions (purification of total DNA from animal 
cells). 
3.4.8. Quantitative real-time PCR 
Quantitative real-time PCR reaction (qPCR) was performed for analyzing GLuc expression upon 
virus infection after cell extraction. For the reaction 5 µL of the purified DNA were mixed in 
duplicates with 10 µL of QuantiTect SYBR® Green PCR master mix and with the forward and 
reverse primers of either GLuc or the housekeeping gene gapdh (all primers are listed in 
chapter 2.6). The qPCR was performed using the LightCycler® for amplification. Thermal 
cycling conditions comprised 15 min at 95°C, 45 amplification cycles of 15 s at 95°C 
(denaturation), 30 s at 58°C (annealing) and 30 s at 70°C (elongation). Melting curve analysis 
followed with 15 s at 65°C and at the end a cooling phase to 37°C was done. Relative 
quantification of GLuc amplification was performed in relation to uninfected controls and 
normalized to the housekeeping gene gapdh using the delta CT method [276]. 
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3.4.9. Flow cytometry 
For analyzation of the EGFP AAV replicon stable cell line, EGFP expression was measured via 
Fluorescence-based flow cytometry assay. Typically, AAVG clones were seeded 1:4 in 
duplicates in a new 6-well plate and infected 24 h later or mock treated. After 3 days cells 
were harvested by digestion with Trypsin/EDTA and washed with PBS. Cell pellets were re-
suspended in 0.8 - 2 mL PBS and measurement was done using the BD FACS Canto™ II 
cytometer. 
3.5. Virological methods 
3.5.1. Virus infection of cultured cells 
For infection of cells under standard conditions, the appropriate cell line was seeded to a 
confluency of about 90% o.n. in cell culture dishes or a total number of 3E+04 cells per well 
were seeded onto a 96-well plate for infections 4 - 6 h before infection. Appropriate amounts 
of virus stocks or inocula were diluted in complete medium to achieve the respective MOIs 
and applied correspondingly to the cells.  
3.5.2. Reconstitution of viruses from BACs 
For reconstitution of adenovirus from viral BACs permissive cells were transfected with the 
corresponding BAC DNA after manipulation of the viral genome. Positive control of the mutant 
Ad BAC lacking the pVI gene (pBA5-ΔpVI-Che) was the Ad5-WT BAC having Cherry expression 
cassette (pBA5-Che BAC). To this end, 293A or 911 cells were seeded onto a 6-well plate one 
day before transfection as described in chapter 3.4.1. The successful transfection was 
controlled by the EGFP expressing control plasmid as well as by the mCherry expression of the 
BAC mutants with a fluorescence microscopy. 4 days after transfection, the supernatants of 
all cells were removed in each well and then the cells together with the propagated viruses in 
the 6-well plate were immediately stored at -80°C. For both, virus trans-complementation and 
for virus reconstitution from BACs for production of virus stocks, viral suspension was thawed 
by adding 700 µL pre-warmed complete media to each well and transfer to +37°C incubator. 
After 15 min, cells were scraped from the plates and transferred with the media to new 2 mL 
Epis. Then three cycles of freezing (5 min in liquid nitrogen) and thawing (10 min at 37°C) 
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followed before the suspension was centrifuged again at 6.000 x g at RT for 10 min. Sn was 
collected for further processing. 
3.5.3. Preparation of viral inocula 
For preparation of low titer virus inocula optional amount and size of cell culture dishes with 
the appropriate cells grown to 90% confluency were infected with either a reconstituted virus 
BAC or a previous virus stock. Ad were propagated in 293A cells upon infection at a MOI of 1. 
Harvesting of lysed cells and Sn followed 1 day after complete cytopathic effect was observed. 
The pooled suspension was centrifuged at 6.000 x g at 4°C for 15 min. Except of 2 mL the Sn 
was collected, and an aliquot was stored in -80°C for safety. The cell pellet was re-suspended 
in the remaining 2 mL Sp. Then three cycles of freezing (5 min in liquid nitrogen) and thawing 
(10 min at 37°C) followed before the suspension was centrifuged again at 6.000 x g at 4°C for 
15 min. Viruses in the Supernatants were harvested and Aliquots of 250 µL were stored at -
80°C. Virus titer was analyzed by endpoint titration (chapter 3.5.5). 
For propagating HSV, Vero cells were infected at MOI 0.01 and cell-virus suspension was 
collected 4 d p.i., harvested and frozen at -20°C. After a thawing process to 37°C, suspension 
was vortexed for 15 sec and centrifuged at 6.000 x g at 4°C for 15 min. Then the Supernatants 
were aliquoted using a volume of 100 µL and stored at -80°C. 
3.5.4. Preparation of high-titer virus stocks 
Large scale adenovirus stocks were purified using the caesium chloride (CsCl) purification 
method. To do so, first a seed stock of the virus had to be generated to be able to propagate 
a bulk stock. Therefore 150 µl of either a previous virus stock or of the 2nd lysate after BAC 
reconstitution (chapter 3.5.2) were used to infect 293A cells grown to a confluency of 80 – 90 
% in a 15 cm culture dish. One day after cytopathic effect was reached 100% of the cells, all 
cells were detached by pipetting up and down. Then suspension was centrifuged at 6000 x g 
for 5 min at 4°C.  Supernatants were removed and replaced with 4 mL of fresh DMEM. The 
virus particles were realized from the infected cells by three cycles of freezing (5 min in liquid 
nitrogen) and thawing (10 min at 37°C). The lysates were clarified by centrifugation at 6.000 x 
g at 4°C for 10 min and stored immediately at -80°C. 
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For the bulk preparation of Ad, 20 x 15 cm dishes of 293A cells grown to 80 - 90 % confluency 
and were infected with 150 µL of the thawed seed stock. When full CPE was evident, cells 
were detached as before and harvested together with the supernatant. After centrifugation 
6.000 x g at 4°C for 15 min, the supernatant was transferred to an extra tube and the 
remaining cell pellet was diluted with 3 - 4 mL of this supernatant. The rest of the supernatant 
was removed. Three cycles of freezing (5 min in liquid nitrogen) and thawing (10 min at 37°C) 
followed, then centrifugation at 6.000 x g at 4°C for 15 min was done, supernatant was 
transferred to a new tube to remove cell debris and kept on ice. Then 25 U Benzonase per mL 
lysate was used and incubated at 37°C for 30 min. Then the lysate was kept on ice again. 
The CsCl purification was done by preparing a CsCl gradient in an Ultraclear Beckman tube. To 
do so, first 3 mL of δ=1,2 CsCl solution (13.85 g CsCl, 50 mL PBS) were added to a fresh tube 
and then 3 mL of δ=1,4 CsCl solution (30.5 g CsCl, 50 mL PBS) were added underneath the 
δ=1,2 CsCl layer w/o disturbing the interface. Then the prepared viral Supernatant was 
carefully added to the top of the gradient and the tube was filled up with δ=1,2 CsCl almost to 
the rim. Centrifugation at 32000 x g at 4°C for 1.5 h followed. After the centrifugation step 
three different layers should be visible within the CsCl gradient, containing cell debris in the 
top layer, empty virions in the second layer and in the lowest layer there should be properly 
packaged virions. The lowest layer was aspirated by puncturing the tube with a hollow needle 
into a 2 mL syringe. 
For the step of desalination of the virus stock, a sephadex column was prepared by 5 x pre-
washing steps with 1 x Hepes buffer. Then the virus was loaded onto the column and 
desalinated virus eluted in the void volume was aliquoted and stored in -80°C.  
3.5.5. Endpoint dilution assay 
An endpoint dilution assay was performed to determine the infectivity of the virus preparation 
[277]. 293A cells were used to estimate the infectivity Ad5 and its vectors and Vero cells for 
HSV-1.  The cells were seeded in 96-well plates to a density of 10 % in 100 µL complete medium 
the day before infection. Next day 10-fold virus dilution series were prepared in twelve parallel 
wells (one dilution step for each row) in an extra 96-well plate starting with a 100-fold dilution 
in complete medium. 100 µL/well from each dilution between 10-2 - 10-9 were transferred to 
the cell cultures plate using the multichannel pipette. For determining virus titer of Ad and 
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HSV, the cytopathic effect of each virus dilution was observed for each infected well after a 1-
week incubation period, whereas HCMV was analyzed after 9 days. The calculation of the 
TCID50/mL comprises the dilution were 50% of the cells show a cytopathic effect using the 
following formula: 
TCID50  = A-D (S-0.5) 
A - Log of highest dilution showing CPE in over 50 % of the wells 
D - Log of dilution factor 
S - ratio of: number of wells per row with CPE versus number without CPE 
For validation of the HSV resistance or sensitivity towards ACV, 104 cells of the stable replicon 
cell line LE2D8 were seeded onto two 96-well plates and 4 h later treated in duplicates with 
96, 48, 12, 6 and 1 µg/mL of ACV in 50 µL completed medium. Next the cells were infection 
with either the sensitive HSV-1 WT (ACV sens) or the ACV resistant HSV-1 (ACV res) at a MOI 
of 0.035 or mock in a volume of 50 µL. Subsequently after an incubation time of 2 days the 
supernatants were collected, and virus load was analyzed in duplicates by endpoint dilution 
assays in Vero cell line.  
3.5.6. Gaussia luciferase assay 
Bioluminescence measurement of Gaussia luciferase (GLuc) reporter gene expression was 
performed to quantify the induction of the GLuc carrying AAV replicon vectors upon virus 
infection. First, the GLuc assay solution was prepared according to the manufacturer’s 
protocol using the BioLux® Gaussia luciferase Flex Assay Kit. Aliquots of 10 mL were stored in 
-20°C and thawed to RT upon usage. 
For the assay, supernatants were collected in different time points after induction and stored 
in -80°C. Right before the assay they were thawed to RT. 20 µL of each sample in technical 
triplicates was transferred to a white 96-well plate. Then 50 µl of the GLuc assay solution was 
added carefully into each well and incubated for 5 min covered for light protection. For the 
evaluation of GLuc expression, the emitted light was measured using an integration time of 1 
second by the Tecan luminometer. For analyzing the fold induction of GLuc, the measured 
relative light unit (RLU) values were compared to the values measured in the supernatants of 
the AAV replicon vector treated but non-infected cells.  
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4. Results 
4.1. Construction of the AAV based replicon 
Replicon vectors represent replication proficient artificial genetic elements that are induced 
specifically in the presence of a viral infection. One major application of replicons utilizes their 
infection-dependent activation to regulate reporter genes, which can be used to trace 
infection with native viruses. The known replicon vectors are restricted to respond to infection 
with one specific virus species that can activate the homologous origin of replication 
embedded in the replicon constructs. To expand the replicon response to more than one virus 
species, we decided to choose the AAV2 genome as a basis for a replicon system reacting to 
infection with large DNA viruses. The replication of AAV is known to be naturally dependent 
on co-infection with helper viruses like adeno- or herpesviruses [215] [216]. Furthermore, the 
genome replication of AAV can be induced by a helper virus infection not only on the single 
stranded (virion) DNA, but also on a circular double stranded, or linear double stranded 
template [239]. For our purpose we used the plasmid pAV1 [278] containing the complete 4.7-
kb genome of AAV2  (Figure 6.A first panel). This plasmid encodes all important cis elements, 
the two ITRs, and the rep gene for the helper virus infection induced AAV DNA replication on 
double stranded templates. Since the structural gene of AAV is kept silent in the absence of 
helper virus infection but is expressed at very high levels during AAV lytic replication cycle in 
the presence of helper virus infection, we aimed to use the properties of p40 regulation for 
controlling the expression of the transgene of interest. We wanted to delete the coding region 
of the Gap gene to prevent formation of infectious AAV particles during replicon induction but 
preserve the cis-elements, which are involved in regulating the expression of the Gap gene.  
Thus, to construct an AAV replicon vector, a hygromycin resistance cassette was inserted into 
pAV1, replacing all Cap coding sequences upstream of the p40 transcription initiation site. This 
hygromycin cassette (HYG) can be used for selection of stable cell lines carrying the AAV 
replicon. The hygromycin cassette is under the control of an SV40 early promoter, which is a 
constitutive promoter initiating transcription independently of activation of any AAV 
promoter. Next, on the 5’ end of the HYG transcription unit, we flanked a multiple cloning site 
(MCS) to facilitate insertion of transgenes. The MCS is now located directly downstream to the 
p40 promoter and upstream to the HYG. Afterwards, to test the responsiveness of our 
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replicon, two different ORFs were inserted between p40 and the hygromycin cassette using 
the MCS as insertion site. The transgene was either coding for a Gaussia luciferase (GLuc) or 
an enhanced green fluorescence protein (EGFP), resulting in pAV1-GLuc-Hyg or pAV1-GFP-
Hyg, respectively (Figure 6A second and third panels). 
 
 
A 
B 
Figure 6: Cloning and Concept of the AAV replicon vector. 
(A) Cloning of the pAV1-GLuc-Hyg replicon vector was done by deletion of the Cap coding locus of the 
plasmid pAV1 containing the whole AAV 2 genome. Instead a hygromycin resistance cassette under 
the control of a SV40 early promoter and either of the transgene GLuc or EGFP were introduced 
downstream of the inducible AAV p40 promoter. (B) Concept of the conditional gene expression by 
AAV replicon vectors. Delivery of the AAV replicon vector should show no or very low level of transgene 
expression. But, infection with a helper virus should activate DNA replication of the AAV replicon 
vector and consequently induce the p40 promoter to drive expression of the reporter gene. 
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The replicon vector without an accompanying virus infection should have a very low or no 
transgene expression. However, as soon as the replicon carrying cell is infected with an 
inducing (helper) virus infection, the lytic AAV genome replication should start. The replication 
should activate the p40 controlled reporter gene expression, which then can be measured by 
the assay specific to the actual reporter gene (Figure 6B). This allows assaying the virus 
infection indirectly by using simple, well-developed, automated methods for the reporter 
detection instead of more complicated or time-consuming methods for direct detection of 
infectious viruses. 
To examine whether the mechanism of transgene expression of the AAV replicon vector was 
in fact regulated by helper virus infection, we transfected three different cell lines transiently 
with the newly constructed pAV1-GLuc-Hyg vector using SuperFect as transfection reagent. 
293A and 911 cells carry the functional E1 gene of adenovirus type 5, which complements the 
deletion of the E1 region of first-generation adenovirus type 5 derived recombinant viruses. 
We used recombinant Ad5-Che that carry deletions of the E1 and the E3 region (the latter is 
not essential for Ad replication in cell culture), and expresses mCherry as transgene in this 
study [279]. In contrast to 293A and 911 cells, the U-2 OS cell line does not carry 
complementing genes for adenoviruses and therefore replication of the E1 deficient Ad5-Che 
vector is not supported in this cell line. Researching not only the general inducibility but also 
the dependence on a productive helper virus replication, we tested the inducibility of our AAV 
replicon in all three cell lines upon infection with Ad5-Che and Ad5 wild-type virus (Ad5-WT). 
Ad5-WT should be permissive in all three cell lines. Therefore, transfected cells were seeded 
72 h post transfection (p.t.) onto 96-well-plates and infected 4 h later with either the E1 
deficient Ad5-Che at a multiplicity of infection (MOI) of 100, the Ad5-WT virus at a MOI of 1 
or kept non-infected (n.i.). The difference of the chosen MOIs between Ad5-Che and Ad5-WT 
were considering the expected limitation in productivity of the E1 deficient Ad5-Che. The 
supernatants were collected 48 h post infection (p.i.) to complete the infectious cycle of Ad5. 
Then, a bioluminescence assay was performed to evaluate the activity of the secreted 
luciferase by light emission, measured by luminometry and the results were expressed in 
relative light units (RLU) (Figure 7). 
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Figure 7: Productive Ad infection induced AAV replicon vector expression. 
293A, 911 and U-2 OS cells were transfected with pAV1-GLuc-Hyg and infected 72 h post transfection 
with either Ad5-Che at MOI 100 or Ad5-WT at MOI 1 or kept non-infected (n.i.). 48 h p.i. the RLU values 
were measured in a bioluminescence assay. Data from three independent experiments are shown; the 
error-bars represent means ± SD; 
Infection-dependent induction of luciferase signal was observed after infection with Ad5-WT 
in all cell lines and after infection with the E1 deficient Ad5-Che only in 293A and 911 cells, 
which complemented the essential gene E1. Here, the GLuc expression increased by 
approximately 60- to 135-fold. In contrast, replicon transfected but non-infected cells or U-2 
OS cells infected with Ad5-Che showed extremely low levels of luciferase activity. The light 
signal measured in transfected but non-infected cells were comparable to background levels 
that can be observed in non-transfected cells (for example in 293A cells these were 39000 [+/-
6000] for transfected but non-infected and 26000 [+/- 2900] for non-transfected cells) 
demonstrating the tightness of the p40 promoter control on transgene expression. 
Next, we wanted to test whether a productive Ad5 infection is able to induce amplification of 
the replicon vector, in order to determine the role of AAV genome replication in the observed 
response. To test the replicon vector amplification, we set up a semi-quantitative real-time 
PCR. We transiently transfected 293A cell line with pAV1-GLuc-Hyg 72 h before subsequent 
infection with Ad5-Che or keeping them uninfected. We harvested the infected and 
uninfected cells 24 and 48 h p.i. and extracted total cell associated DNA. Vector DNA copy 
numbers were analyzed by performing a semi-quantitative RT-PCR (described in chapter 
3.4.8). The back calculation of the vector copy number (CN) from the observed CT values 
confirmed an increase of replicon vector DNA copies from 2/haploid host genome to 
145/haploid host genome (24 h p.i.) and from 1/haploid host genome to 214/haploid host 
genome (48 h p.i) after infection with Ad5-Che (Figure 8). 
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Figure 8: Amplification of the AAV replicon vector after Ad5-Che infection. 
293A were transfected with pAV1-GLuc-Hyg and infected 72 h post transfection with Ad5-Che at MOI 
1 or kept non-infected (n.i.). 24 and 48 h p.i. copy number of the PCR products gapdh (cellular 
housekeeping gene) and vector encoded GLuc gene (Gaussia luciferase gene) were determined by 
semi-quantitative RT-PCR. Vector copy numbers were calculated relative to the haploid host genomes 
by the CT method. Shown is one representative experiment out of 3 replicates. 
Since a robust amplification of the replicon encoded GLuc gene only appeared in virus-infected 
cells, the full activation of the replicon vector occurred in parallel with the infection-
dependent AAV replication after infection with activating viruses. 
These data strongly indicated that the transgene induction of the AAV replicon vector was 
dependent on a productive helper virus infection. 
4.2. Characterization of the AAV replicon system  
The initial reporter gene induction data were promising with regard to the responsiveness of 
the newly constructed AAV replicon vector. However, the data were highly variable. For 
further applications, such as trans-complementation of essential viral genes and in diagnostic 
or screening approaches as reporter for viral replication, the system had to be further 
optimized regarding its reproducibility. First, we aimed to test the different methodologies for 
the delivery of the AAV replicons in target cells. 
Since the AAV replicon was significantly inducible after transient transfection, we primarily 
wanted to optimize this method for delivering the replicon because this system is very flexible, 
allows to target different cell types and requires no modification or further processing of the 
easy-to-produce plasmid preparations. In addition, transient transfection allows further 
characterization of the genetic elements of the replicon required for its performance. To get 
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a simpler protocol and a better reproducibility, a stable cell line could be constructed for 
specific applications as second step. Moreover, since recombinant AAV genomes can be 
packaged into recombinant AAV particles, we wanted to test a new, to our knowledge never 
applied before, approach to deliver replicons using transduction.   
4.2.1. Delivery of the AAV replicon by transient transfection and its 
applications 
The previous experiment showed that the induction of the AAV replicon vector was 
dependent on infection of Ad5 after transient transfection of pAV1-GLuc-Hyg with SuperFect 
as transfection reagent in 293A, 911 and U-2 OS cells. We furthermore wanted to test the AAV 
replicon response using different transfections reagents. After that, we wanted to explore 
which promoters are useful in the replicon vector context and, finally, which viruses can 
significantly induce the replicon system. 
4.2.1.1. Comparing transfection reagents 
Transient transfection generally allows flexibility concerning different cell lines and viruses. 
However, the various methodologies of transfection induce the innate immune response 
differently. To evaluate the optimal transfection reagent for further studies on the AAV 
replicon system, we wanted to test the major groups of different chemical transfection 
reagents. Therefore, SuperFect, which consists of activated dendrimers, was compared with 
two other reagents belonging to other chemical classes: JetPEI, based on polyethylenimine, 
and FuGene HD®, consisting of a proprietary blend of lipids. 
At first the replicon vector pAAV-GLuc-Hyg was introduced with the respective reagent into 
293A cells. For all reagents we used 5 µg total DNA, which was very close to the suggested 
DNA amounts by the vendors of the different reagent in 6-well plate format. To evaluate the 
primary transfection efficacy, 0.25 µg of pO6-GFP was co-transfected. After 3 days the 
transfected cells were trypsinized and either seeded on 96-well plates at a density of 30.000 
cells per well or subjected to FACS analysis to control the transfection efficiency. 6 h later the 
seeded cells were infected with Ad5-Che. 48 h p.i. the AAV replicon derived GLuc expressions 
were measured in the supernatants to characterize the replicon response. 
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After transient transfection, FACS analysis, using the three different transfection reagents, 
revealed a transfection efficiency of 94.93% using PEI, 41.57% using SuperFect and 97.23% 
using FuGene HD® reagents with a standard deviation of 2.9, 10.2 and 1.5, respectively. Data 
of the GLuc measurement showed a significant induction of the AAV replicon system in 293A 
cells irrespective of the transfection reagent (Figure 9).  
 
Figure 9: Comparison of three different chemical transfection reagents. 
293A cells were transfected with pAAV-GLuc-Hyg, using SuperFect, jetPEI or FuGene as transfection 
reagent. Cells were infected 72 h p.t. with Ad5-Che at indicated MOI and 48 h p.i. a bioluminescence 
assay was performed. The induction upon infection was calculated by comparing the RLU values 
recorded after measurements of infected to non-infected supernatants Data from three independent 
experiments are shown; the error-bars represent means ± SD; (Two-Way-ANOVA was performed for 
statistical analysis; ns: p > 0.05, *: p < 0.05, **: p < 0.01, ***: p < 0.001) 
As noted above, the variation of reporter gene expression between three independent 
experiments was very high in the case of SuperFect and jetPEI. Using SuperFect, the GLuc 
expression was induced 8-fold after infection at MOI 1, 49-fold at MOI 10 and 96-fold at MOI 
100 compared to non-infected but transfected cells. The calculated standard deviation 
between the different experiments was 2, 22 and 66 for the respective virus loads. Similarly, 
jetPEI as transfection reagent resulted in a 17-fold induction at MOI 1 and in a 47-fold 
induction at both MOI 10 and MOI 100 whereas the standard deviation was 11, 42 and 47. 
However, transfection with FuGene achieved the highest GLuc induction of 38-, 129- and 141-
fold after infection with MOI 1, 10 and 100, respectively. Accordingly, transfection with 
FuGene resulted in the best induction and the best reproducibility of replicon vector 
induction. Based on these observations we decided to use FuGene in further experiments 
because it combines the highest efficacy of transfection, best inducibility, and best 
reproducibility among the reagents tested. 
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4.2.1.2. Trans-activation of different viral promoters during infection 
Next, we wanted to test the importance of the p40 promoter for the inducibility of the AAV 
replicon. Different potential applications may need different expression levels of the regulated 
gene of interest, which can most efficiently be regulated by using different promoters. In the 
context of our basic replicon, both the genome replication and transactivation of the natural 
p40 promoter were responsible for the induction of the transgene expression in presence of 
helper functions. To evaluate the intrinsic features of the AAV p40 promoter for the replicon 
response, we inserted two other well-characterized constitutive promoters into the replicon 
construct and tested their inducibility upon Ad infection. We choose a viral promoter, the 
simian virus 40 major late promoter (SV40L) [280], and a cellular mouse metallothionein I 
promoter (MT) [281] as model promoters. 
To do this, the AAV p40 promoter was inactivated by mutation of the TATA sequence of p40 
in order to avoid transgene expression activation due to the AAV specific promoter (Figure 10) 
[232]. The mutated P40 promoter was synthetized and cloned in an extra plasmid together 
with either the SV40L or the MT promoter sequences, and a tripartite leader sequence for 
increasing the efficiency of GLuc mRNA export [282]. Then, the cassettes were transferred to 
the pAV1-GLuc-Hyg vector instead of the AAV p40 promoter on the 5’ end of the GLuc ORF. 
These constructs should be regulated mainly by induction of vector amplification similarly to 
the published constitutive promoter based MCMV replicon. 
 
Figure 10: Cloning of two different constitutive promoters instead of the AAV p40 promoter. 
For the cloning of the constructs pAV1-GLuc-P40M-SV40L-TPL and pAV1-GLuc-P40M-MT-TPL, the AAV 
replicon p40 promoter was eliminated in the pAV1-GLuc-Hyg construct by insertion of a mutated p40 
promoter together with either the MT or the SV40L promoter fused to a tripartite leader sequence 
upstream to the transgene (GLuc) ORF. 
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The AAV replicon plasmids with the respective promoters, pAV1-GLuc-P40M-SV40L-TPL and 
pAV1-GLuc-P40M-MT-TPL, were co-transfected with the tracer plasmid pO6-A5-CMV-GFP into 
293A cells. After controlling the transfection efficiency, the cells were split into 96-well plates 
and 72 h after transfection the cells were either infected with the Ad5-Che at different MOIs 
or kept non-infected. 48 h p.i. the GLuc expression was measured. 
 
Figure 11: Trans-activation of different viral promoters by infection. 
293A cells were transfected with pAAV-GLuc-Hyg (p40) or the respective constructs with the simian 
virus 40 major late promoter pSV40L or the metallothionein I promoter pMT and infected with 
different dose of Ad5-Che or kept non-infected. The supernatants were collected 48 h p.i. and a 
bioluminescence assay was performed. The induction upon infection was calculated by comparing the 
RLU values recorded after measurements of infected to non-infected supernatants. Data from three 
independent experiments are shown; the error-bars represent means ± SD; (Two-Way-ANOVA was 
performed for statistical analysis; **: p < 0.01, ****: p < 0.0001) 
The background GLuc expression levels of non-infected AAV p40 promoter transfected cells 
were 1.9-fold lower compared to SV40L promoter transfected cells and 1.8-fold lower than 
the MT promoter transfected cells. The MT promoter driven replicon appeared to be none-
inducible with Ad5-Che infection at any MOI tested (Figure 11). The simian virus promoter 
SV40L showed 2-, 10- and 23-fold induction of GLuc expression after infection with Ad5-Che 
at MOI 1, 10 and 100, respectively. Nevertheless, the highest increase of the transgene 
expression was significantly demonstrated by the AAV specific promoter p40, where GLuc 
expression was increased 11-, 90- and 207-fold. This data show that p40 promoter-specific 
factors play an important role in the replicon response. The p40 promoter showed the lowest 
background activity, it expressed the highest level of transgene product upon induction, and 
consequently showed the highest inducibility and also the highest expression levels among 
the promoters tested. Therefore, the promoter p40 of AAV was chosen for all further 
experiments in these studies. If lower transgene expression levels are favored upon induction 
(toxicity), the pSV40L based constructs may provide a useful alternative of the p40 construct. 
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4.2.1.3. Induction of the AAV replicon system by different human adenovirus 
serotypes 
Several adenovirus serotypes have been shown to provide helper functions for AAV [283] 
[284]. To test different viruses as inducers, we first tested how efficient helper functions were 
provided by different Ad. To this end, selected serotypes were tested, representing 5 out of 7 
human Ad species for their ability to induce the AAV replicon response. 
At first, we wanted to determine the optimal virus load and time kinetics that is required to 
induce a significant AAV replicon response by wild-type Ad5, which belongs to species C. We 
used this serotype as a model inducer. With this information we could limit the test conditions 
to compare the helper efficiencies of different Ad serotypes. Therefore, the AAV replicon 
vector was transiently transfected in 293A cells and 72 h p.t. the cells were seeded into 96-
well plates and, 4 hours later, infected with Ad5 at different MOIs to find out the minimal and 
maximal inducible infection dose. The supernatants of infected and non-infected cells were 
collected 1, 2, 3, and 4 d p.i. and afterwards the reporter gene expression was evaluated by 
bioluminescence measurement in the supernatants.  
 
Figure 12: Induction of the AAV replicon by different Ad serotypes upon transfection. 
(A) Cells were infected with Ad5 at indicated MOI 72 hours post transfection (h p.t.). The supernatants 
were collected at different time points and a bioluminescence assay was performed. Fold induction of 
infected compared to non-infected RLU values were calculated. (B) Inducibility of GLuc after infection 
with different adenovirus species and serotypes, species A – serotype Ad12 (A12), species B – serotype 
Ad3 and Ad11 (B3 and B11), species C – serotype mutant Ad5-Che (C5), species D – serotype Ad9 and 
Ad17 (D9 and D17) and species E – serotype Ad4 (E4), in comparison with Ad5-Che mutant virus at MOI 
1 was examined 3 d p.i. by collecting the supernatants and comparison of infected versus non-infected 
RLU values. Data from three independent experiments are shown; the error-bars represent means ± 
SD; 
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The results revealed that the best dynamic range of induction can be achieved with a dose of 
MOI 1 (Figure 12A) for Ad5 infection. The induction for higher MOIs (MOI 10 and 100) reached 
a plateau of about 180-fold after 3 d p.i. and at the lowest dose (MOI 0.1) the levels of 
induction were very low. At MOI 1 in contrast, we received a clear dose response until 
collection at 3 d p.i. The induction of reporter gene expression was 133-fold and doubled 
within a 24 h period. The replication cycle of the specific Ad serotypes may differ from each 
other. Therefore, we decided to take 3 d p.i., which is the latest time point of significant 
increase observed by Ad5. Having an average replication cycle of 24h this is one of the best 
growing serotypes.  
In order to test the responsiveness of the AAV replicon to different Ad serotypes we 
transfected 293A cells transiently with pAV1-GLuc-Hyg. Then, the transfected cells were 
seeded on 96-well plates and infected with 7 different Ad serotypes: Ad12 of species A, Ad3 
and Ad11 of species B, Ad9 and Ad17 both belonging to species D, and Ad4 of species E. As 
control, and representing species C, we used Ad5-Che infection at MOI of 1. After analysis of 
the transgene expression 3 d p.i. by bioluminescence assay, the height induction by all tested 
Ad serotypes was compared to non-infected cells (Figure 12B). The infection with Ad12 of 
species A showed the highest induction of GLuc expression (87-fold), whereas the Ad5-Che 
infection induced the GLuc expression 31-fold, similarly as observed before (Figure 9). 
Interestingly, most Ads, besides Ad12, displayed the same range of induction. Ad species B 
viruses for example induced the bioluminescence expression 41- and 54-fold, whereas Ad 
species D viruses showed a 39- and 37-fold induction. Species E derived virus Ad4 was 
demonstrated to induce the least GLuc expression with only 21-fold. The data indicated that 
the AAV replicon system is generally applicable for assays of human adenovirus infections.  
4.2.1.4. Induction of the AAV replicon by herpes simplex viruses 
As Ad, herpesviruses are also known helper viruses for AAV. Therefore, we were primarily 
interested in testing if the AAV replicon vector is inducible by herpes simplex viruses. Both 
herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) can productively 
infect Vero cells, the standard cell line culturing these viruses in clinical virology. Therefore, 
we decided to test these herpesviruses first for their ability to induce AAV replicons upon 
transient transfection of Vero cells. 
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We transiently transfected Vero cells with pAV1-GLuc-Hyg according to the protocol used for 
293 cells and seeded those 72 h later into a 96-well plate at density of 3x104/well. After 4 h, 
the cells were infected with either HSV-1 or HSV-2 using different doses. To examine the GLuc 
expression over time, supernatants were collected after 1, 2, and 3 days after infection. The 
induction of luciferase expression of HSV infected cells were normalized to the values 
obtained in supernatants of non-infected cells (Figure 13A).  
 
Figure 13: Infection with HSV-1 and HSV-2 activates reporter gene expression. 
Vero cells were transfected with pAAV-GLuc-Hyg and infected with different particle numbers of (A) 
HSV-1 and (B) HSV-2. The supernatants were collected at different time points and a bioluminescence 
assay was performed. Fold induction of infected compared to non-infected RLU values were calculated. 
Data from three independent experiments are shown; the error-bars represent means ± SD; 
The experiments revealed that 3 d p.i. the AAV replicon assay was highly inducible at a very 
low infection dose, achieving a plateau after infection at MOI 0.01. For example, infection of Vero 
cells at MOI of 0.001 induced the replicon encoded reporter gene expression 246-fold, 
compared to a 392-fold induction with infection at MOI of 0.01. Infection with the lowest dose, 
at MOI 0.01, showed a significant induction after 2 d p.i. (119-fold). At higher HSV-1 infection 
density (MOI 0.1 or more), a significant induction was already detected after 24 h p.i. With 
MOI 0.1 and MOI 1 the induction was 18-fold and 120-fold, respectively. 
However, induction of the transiently transfected AAV replicon vector with HSV-2 was much 
lower than after infections with HSV-1 (Figure 13B). In this case, the induction of GLuc was at 
maximum 17-fold at a MOI of 0.1. Taken together, the reactivity of the transiently transfected 
AAV replicon system is excellent using HSV-1 infection in Vero cells. On the other hand, HSV-
2 barely induced the replicon-encoded transgene under the same conditions. 
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4.2.2. Construction and characterization of stable cell lines carrying AAV 
replicons 
Despite the flexibility of the transient transfection concerning the investigation of the AAV 
replicon in different cell lines, the reproducibility of the assay needed to be improved. 
Especially applications, such as phenotypic tests in virus diagnostics seek high level of 
standardization. Therefore, we wanted to test whether it is possible to generate cell lines that 
stably maintain the AAV replicon. To this end we wanted to generate cell lines carrying 
different reporter genes under the control of AAV replicon. For quantitative detection of virus 
infection using flow cytometry (FACS), the enhanced green fluorescent protein gene (EGFP) 
was selected and incorporated to the AAV genome as described earlier (chapter 4.1). EGFP is 
known to be a very stable protein, with a half-life of 24 h [285] and can easily be detected in 
the presence of low level induction due to its propensity to accumulate. The other transgene 
we wanted to test with this system, was the GLuc, which we could test using the construct we 
used in the transient assays. The advantage of this reporter gene is its secretion from 
mammalian cells into the cell culture medium, which allows testing without the need of cell 
lysis [286]. The sensitivity of GLuc is very high and, due to its great stability, the possibility of 
collecting the supernatants at different time points and measure their bioluminescence later, 
makes it a useful tool for high throughput applications. 
4.2.2.1. Establishment of an EGFP expressing AAV replicon cell line 
293A cells were chosen as a platform to construct the EGFP reporter based stable AAV replicon 
cell line. This cell line can be infected with both Ad and HSV. Therefore, the pAV1-EGFP-Hyg 
was transfected into 293A cells using FuGene, and individual cell clones were isolated by 
limiting dilution in the presence of hygromycin for selection. 25 cell clones named AAVG#1-25 
were isolated, propagated until a stable stage of growth (usually 6 passages) and frozen for 
further testing. After establishing the clones based on their hygromycin resistance, they were 
tested for their ability to express EGFP upon Ad infection using FACS analysis.  
To analyze the AAVG clones, they were recovered from their frozen stocks and either infected 
with Ad5-Che using a MOI of 100 or kept mock infected. FACS analysis of the non-infected and 
infected cell clone was done 2 d p.i. Among these cell clones, all showed an induction of green 
fluorescence upon Ad infection compared to non-transduced 293A cells, which had a low level 
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autofluorescence (1%). Most of the clones showed a higher proportion of green fluorescence 
positive cells after infection, ranging from 11% to 72%, and indicating Ad5 infection induced 
expression of EGFP. Interestingly, AAVG#7 did show a high proportion of green fluorescence 
that was not further induced by Ad infection. Out of these cell clones the 4 most promising 
clones were selected for further analysis: AAVG#9, AAVG#16, AAVG#20 and AAVG#K, together 
with the non-inducible but GFP fluorescence positive clone AAVG#7. In order to compare the 
inducibility of their GFP expression, the different AAVG clones were either infected with Ad5-
Che at a MOI of 100 or with HSV at a MOI of 1. After 48 h p.i., EGFP expression in the cells was 
analyzed by FACS (Figure 14).  
As expected, AAVG#7 showed green fluorescence independently of virus infection. The other 
selected clones demonstrated a similar increase of transgene expression of 4.4-fold (AAVG#9), 
3.8-fold (AAVG#16), 3.3-fold (AAVG#20) and 3.5-fold (AAVG#K) after Ad5-Che infection. In 
general, the induction after Ad5-Che infection was slightly higher compared to the induction 
of EGFP expression after HSV-1 infection, which was 2.5-fold (AAVG#9), 3.5-fold (AAVG#16), 
1.5-fold (AAVG#20) and 3.6-fold (AAVG#K). Considering the insignificant effect of Ad5 and 
HSV-1 on the reporter gene expression of the AAVG clones, these clones appeared to be 
minimally reactive and therefore represented no advantage over the assay based on the 
transient transfection of AAV replicon. 
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Figure 14: FACS analysis of stable AAV EGFP replicon clones. 
The stable cell lines AAVG#7, AAVG#9, AAVG#16, AAVG#20 and AAVG#K were either non-infected 
(n.i.), infected with the mutant virus Ad5-Che at MOI 100 or with HSV-1 at MOI 1. EGFP capacities were 
determined 48 h p.i. using FACS analysis. Shown is one representative experiment out of two; 
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4.2.2.2. Construction of a GLuc expressing AAV replicon cell line  
Besides EGFP, GLuc represents another possible transgene for the construction of an inducible 
stable cell line. To construct stable AAV replicon clones with GLuc as transgene, the vector 
pAV1-GLuc-Hyg was transfected into 293A cells and single clones were selected by limiting 
dilution under hygromycin selection. Overall, 66 clones were isolated, propagated and tested 
for the inducibility of the transgene expression upon Ad infection. For testing the conditional 
expression of GLuc, the clones were seeded into 96-well plates at 3x104/well density and 
either kept non-infected or infected with the recombinant Ad5-Che at a MOI of 100. 48 h p.i. 
bioluminescence assays of the collected supernatants were performed and compared to the 
respective values obtained in non-infected cultures. Only 1 clone out of the 66 tested was 
responding to the Ad5-Che infection with an about 30-fold induction of GLuc expression.  
This clone, LE2D8, was the only one we further analyzed to define the best conditions of future 
applications. LE2D8 cells were either infected with Ad5-Che at MOI 100 on the same day of 
seeding (day 0), or within the following 3 days (day 1 – day 3). The supernatants were collected 
at different days, ranging from 1 day p.i. to 4 days p.i., in order to test the optimal induction 
time (Figure 15).  
 
Figure 15: Characterization of LE2D8. 
Stable cell line LE2D8 was infected with the Ad5-Che using a MOI of 100 at the same day (Day 0) to day 
3 after seeding, following supernatants collection at different time points (1 – 4 days post infection (d 
p.i.)). A bioluminescence assay was performed, and the inductions of infected cells were calculated by 
normalizing to the values of non-infected cells. Data from three independent experiments are shown; 
the error-bars represent means ± SD; 
The highest induction of the transgene upon Ad infection was detected when LE2D8 cell clones 
were infected at the same day of seeding and analysis of the bioluminescence done on day 3 
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after transduction. Here, the induction of luciferase expression was 40-fold. Infection on the 
day of seeding generally showed an increase of the signal from day 1 to day 3 post infection 
of 1.5-fold, 13-fold and 40-fold. At day 4 the expression of GLuc was slightly decreasing to 35-
fold. If cells were infected 24 hours after seeding, the variation between the experiments 
started to increase considerably. Here, the induction of the transgene was 20-fold (1 day-), 
11-fold (2 days-) and 42-fold (3 days after infection) with a standard deviation (SD) nearly as 
high as the values itself (26, 14 and 30). When the stable cell line was transduced 2 days after 
seeding, the induction was 20-fold with a SD of 27 after collection at day 1 - and 26-fold with 
a SD of 17 at day 2 post transduction. However, when the infection was performed 3 days 
after seeding, no induction of GLuc was detected.  
In summary, the reproducibility of the experiments was better when all were infected on the 
day of seeding, while infection on later days after seeding gave unsatisfactory results for Ad5-
Che induction. 
Concerning the overall time for one assay, the possibility of immediate infection after seeding 
resulted in a shortened assay duration. The bioluminescence after infection of the stable cell 
line was lower when compared to results after infection of transiently transfected cells using 
the same infection conditions (see Figure 7). However, the loss of reproducible inducibility 
culturing the cells together with the extremely low cloning efficiency indicated the instability 
of the AAV replicon construct in stable cell lines. 
4.2.2.3. Human Ad5 and HSV-1 infection induce the AAV replicon in the cell line 
LE2D8 
Based on these findings, the link between the time point of analysis and signal strength was 
nevertheless further evaluated. Therefore, the inducibility of the LE2D8 cell line infected by 
Ad5-Che and HSV-1 was investigated at different MOIs right after seeding. The supernatants 
of Ad5-Che infected cells were collected and analyzed from 24 to 84 h p.i. and of HSV-1 
infected cells from 12 – 60 h p.i. (see Figure 16). 
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Figure 16: Infection of LE2D8 with HAd5-Che and HSV-1. 
(A) The stable cell line LE2D8 was infected with the mutant virus Ad5-Che at a MOI of 1, 10 and 100 or 
kept mock infected and at 24, 36, 48, 60, 72 and 84 h post transduction the induction of GLuc was 
measured. (B) Infection of LE2D8 with HSV-1 at a MOI of 0.1, 1 and 10 or no infection was done. Then 
supernatants collection and measurement of GLuc induction at different time points (12, 24, 36, 48, 
60 h p.i.) followed. The induction of the bioluminescence for both viruses was calculated by comparing 
infected and non-infected values. Data from three independent experiments are shown; the error-bars 
represent means ± SD; 
Both viruses showed a time dependent increase that was not reaching the plateau in the 
tested time. Detailed analysis of Ad5-Che revealed that the expression of GLuc was highly 
dependent on the virus dose. The induction after infection at a MOI of 1 was not significant. 
There was no induction compared to the non-infected cells within the first 24 h p.i. and an 
increase to 4-fold followed only at 84 h p.i. At a MOI of 10, the expression of the transgene 
was higher and increased to 16-fold at 84 h p.i. The highest values of the bioluminescence 
compared to non-infected cells with an increase of 29-fold after 84 hours were reached with 
the highest dose of Ad5-Che. In contrast, the induction of the stable AAV replicon cell line by 
infection with HSV-1 was less dependent on the virus dose, compared to Ad5-Che infections. 
This indicates that HSV-1 infection reached the induction limit faster and at much lower virus 
load. The induction of GLuc could be already detected 24 h p.i. after infection at a MOI of 1 
and 10. The induction compared to non-infected cells was 11-fold and 17-fold. When LE2D8 
cells were infected with HSV-1 at a MOI of 0.1 the earliest time point of a significant 
bioluminescence signal was 36 h p.i. with an induction of 8-fold compared to non-infected 
cells. The highest values were reached 60 h p.i. Here, the induction of GLuc was 58-fold (MOI 
0.1), 68-fold (MOI 1) and 72-fold (MOI 10).  
Results 
75 
Overall, the induction of the stable cell line LE2D8 revealed lower bioluminescence compared 
to the transient system. Nevertheless, the signal strength showed a clear correlation between 
time after infection and MOI for both viruses tested. 
4.2.2.4. The replicon response in LE2D8 cells by various Ad serotypes and HSV-2 is 
limited 
Based on the data from the transient transfection, we were interested to find out whether the 
response in the stable AAV replicon cell line was also inducible by different serotypes of Ads. 
Since the induction of GLuc after Ad5-Che infection of the stable cell line LE2D8 showed lower 
values compared to infection of transiently with pAV1-GLuc-Hyg transfected cells, the aim was 
a proof of principle and the usefulness of LE2D8 for approaches testing different adenovirus 
serotypes. Infection of LE2D8 cells was performed, as before, right after seeding and the 
bioluminescence signal was measured 3 d p.i. Afterwards the induction of GLuc was calculated 
compared to non-infected cells. A marginal increase of the signal could be seen for all viruses. 
The highest induction of GLuc, 15-fold, was reached after Ad12 infection, just like after the 
transient transfection. These results confirmed that the replicon response in LE2D8 
recapitulate the induction seen after transient transfection of the AAV replicon but in a lower 
level (see Figure 17). However, a lower level of inducibility was not observed when the LE2D8 
cell line was used to test HSV-2. 
Figure 17: Infection of LE2D8 with different HAdV-serotypes. 
The stable cell line LE2D8 was transduced with either species C – serotype mutant Ad5-Che (C5) as 
control or with species A – serotype Ad12 (A12), species B – serotype Ad3 and Ad11 (B3 and B11), 
species D – serotype Ad9 and Ad17 (D9 and D17) and species E – serotype Ad4 (E4) at MOI 1 or kept 
mock infected. 3 d p.i., the induction of GLuc was measured. The fold induction of GLuc was calculated 
for all viruses by comparing infected and non-infected RLU values. Data from three independent 
experiments are shown; the error-bars represent means ± SD; 
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To find out whether LE2D8 cells would be a good tool to test HSV-2, they were seeded into a 
96-well plate and infected 4 h later with HSV-2. The virus was a patient isolate (used with 
permission), expanded in cell culture and used at a dilution of 1:10. The GLuc expression was 
subsequently measured after 48 and 72 h p.i. Compared to transient transfection of Vero cells, 
the induction of LE2D8 upon HSV-2 infection indicated no significant signal increase (Figure 
18). 
 
Figure 18: Infection of LE2D8 with HSV-2. 
The stable cell line LE2D8 was infected with HSV-2 using 1:10 diluted viruses. 48 and 72 h p.i., the 
induction of GLuc was measured. The fold induction of GLuc was calculated by comparing infected and 
non-infected RLU values. Data from three independent experiments are shown; the error-bars 
represent means ± SD; 
4.2.3. Induction of frozen AAV replicon vector transfected cells 
Since generating cell lines that stably maintain AAV replicons did not yield a real alternative to 
transient transfection, we explored another way of controlling experiment-to-experiment 
variations.  
In order to do so, we transfected a large batch of 293A cells with pAV1-GLuc-Hyg and re-
suspended them after either 48 or 72 hours in standard freezing medium at a density of 3x104 
/100 L and seeded them in 96 well plates. The plates were then frozen to -80oC. Right after 
thawing, fresh medium was added and then the cells were incubated for 2 hours under normal 
cell culture conditions. After that, supernatants were exchanged to fresh medium. Six h after 
thawing, the cells were ready to be infected with Ad5-Che at different MOIs. The GLuc signals 
in the supernatants were analyzed 48 h p.i. and compared to non-infected cells, which were 
treated the same way. The results showed that freezing and thawing of transfected cells for 
an induction experiment is possible (Figure 19A). The induction was higher when the 
Results 
77 
transfected cells were frozen already at 48 h post transfection. Interestingly, independent of 
the freezing time-point after transfection, the signal was not reflecting the number of viral 
particles used for infection. If the cells were frozen 48 h after transfection, infection at MOI of 
1 resulted in a 126-fold induction of GLuc, whereas the signal decreased to 99-fold and 67-
fold at MOI 10 and MOI 100. The same effect, but lower, could be seen if the cells were frozen 
72 h after transfection. Here, the signal strength decreased from 73-fold at MOI 1, to 59-fold 
at MOI 10 and 46-fold at MOI 100. It seems that a combination of freezing and thawing 
procedure and infection with high dose of Ad has a negative impact on the replicon response. 
 
Figure 19: Frozen AAV replicon transfected cells are induced by helper virus infection. 
293A cells were transfected with pAV-GLuc-Hyg, and either after 48 or 72 h post transfection (p.tf.) the 
cells were seeded in a 96 well plate format and frozen. (A) Cells were thawed and 6 h post thawing 
(p.th.) infected with Ad5-Che at indicated MOI. (B) After thawing of the cells, they were infected either 
6 or 18 h p.th. with HSV-1 at indicated MOI. The induction of GLuc in the supernatants of Ad5-Che and 
HSV-1 infected and non-infected cells were measured. The fold induction of GLuc was calculated for 
all samples by comparing infected and non-infected RLU values. Data from three independent 
experiments are shown; the error-bars represent means ± SD; 
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Consequently, we infected the pre-transfected, frozen and thawed cells with HSV-1 at 
different MOIs to proof whether this effect can be seen using another helper virus as well. For 
this, AAV replicon transfected cells in the prior frozen plates were infected 6- or 18 h after 
thawing. The second time point for infection was chosen in order to let the cells recover for a 
longer period before infection to avoid possible toxic effects of infection with higher MOIs 
(Figure 19B). Here MOI of HSV-1 correlates with the strength of induction of GLuc expression. 
Cells frozen 48 h after transfection and infected 18 h after thawing at MOI 0.01, 0.1 and 1, 
showed the highest induction of GLuc expression (103-, 419- and 649-fold, respectively). 
Freezing the plate 72 h post transfection resulted in a lower induction of the signal. If the cells 
were infected 6 h after thawing, the bioluminescence signals were independent of the freezing 
time point after transfection and were about 90-, 270- and 315-fold, respectively. The 
correlation of the time of infection after freezing and toxicity effects seen with Ad at higher 
viral load could not be confirmed with HSV-1. 
In conclusion, freezing of already transfected and seeded cells is functioning very well. The 
cells in the 96-well plate format could easily be prepared in a larger amount of plates and 
thawed in the respective quantity. The freezing and thawing of the AAV replicon transfected 
cells can be used as an alternative to save time after transfection and to have a ready to use 
system. Nevertheless, this new approach is restricted to cell lines that can be well transfected 
and are robust enough to withstand this protocol. 
4.2.4. Induction of the AAV replicon vector packaged into recombinant 
AAV2 particles 
The so-far tested transfection-based methods for delivery of the AAV replicon did not fulfill all 
standardization characteristics and applicability requirements for the development of a 
reporter assay on virus growth. This can be due to the poor reproducibility of transfection 
based experiments. In addition, delivery of all previously described plasmid-based replicons is 
limited to transient or stable transfection. This restricts the use to only well transfectable cell 
lines for the replicon assays. Testing the inducibility of AAV replicon by other viruses, such as 
human cytomegalovirus (HCMV), which are permissive to only a limited set of target cells, is 
inhibited by the poor transfectability of these cells. 
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In our AAV replicon vector, the ITRs are required as cis elements for the incorporation of its 
genome into recombinant AAV (rAAV) particles. This allows to test whether the AAV replicon 
can be packaged and delivered as recombinant AAV particle. For this purpose, we analyzed 
the transduction efficacy of different rAAV particle serotypes for their ability to transduce 
293A cells, Vero cells and HFF (Human foreskin fibroblasts) cells. This was done to test whether 
packaging systems other than AAV2 are beneficial for the target cell range for the replicon 
assay. Next, we tested if the AAV replicon vector can be packaged into recombinant AAV 
particles by standard co-transfection methodology using AAV2 based packaging plasmids 
[287]. 
4.2.4.1. Transduction efficiency of different recombinant AAV serotypes on Vero 
and HFF cells 
To identify the best rAAV serotype for transduction of Vero cells and HFF cells we used rAAV 
particles carrying EGFP under the control of a CMV promoter (rAAV-CMV-GFP). We tested 
recombinant capsids derived from AAV serotype 1, 1/2 (a hybrid between serotype 1 and 2), 
2, 4, 5 and 6. First, both Vero and HFF cells were transduced with 10000 particles per cell (p/c) 
of the 6 different rAAV-CMV-GFP serotypes. We then analyzed the transduction efficiency of 
the different rAAV serotypes in the cell lines 48 h and 6 days post transduction using 
fluorescence microscopy (Figure 20). The particle rAAV2-CMV-GFP showed the highest 
number of transduction efficiency. 
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Figure 20: Analysis of transduction efficacy of different AAV serotypes. 
HFF and Vero cells were transduced with 10,000 particles per cell (p/c) of different rAAV-CMV-GFP 
serotypes, namely 1, 1/2, 2, 4, 5 and 6. All cells were analyzed for their ability to be transduced by 
fluorescence microscopy 48 h and 6 days post transduction. 
Consequently, the recombinant AAV2-CMV-GFP particles were further analyzed for their 
optimal transduction dose, applying of 100, 1000 and 10000 p/c. We also included two 
additional cell lines - 293A and A549 - which are both possible options to carry out replicon 
induction experiments after Ad infections. After transduction, the cells were analyzed by 
fluorescence microscopy after 24, 48 and 72 h post transduction. In all cell lines the GFP signal 
obtained correlated with the dose of recombinant particles (Figure 21). 
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The observed transduction efficiency was different for each cell line. 48 h post infection, the 
efficacy of GFP expression in 293A, Vero and HFF cells was high, whereas after the same 
timespan A549 cells revealed a low transduction rate of rAAV2-CMV-GFP, which then slightly 
increased after 72 h (Figure 22). 
 
Figure 22: Analysis of transduction efficacy of A549 cells with rAAV2 particle after 72 h. 
A549 cells were transduced with 100, 1000 and 10.000 particles per cell (p/c) of rAAV2-CMV-GFP. 72 
h post transduction, cells were analyzed for their ability to be transduced by fluorescence microscopy. 
 
In conclusion, the serotype 2-derived rAAV particle showed an acceptable transduction rate 
in at least one cell line of interest. 
Subsequently, we tested the production of serotype 2 rAAV particles carrying the AAV 
replicon. The AAV replicon vector pAV1-GLuc-Hyg contains two ITRs serving as viral origin of 
Figure 21: Analysis of transduction efficacy of rAAV2 particles. 
293A, Vero, A549 and HFF cells were transduced with 100, 1000 and 10000 particles per cell (p/c) of 
rAAV2-CMV-GFP. 48 h post transduction, cells were analyzed for their transduction capacity by 
fluorescence microscopy. 
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replication and packaging signal. These two ITRs flank the rep gene and the transgene under 
the control of the p40 promoter, which should be transferred as DNA vector genome into the 
rAAV particle. For the replicon containing rAAV2 particle production we used the helper 
plasmid pDP2rs, which provides the structural and non-structural genes of AAV2 and the Ad 
helper functions [287]. The AAV replicon containing serotype 2-derived recombinant AAV 
particles we named rAAV2-REP-GLuc. 
The semi-quantitatively analyzed ITR differed from the GLuc genome copy numbers along 
different productions of rAAV2-REP-GLuc. These irregularities also revealed a difference 
between ITR and GLuc sequences of 14- and 24-fold in single productions of rAAV2-REP-GLuc 
batches as well as differences between batches concerning the gene copy number of GLuc 
(Table 4.2.4.1.1). 
We did not investigate the reason for these irregularities and decided to use the GLuc-PCR 
based genome counts instead of the commonly used ITR-counts for the particle number 
calculations, since the gene copy number measured using the GLuc gene corresponded to the 
expression data (see later). 
Table 4.2.4.1.1: Comparison of ITR and GLuc copy number by quantitative PCR. 
  ITR copy number Gluc copy number 
rAAV2-REP-GLuc batch 1 N/A 3,40 x 1010 
rAAV2-REP-GLuc batch 2 2,38 x 1011                  5,76 x 109 
rAAV2-REP-GLuc batch 3 3,98 x 1011 2,29 x 1010 
rAAV2-REP-GLuc batch 4 4,25 x 1011 2,17 x 1010 
4.2.4.2. Induction of rAAV-based replicon response 
We selected 293A cells for a first functional test of the transduced rAAV2-REP-GLuc, since this 
cell line showed appropriate induction rates for both Ad and HSV-1 infections after replicon 
transfection. Therefore, 293A cells were seeded onto 96-well plates at a density of 3 x 104 per 
well and right after seeding transduced with 1 to 10000 p/c of rAAV2-REP-GLuc. After an 
incubation time of 6 hours, the transduced cells were infected with either Ad5-WT at MOI 10, 
HSV-1 at MOI 0.1, or kept non-infected. 48 h later a bioluminescence assay was performed to 
measure the GLuc induction and to compare the induction of infected to non-infected but 
transduced cells (Figure 23). 
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Figure 23: Transduction of 293A cells by replicon containing recombinant AAV particles. 
293A cells were transduced with the indicated number of replicon-containing recombinant AAV 
particles (rAAV2-REP-GLuc) per cell (p/c) and 6 h later infected with (A) Ad5-WT at MOI 10, (B) HSV-1 
at MOI 0.1, or kept non-infected. 48 h p.i. GLuc induction was measured and compared to values of 
transduced but non-infected cells. Shown are data from three independent experiments, done in 
triplicates; the error-bars represent means ± SD; 
We observed an infection-dependent induction of the replicon gene expression of at least 10-
fold under all conditions tested. A transduction dose-dependent increase of the GLuc reporter 
gene expression after Ad5-WT infection was also detectable up to the amount of 100 rAAV2-
REP-GLuc per cell. Interestingly, transduction with higher particle numbers resulted in a 
proportional decrease of the signal. Nevertheless, the 537-fold induction after HAd5 infection, 
compared to non-infected but transduced cells, was the highest induction we could observe 
in our study up to this point for Ads. In case of HSV-1 infection, the induction also increased 
dose-dependently in the low-dose settings.  In contrast to Ad5-WT, HSV-1 infection resulted 
in a plateau of GLuc induction after transduction with 1000 p/c. With an induction of 613-fold 
following HSV-1 infection, the rAAV2-REP-GLuc also showed a better inducibility of GLuc 
compared to previously tested delivery methods of the AAV replicon vector. The subsequent 
decrease or constant signal with increasing amounts of rAAV2-REP-GLuc particles after Ad5 
and HSV-1 infections indicated a potential toxicity of AAV transduction at high dose. The big 
variation of induction levels also indicated suboptimal conditions for the replicon response 
upon transduction of 293 cells. 
Nevertheless, the reporter gene of the rAAV2-REP-GLuc was better inducible in 293A cells than 
in any other experiment before. Therefore, we decided to test other cell lines and viruses for 
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their ability to induce the AAV replicon response after delivery by rAAV particle transduction. 
For each cell line and virus, we tested multiple conditions of transduction, infection, and 
collection of the supernatants to draw a comprehensive conclusion of the applicability of the 
AAV replicon system. 
Hence, A549, Vero and HFF cells were seeded onto 96-well plates at a density of 3 x 104/ well 
and transduced with different doses of the rAAV2-REP-GLuc right after seeding. After 6 hours, 
the cells were infected with Ad5-WT at MOI 10, with HSV-1 and HSV-2 at MOI 0.1 and with 
HCMV at MOI 1. The supernatants of infected and non-infected cells were collected for 
analysis at different time points after the respective virus infections. 
In the rAAV2-REP-GLuc transduced A549 cells, the replicon encoded reporter gene expression 
was induced by infection with Ad5-WT at MOI 10 to an unexpectedly high value of 13500-fold 
compared to non-infected cells 48 h p.i. This result was in sharp contrast to the low 
transduction efficacy we observed in this cell line after transduction of the constitutive GFP 
expressing rAAV2-REP-GLuc in the previous experiment (chapter 4.2.4.1). In addition, the 
reporter gene induction directly correlated with the number of AAV replicon containing rAAV 
particles without showing a drop at higher doses (Figure 24A). HSV-1 was able to significantly 
induce the transgene expression 54-fold in transduced Vero cells with 600 p/c after 24 h p.i. 
Similar to A549 cells after Ad5-WT infection, this cell line showed a transduction dose-
dependent increase of the GLuc induction. The induction also increased linearly by time, 
showing an about 7-fold increase from 24 h p.i. to 48 h p.i. The highest induction, 2800-fold 
compared to non-infected transduced Vero cells, was observed on day 2 after transduction of 
10000 particles and infection with HSV-1 (Figure 24B). 
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Figure 24: Induction of AAV replicon after transduction. 
(A) A549 cells were transduced with indicated dose (p/c) of rAAV2-REP-GLuc and 6 h later infected with 
Ad5-WT at MOI 10. 48 h p.i. supernatants were collected, GLuc induction measured and compared to 
those of transduced but non-infected A549 cells. (B +C) Vero cells were transduced with indicated 
rAAV2-REP-GLuc doses (p/c) and infected with (B) HSV-1 or (C) HSV-2 at MOI 0.1 6 h later. Supernatants 
were collected at 24- and 48 h p.i. and induction were calculated as above. (D) HFF cells were 
transduced with 1000, 3000 and 10000 p/c of rAAV2-REP-GLuc and 6 h later infected with HCMV at 
MOI 1. Supernatants were collected after 48 h p.i., 4- and 7 d p.i. GLuc activity was analyzed by 
bioluminescence and induction was calculated. Data represents three independent experiments, done 
in triplicates; the error-bars represent means ± SD; 
In previous experiments we could not induce the AAV replicon system significantly with two 
other herpesviruses: HSV-2 and HCMV. The stability of the transduced rAAV2-REP-GLuc 
motivated us to re-test the inducibility of the AAV replicon after infection with these viruses. 
The supernatants of HSV-2 infected Vero cells were therefore analyzed after 24 and 48 hours 
and the supernatants of HCMV infected HFF cells at 48 h p.i., 4- and 7 d p.i., taking the longer 
replication time of HCMV in comparison with Ad5 or α-herpesvirinae into account. As a result, 
both viruses were able to significantly induce the AAV replicon system after transduction of 
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the corresponding cell line. HSV-2 showed an induction of 21-fold 24 h p.i. after transduction 
with 1000 p/c and a 100-fold induction with 10000 p/c. Two days after infection, the GLuc 
induction increased to 215-fold at 10000 particles of rAAV2-REP-GLuc per cell. In case of 
HCMV, hardly any induction could be seen at 48 h p.i. 4 p.i., we measured a 76-fold increase 
at transduction levels of 10000 p/c compared to non-infected but transduced HFF cells. The 
effect was even more significant 7 days after infection, when the induction of the transgene 
was 165-fold compared to non-infected cells. Interestingly the level of induction after 
transduction of either 1000 or 10000 particles was only moderately increased (77- and 76-fold 
at 1000 p/c and 143- and 165-fold at 10000 p/c). Yet, the deviation between the two 
independent experiments, each performed in technical triplicates, was very high. 
The results revealed that the nature of target cell line plays an important role in both the 
inducibility and the reproducibility of the AAV replicon induction. High level inducibility, 
significant dose response, and good reproducibility were observed upon transduction of A549 
cells and infection with Ad5 as well as transduction of Vero cells and infection with HSV-1 and 
2. In contrast, 293A cells were not optimal using the same viruses for induction of AAV replicon 
containing rAAV particles. Further optimization is also needed for replicon induction by HCMV 
infection in transduced HFF cells. Nevertheless, with the ability of transducing the AAV 
replicon vector via a viral vector in more cell lines than before, the efficacy of the replicon 
induction increased significantly for all tested viruses. Furthermore, with the new delivery 
method, a significant induction of the AAV replicon system was observed for the first time 
after HSV-2 and HCMV infection. 
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4.3. Applications 
The different delivery systems of the AAV replicon offer several possible applications: We 
tested the AAV replicon vector for its applicability for trans-complementation, since this is a 
feasible method to investigate essential genes [214]. Furthermore, we established a suitable 
AAV replicon-based resistance test in order to analyze the application of the AAV replicon 
system in the field of diagnostic. Additionally, we developed a new screening platform for 
antiviral inhibitors using the AAV replicon vector. For the first time, this allows high-
throughput tests of inhibitors against genetically unmodified large DNA viruses. 
4.3.1. Trans-complementation of HAd5 late protein pVI by the AAV replicon 
vector 
For analyzing the trans-complementation potential of the AAV replicon system, we selected 
pVI, an essential late viral gene of HAd5, as a target. pVI is important for the activation of Ad 
genomes during the entry phase, for the endosomal escape, for the nuclear transport of Ad 
particles and it is an allosteric activator for the viral encoded cysteine protease [162]. In 
addition, pVI is toxic in isolated expression and therefore trans-complementing cell lines were 
not reported so far. Previously the pVI functions were studied in the same laboratory that 
provided the required tools to perform a proof-of-principle experiment for trans-
complementation using AAV replicon [288]. 
Adenovirus late proteins such as pVI are expressed only after the onset of viral DNA 
replication. For the expression of the toxic Ad5 pVI in trans, the AAV replicon system seemed 
to be a plausible alternative, since the expression of the transgene in the AAV replicon vector 
is dependent on the early functions of Ad. Without helper virus infection the reporter genes 
were practically silent in all our previous experiments. The early phase of Ad replication 
therefore is a prerequisite for viral DNA replication, onset of Ad late gene expression, and 
induction of p40 controlled transgene expression in the AAV replicon.  
For the trans-complementation of pVI deletion of Ad5 with the AAV replicon vector, cloning 
of pVI as transgene into the pAV1-Hyg vector was necessary. Furthermore, an Ad5 mutant 
lacking the pVI gene had to be constructed as well. In theory, upon infection with the Ad5 
mutant, the AAV replicon vector with pVI as transgene should be induced. Expression of the 
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essential pV gene could then complement the missing gene for production of the virions in 
the replicon containing cells. 
4.3.1.1. Construction of a HAd5ΔpVI mutant and the pIV expressing AAV replicon 
The deletion of the protein pVI would lead to an Ad5 mutant which is not able to spread. To 
test whether a deletion of the essential pVI gene can be trans-complemented and reverse this 
defect in trans, we constructed the viral mutant Ad5ΔpVI. We generated the genomic 
constructs using the E1-E3 deleted Ad5 BAC, namely the pBA5-FRT, as a basis. This BAC can be 
genetically tagged by site specific recombination at its FRT site. Additionally, the E1-E3 deleted 
viruses derived from this BAC should possess WT-like growth properties in 293 and 911 cells.  
To mark the genome before deleting the pVI gene, we introduced a mCherry expression 
cassette (Che) using the Flp/FRT recombination system with pBA5-FRT as an acceptor and 
pO6-A5-mCherry as donor plasmid leading to pBA5-Che. The correct insertion of the marker 
gene was checked by restriction digest and verified by sequencing the insertion sites. We 
deleted the pVI gene from the pBA5-FRT and inserted a zeocin resistance cassette by 
homologous recombination in E. coli SW102 cells. For this approach the selection marker was 
flanked on both ends with sequences homologous to those in the region exactly up and down-
stream of the pVI gene.  
We verified the replacement of pVI to a selection marker, leading to pBA5-ΔpVI-Che, by 
fragment length polymorphism, comparing the original pBA5-FRT BAC and the pBA5-FRT-Che 
BAC (Figure 25). Finally, the constructs were verified by Sanger sequencing at the site of the 
mutagenesis (see chapter 3.2.9). 
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Figure 25: Construction of a genetically marked pVI deletion mutant of Ad5 genome by BAC 
technology. 
Specific changes in the restriction pattern after insertion of the mCherry marker and deletion of the 
pVI gene were tested by restriction analysis. BAC DNA of Ad5-WT (wt or pBA5-FRT), pBA5-Che (wtC), 
and pBA5-ΔpVI-Che (ΔpVI) were digested with DraIII and HindIII (right panel). E.g. cleavage of Ad5-WT 
with DraIII resulted in fragments of 9.5, 8.3, 7.7, 4.5, 3.4, 3 and 0.85 kbp. Flip-in reaction of Che to 
pBA5-Che resulted in the loss of the fragment at 8.3 kbp but addition of 6 and 5.7 kbp. Deletion and 
replacement of pVI gene leaded to the addition of the fragments of 2.6 and 0.3 kbp (the last one is not 
visible anymore) and in the deletion of 3 kbp (additional fragments are indicated with blue 
arrowheads). These results were further confirmed by HindIII restriction. Here, the loss of fragment 
9.4 kbp and the addition of fragments 6.6, 2.9, 1.9, 1 and 0.2 and 0.07 kbp (latter two were not visible) 
demonstrated the difference between wt and wtC. Whereas the difference between wtC and ΔpVI 
could be displayed by the addition of fragment at 12.5 kbp and loss of fragment at 4.6 kbp. 
In addition to the mutated pBA5-ΔpVI-Che BAC, we also constructed a corresponding AAV 
replicon. For that purpose, we replaced the pAV1-GLuc-Hyg replicon vector (GLuc ORF) with 
the Ad5 pVI ORF, thus in direct control of the p40 promoter. This construct was named pAV1-
pVI-Hyg (see chapter 3.2). 
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4.3.1.2. Assessment of the AAV replicon system for trans-complementation 
In order to trans-complement the deleted pVI protein of the mutated Ad5 BAC during virus 
rescue, sub-confluent 293A cells were transfected in a 6-well plate at first with either pAV1-
pVI-Hyg or with pAV1-GLuc-Hyg. The replicon vector with GLuc served here for two purposes: 
as a control for potential inhibitory effects of the AAV replication, and to exclude the negative 
effects of the transfection process on the reconstitution of Ad5. Three days after replicon 
transfection, the cells were re-transfected with either the mutated pBA5-ΔpVI-Che or with the 
wt pBA5-Che BACs. Then the cells were harvested five days after the BAC transfection 
according to the standard rescue protocol for the Ad5 BACs. We subsequently re-suspended 
the harvested cells in normal media and lysed them by three freeze and thaw cycles in order 
to release reconstituted viruses. Finally, the lysates were cleared from cell debris by 
centrifugation. A new batch of 293A cells was transfected with either pAV1-pVI-Hyg or with 
pAV1-GLuc-Hyg replicons again. 72 hours after transfection, this batch was treated with the 
cleared lysates of the rescue cultures and viral plaque formation was examined in the course 
of the next seven days in order to quantify the efficiency of the virus rescue. 
Due to the high variability of BAC transfection efficiency, this experiment was repeated six 
times. All results are summarized in Table 4.3.1.2.1. We did not observe any trans-
complementation of the pVI deletion for the pVI gene deleted pBA5-ΔpVI-Che (ΔpVI-BAC) by 
the pAV1-pVI-Hyg replicon (pVI-R) and even the wt BAC, pBA5-Che, failed to be rescued in 
replicon transfected cells. In half of the experiments, a rescue of the wt BAC was observed 
despite the presence of pVI-R transfection but not in presence of pAV-GLuc-Hyg (GLuc-R), 
independent of the amount of the AAV replicon vector DNA transfected into the cells.  
Growing of the rescued wt Ad5 BAC, pBA5-Che, happened independently of the presence of 
pre-transfected or non-pre-transfected cells. Altogether, the number of plaques varied 
significantly between experiments. 
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Table 4.3.1.2.1: Rescue after trans-complementing pVI gene in mutated Ad5 BAC. 
Transfer of rescued virus with 
cells: 
WT BAC 
WT BAC 
+ pVI-R 
WT BAC 
+ GLuc-R 
pBA5-
ΔpVI-Che 
pBA5-
ΔpVI-Che 
+ pVI-R 
pBA5-ΔpVI-
Che  
+ GLuc-R 
non-pre-transfected 16.7 ± 15.9* 0.8 ± 1 0 0 0 0 
pre-transfected with GLuc 
Replicon 
12.8 ± 19.8 1.0 ± 2 0 0 0 0 
pre-transfected with pVI 
Replicon 
12.2 ± 15.1 0.8 ± 1.2 0 0 0 0 
*This table shows the mean and standard deviation of counted plaques from three independent experiments. 
To exclude an inhibitory effect by pre-transfection of the AAV replicon vectors on the virus 
reconstitution process, a recombinant AAV2 vector was packaged with pAV1-pVI-Hyg (named 
rAAV2-R-pVI). Here, 293A cells were transduced with the rAAV-R-pVI, containing the essential 
pVI gene for trans-complementation using 500 rAAV p/c. 5 days later, cell lysates were 
prepared and, to test virus rescue, the lysates of wt BAC and the mutated BAC were 
transferred to two groups of cells, one treated and one not treated with rAAV2-R-pVI using 
the same schedule as for the BAC transfection. 
Unfortunately, the pVI trans-complementation did not function upon transduction of the pVI 
containing rAAV replicon vector. The influence of the recombinant AAV replicon vector 
(rAAV2-R-pVI) transduction after transfection of the pBA5-ΔpVI-Che BAC vector was the same 
as observed after transfection of the AAV replicon vector and resulted in no viral progeny 
(Table 4.3.1.2.2) in three independent experiments.  
In contrast, we were able to rescue the wt BAC Ad5-Che independent of the presence of the 
recombinant AAV replicon vector. We even had to dilute the viral lysate and repeat the second 
part of the latter two experiments because of very high plaque numbers. Since trans-
complementing pVI of the mutated Ad5 BAC failed, we did not aim to investigate the reason 
for the high amount of plaques. 
Table 4.3.1.2.2: Rescue after trans-complementing pVI with rAAV2-R-pVI in mutated Ad5 BAC. 
  Ad5-Che +rAAV2-R-pVI pBA5-ΔpVI-Che+rAAV2-R-pVI 
Transfer of rescued virus with cells: Exp. 1 Exp. 2 Exp. 3 Exp. 1 Exp. 2 Exp. 3 
non-pre-transduced 152* 1880 1270 0 0 0 
pre-transduced with rAAV2-R-pVI 158 640 1860 0 0 0 
*counted plaques. 
To test a potential effect of the timing of the AAV replicon transduction, the transfection of 
the BAC DNAs was performed one day before transduction, on the same day, and two days 
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after the transduction of the 293A cells. As before, plaques were counted after seven days. 
Independent of the transduction time point, the trans-complementation of pVI was not 
successful after transducing 293A cells with the rAAV2-R-pVI vector. Nevertheless, 
independent of timing, the inhibitory effect of the replicon transfection on Ad-WT rescue was 
not observed by transduction of the replicons as rAAV particle.  
Overall, independent of the AAV replicon delivery to the cells, we were not able to observe 
trans-complementation of the pVI gene of the Ad deletion mutant. Transfection of the AAV 
replicon vector showed a toxic effect on virus rescue even independently of the pVI gene. This 
toxic effect was not observed if the AAV replicon vector was delivered packaged in a 
recombinant AAV2 vector. Nevertheless, the genetic defect of the pVI deletion in the viral 
mutant could not be rescued in the course of this work. 
4.3.2. AAV replicon system for diagnostic approaches 
For patients suffering from a drug-resistant HSV infection, a timely decision on switching to an 
effective antiviral therapy plays an important role in therapy success. Successful antiviral 
therapy of herpesvirus infections in immunocompromised patients, such as transplant 
recipients, newborns, leukemia patients, and patients with AIDS, are dependent on availability 
of phenotypic or genotypic drug resistance tests. The prevention of aggravation of the disease 
in these patients, by either increasing the dose of intravenous ACV administration or switching 
to another drug is very important. Concerning phenotypic methods, the “gold standard” for 
drug resistance testing for HSV isolates is still the plaque reduction assay (PRA), which is very 
labor and time intensive [123]. With tailoring the AAV replicon system as a quantitative 
reporter of viral growth in an antiviral drug resistance test, we aimed to establish a fast, 
reliable, easy to handle alternative to the PRA.  
The major potential to analyze the infectivity of herpes- or adenovirus samples relies on the 
ability of the AAV replicon vector to express a readily quantifiable reporter gene product upon 
infection. This reporter gene can be detected directly, in contrast to the indirect assay, which 
is needed to test the infectivity itself. At the same time, the absence of the reporter signal 
must reliably indicate the absence of infection or virus spread and both the positive and the 
negative results need to be highly quantitatively reproducible. 
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4.3.2.1. Establishment of the AAV replicon-based drug resistance test for HSV-1 
based on the LE2D8 cell line  
For testing the general ability of the AAV replicon system to respond to a drug treatment, we 
first examined the impact of the widely used drug ACV to an ACV sensitive HSV-1 laboratory 
strain by the induction of the replicon encoded reporter gene. Important to notice at this point 
is that ACV is highly specifically inhibiting HSV DNA metabolism [96]. Therefore, an influence 
of ACV on the replication of the AAV based replicon system itself is not to be expected, since 
the AAV genome replication is entirely dependent on host DNA polymerases [253]. 
For a reliable diagnostic assay, reproducibility of the measurements is very important. To 
proof this, the infection of the AAV replicon transformed stable cell line LE2D8 was chosen for 
the assay. To this end, LE2D8 cells were propagated in presence of hygromycin selection and 
frozen in a large batch with the aim of using a freshly thawed LE2D8 each time to avoid signal 
loss due to potential instabilities during passaging. Hence, freshly thawed LE2D8 cells were 
seeded after one passage on 96-well plates and infected with different doses of WT HSV-1. 
The doses ranged from 0.1 to 0.001 MOI in order to test the induction of the replicon encoded 
expression of GLuc at different time points. We aimed to identify the lowest viral dose still 
inducing a significant reporter signal within a reasonably short time after infection. 
Infection of LE2D8 cells with HSV-1 at MOI 0.1 showed a constant induction of the 
bioluminescence signal of 97- to 125-fold over a period of 2 – 6 days. In contrast we measured 
no induction of infection at MOI 0.001 at day 2 to day 4, and an induction of 21-fold after 6 
days post infection. The bioluminescence signals after infection at MOI 0.005 to MOI 0.075 
showed constantly increasing values, indicating an increase of viral spread over time. 
To test the effect of ACV on HSV-1 viral replication, we chose infection at MOI 0.035 with an 
induction of the bioluminescence signal by 55-fold after 3 days. Using this low initial viral dose 
ensures that the final signal strength will be a result of significant virus spread, providing ideal 
conditions for the inhibitors of the virus replication to affect the final replicon signal. For 
testing the effect of the ACV treatment on the induction of the AAV replicon in LE2D8 after 
HSV-1 infection, the cells were seeded as described above and treated with ACV at 
concentrations ranging from 0.22 to 426 µM or kept non-treated directly after seeding. 4 h 
after ACV treatment the cells were infected with HSV-1 at MOI 0.035 or kept non-infected. 48 
h p.i. the bioluminescence was measured in the supernatants of infected- and non-infected 
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cells. The bioluminescent signals of ACV-treated or n.t. but infected cells were compared to 
non-treated and non-infected cells and the induction was calculated for each individual 
reaction. Then, the induction of GLuc expression of non-treated cells infected with HSV-1 was 
defined as 100% and the induction of the ACV treated cells was normalized to the induction 
observed non-treated cells and expressed as % non-treated. (Figure 26).  
 
Figure 26: ACV dose-response to HSV-1 replication measured by the Replicon assay. 
LE2D8 stable AAV replicon cell line was treated with indicated concentrations of ACV or kept non-
treated (n.t.) and infected with HSV-1 at a MOI of 0.035 or mock infected. 48 h p.i. Supernatants were 
collected and analyzed. GLuc induction values of infected cells were compared to non-infected cells. 
The fold activity of the n.t. cells was set to 100 % and activities of ACV treated cells was depicted as % 
of non-treated values. Data from three independent experiments are shown; the error-bars represent 
means ± SD; 
In summary, we observed a clear decrease of HSV-1 induced reporter gene expression upon 
treatment with increasing concentrations of ACV. The half maximal inhibitory dose (IC50) to 
reduce the HSV-1 infection-dependent induction of GLuc expression was calculated to be 
32 µM. This value is much higher than IC50s described in the literature: depending on the assay 
conditions and the cell line in use the half inhibitory concentration of ACV should not exceed 
8.9 µM [289]. 
Since ACV treatment clearly inhibited the replicon induction by an ACV sensitive strain, we 
wanted to test the replicon response of a drug-resistant HSV-1 strain in the presence of ACV. 
To this end, the LE2D8 cells were seeded and treated as above. Then, the cells were either 
infected with the WT laboratory strain HSV-1 (ACV sens) or with a known ACV resistant clinical 
isolate HSV-1 strain (ACV res) at a MOI of 0.035. ACV res is used as resistant control strain for 
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phenotypic resistance tests at the Clinical Virology Laboratory of the Max von Pettenkofer-
Institute. Experiment were performed as described above (Figure 27).  
 
Figure 27: HSV-1 resistance to ACV can be evaluated with LE2D8 cells. 
The LE2D8 cells were treated with indicated concentrations of ACV and infected with either the ACV 
sensitive WT HSV-1 strain (ACV sens) or with the isolated ACV resistant HSV-1 strain (ACV res). After 
48 h p.i. Supernatants were collected and bioluminescence assay of GLuc activity was performed. 
Depicted is the induction of the bioluminescence signal in the ACV treated cell relative to non-treated 
cells (100%). Data from three independent experiments are shown; the error-bars represent means ± 
SD; 
The WT strain in these experiments was inhibited at a higher IC50 of 74 µM by ACV compared 
to the last experiment. Nevertheless, the ACV res strain induced the same replicon response 
in presence of all tested concentrations of ACV. The ACV res strain could therefore be clearly 
distinguished from the ACV sens strain starting at an ACV concentration of 53 µM. 
Interestingly, the replicon response after ACV sens infection is even increasing after treatment 
at lower inhibitor concentrations. It seems that the AAV replicon response has an advantage 
if the inducing virus is not fully inhibited. The prolonged survival of the infected cells seems to 
allow a higher marker expression after AAV replicon induction. 
To verify that the differences in the replicon response observed under ACV treatment were 
indeed reflecting differences in HSV-1 replication, we tested the HSV-1 production after 
infection of LE2D8 cells with either the WT laboratory strain HSV-1 (ACV sens) and the ACV 
resistant HSV-1 strain (ACV res) by endpoint dilution assay. LE2D8 cells were seeded and 
treated with ACV as above. Supernatants were collected 48 h p.i. and the infectious HSV-1 
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loads in each supernatant sample were determined by limiting dilution (see chapter 3.5.5). 
The result of one representative experiment is depicted in Figure 28. 
 
Figure 28: The production of infectious particles after infection of LE2D8 cells in the presence of ACV 
was dependent on the ACV sensitivity of the HSV-1 strain. 
The LE2D8 cells were infected with either the ACV sensitive WT HSV-1 strain (ACV sens) or with the 
isolated ACV resistant HSV-1 strain (ACV res) using MOI of 0.035. Treatment with indicated 
concentrations of ACV (4.4 - 426 µM) followed. 48 h p.i. Supernatants were collected, and endpoint 
dilution-assays performed. TCDI50 values per ml were calculated, depicted are normalized values in % 
of the virus production in n.t. cells.  
In infected cells, a treatment with 4.4 µM ACV resulted in more than 50% reduction of WT 
HSV-1 virus production compared to non-treated cells. In contrast, the resistant HSV-1 strain 
showed a reduction of 50% in infectious virus particle production only at a concentration of 
53 µM ACV. Generally, the assay on virus production appeared to be more sensitive to ACV 
treatment compared to the replicon response in stable transfected cells.  
All HSV-helper functions for AAV replication are expressed early after infection while release 
of virus particles is the last event in the HSV-1 life cycle. Apparently, infection of the cell and 
early gene expression, naturally required for the production of infectious particles, is sufficient 
to induce replicon response after the ACV targeted DNA replication. Thereby, the replicon 
assay detects the difference in virus spread whereas the end point dilution assay shows the 
virus production in infected cells. However, both assays were clearly revealing the difference 
in the ACV resistance of the two HSV-1 strains in our experiments, with the replicon-based 
response yielding more reliable results.  
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4.3.2.2. Resistance test of clinical HSV-1 isolates based on the replicon response in 
LE2D8 cells 
To be useful in everyday practice, a resistance test should be robust enough to tolerate 
differences in probe quality, which are inherent in-patient derived probes. The above tests 
were performed with well characterized HSV-1 strains using quantified virus stocks. To 
challenge the robustness of the newly developed replicon-based resistance test, we selected 
seven ACV resistant and seven ACV sensitive HSV-1 strains. All strains were obtained by virus 
isolation directly from clinical samples during daily praxis of Virological Diagnostic Laboratory 
of the Institute of Virology of the University Medical Center Freiburg. The virus isolates were 
propagated on Vero cells according to the standard HSV-1 isolation protocol until the primary 
cultures showed 80-100% CPE. Afterwards, according to the normal diagnostic protocol, the 
supernatants were collected, aliquoted and stored at -80oC. All isolates used in this test were 
typed by indirect immunofluorescence assay and found to be HSV-1. Their ACV resistance was 
diagnosed using plaque reduction assay (PRA). LE2D8 cells with a defined low passage number 
were seeded on 96-well plates and then either treated with 0.8, 4, 20, 100 and 500 µM ACV 
in order to produce a dilution series used in the standard PRA or left untreated. 6 h later the 
cultures were infected with the HSV-1 culture supernatants at dilutions of 1:10, 1:100 and 
1:1000. 2 days after infection the bioluminescence was measured, and the relative induction 
of the AAV replicon encoded reporter was calculated as before (see 4.3.2.1).  
Table 4.3.2.2.1 summarizes the relative induction compared to non-infected LE2D8 cells and 
shows the bioluminescence signals of ACV resistant and ACV sensitive clinical HSV-1 isolates 
tested with a dilution of 1:10, 48 h after infection of the LE2D8 cells. 
Table 4.3.2.2.1: Resistance test of clinical HSV-1 isolates with LE2D8 cells. 
ACV sens # 824670 # 842369 #842913 #854014 # 838500 # 847890 # 848759 
n.t. 79.8* 123.5 51.6 48.3 36.7 72.3 51.3 
0,8 µM 173.1 151.5 97.2 76.1 57.8 129.7 76.7 
4 µM 97.4 59.1 68.7 54.3 69.3 83.3 71.4 
20 µM 25.5 10.9 17.4 17.5 22.8 14.9 28.8 
100 µM 13.6 4.4 5.0 5.3 7.4 4.3 5.7 
500 µM 12.3 3.4 3.9 3.7 3.5 3.8 4.2 
*fold induction of RLU values from infected compared to non-infected LE2D8 cells. 
ACV res # 852044 #846206 #861747 # 845708 # 854437 # 860929 # 845531 
n.t. 196.1 81.0 34.0 44.3 42.3 16.3 63.3 
0,8 µM 204.5 93.3 30.3 47.0 40.0 22.8 44.5 
4 µM 198.1 96.1 35.9 68.6 51.0 24.3 54.2 
20 µM 187.7 119.1 21.3 85.8 57.4 19.9 47.2 
100 µM 311.8 136.1 27.3 68.0 42.4 17.0 101.2 
500 µM 426.2 37.0 18.9 21.7 31.8 13.5 133.4 
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The cumulative results obtained by the infection with 1:10 diluted supernatants are depicted 
in Figure 29. 
 
Figure 29: LE2D8 resistance test in the diagnostic context. 
LE2D8 was treated with indicated concentrations of ACV and infected with 14 different patient derived 
HSV-1 isolates using a 1:10 dilution of propagated viruses. Supernatants were collected 48 h p.i. and 
GLuc assay was performed. Fold induction of treated compared to non-treated cells was calculated 
and then the fold activity of the non-treated cells was set to 100% and the activity of the ACV treated 
cells was depicted as % of the non-treated values (****: p < 0.0001, ns: p > 0.05, Two-Way-ANOVA, 
depicted are means ± SD). 
At a 1:10 dilution of the viral isolates, the bioluminescence signal induced by the infection of 
the non-treated LE2D8 cells was in average 66-fold for sensitive strains and 68-fold for 
resistant strains, which indicated the robustness of the assay after accounting the passage 
number of the stable cell line. In general, the GLuc induction of all sensitive HSV-1 isolates 
decreased with increasing amounts of ACV concentrations. In sharp contrast to the sensitive 
HSV-1 isolates, the resistant HSV-1 isolates showed a different pattern. The IC50 of ACV for all 
sensitive HSV-1 isolates was 25 µM whereas the mean IC50 value for the resistant HSV-1 
isolates was not obtainable due to the lack of the useful regression curve for many strains. 
The resistant viral isolates induced a similar replicon response than the non-treated cells in 
the presence of almost all ACV concentration. Two isolates showed no reduction at any 
concentration, but the replicon response even increased up to over 200% compared to n.t. 
values. This increase of the replicon response after treatment of the cells with suboptimal 
inhibitory concentration of ACV was also evident after infection with ACV sensitive strains 
demonstrated as a peak at 0.4 µM in the cumulative curve. In summary, detection of ACV 
resistance for all HSV-1 strains could be indicated by the sustained replicon response at high 
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ACV concentration after 2 days of the assay start. In comparison the PRA took 5 to 7 days until 
results could be evaluated. 
4.3.2.3. Establishment of an AAV replicon-based drug resistance test for HSV-
based rAAV transduction  
Considering that the AAV replicon packaged in recombinant viral particles, in comparison with 
the stable AAV replicon vector carrying cell line LE2D8, was able to be induced not only by 
HSV-1 but also HSV-2 we evaluated the applicability of rAAV2-REP-GLuc for drug-resistance 
testing. We also hoped that the transduction would allow us to find the optimal cell line for 
the assay and that this would lead to IC50 values mirroring the results from PRA. 
Therefore, we choose Vero cells which were efficiently transduced by rAAV (see chapter 
4.2.4.1). First, we wanted to test the replicon response upon rAAV2-REP-GLuc transduction 
using ACV-sensitive standard HSV-1 and HSV-2 strains. For that purpose, Vero cells were 
transduced with 600 p/c of rAAV2-REP-GLuc directly after seeding 3 x 104 cells/well in 96-well 
plate. The transduced cells were treated with 0.8, 4, 20, 100 and 500 µM ACV or left untreated 
right after seeding. 6 h later they were infected with either HSV-1 or HSV-2 at MOI of 0.035. 
After 48 h p.i., we measured the induction of the replicon encoded GLuc expression 
bioluminescence assays (Figure 30). 
 
Figure 30: ACV susceptibility testing after HSV-1 and HSV-2 infection with rAAV replicon. 
Recombinant AAV replicon vector transduced Vero cells were treated at indicated concentrations of 
ACV and infected with (A) HSV-1 and (B) HSV-2 at a MOI of 0.035. Supernatants were collected after 
48 h p.i. and induction of the replicon encoded reporter gene in presence of ACV is depicted as % of 
the response of the non-treated cells. Data from three independent experiments are shown; the error-
bars represent means ± SD; 
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The replicon inductions of the ACV treated samples were normalized to the non-treated 
samples, which were set to 100%. In general, both HSV-1 and HSV-2 induced a measurable 
replicon response upon infection, which decreased by increasing amounts of ACV. The HSV-1 
induced replicon response showed an IC50 of 1.87 µM (Figure 30A), whereas for HSV-2 (Figure 
30B) we observed an IC50 of 19.1 µM towards ACV. The results of both viruses indicate a more 
sensitive assay system if transduction of the AAV Replicon vector is used for delivery. 
Furthermore, as observed before, HSV-1 was more sensitive to ACV treatment than HSV-2.  
Summarizing these results, transduction by AAV particles provides a useful tool to test ACV 
resistance with the AAV replicon system. The calculated IC50 values for HSV-1 correspond to 
the published in vitro inhibitory concentrations of ACV tested by PRA. The IC50 value for HSV-
2 in contrast is 2-fold higher compared to the concentrations published in the literature. 
4.3.2.4. ACV resistance test of clinical HSV isolates using recombinant AAV-based 
replicon assay 
For setting up a transduced replicon-based resistance test for clinical isolates, we reconsidered 
some conditions based on the preliminary test described before. We decided to increase the 
rAAV2-REP-GLuc particles from 600 p/c to 1500 p/c to gain higher induction levels after HSV-
2 induction. We used the set of 10 clinical HSV-1 isolates, which we had evaluated with the 
LE2D8 cell line-based tests before. In addition, we selected 4 sensitive and 3 resistant HSV-2 
isolates, which were also derived from the Virological Diagnostic Unit in Freiburg and were 
treated and diagnosed the same way as the HSV-1 isolates. Vero cells were seeded in a 96-
well plate, transduced with 1500 p/c of rAAV2-REP-GLuc and incubated overnight. We decided 
to prolong the incubation after transduction to increase the efficiency of the replicon delivery, 
as longer incubation after transduction resulted in higher transgene expression in the pilot 
assays (see chapter 4.2.4). On the next day, the transduced cells were treated either with 0.8, 
4, 20, 100, 500 µM ACV or left untreated and infected right after the ACV treatment with HSV 
isolate, containing culture supernatants at 1:10 and 1:100 dilution (as before for the cell line 
tests). The supernatants were collected 24 and 48 h p.i. Then the light emission in the 
supernatants were measured with a plate luminometer and analyzed as described before. The 
detailed fold inductions of the RLU results obtained for the HSV-1 tests are listed in Table 
4.3.2.4.1 the cumulative analysis of the relative values is depicted in Figure 31. 
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Table 4.3.2.4.1: Resistance test of clinical HSV-1 isolates using the replicon containing rAAV particles. 
ACV sens # 842369 # 842913 # 838500 # 847890 # 848759 
24 h p.i. 48 h p.i. 24 h p.i. 48 h p.i. 24 h p.i. 48 h 
p.i. 
24 h p.i. 48 h p.i. 24 h p.i. 48 h 
p.i. n.t. 159.4 417.9 103.8 315.4 97.4 236.0 180.2 116.7 159.5 161.4 
0.8 µM 158.6 556.2 103.7 437.9 115.4 336.2 177.5 206.8 199.6 260.5 
4 µM 79.7 496.1 55.2 349.0 78.7 309.4 33.0 57.7 75.9 135.0 
20 µM 4.9 50.5 4.5 42.9 22.6 188.2 2.1 1.2 2.7 7.0 
100 µM 1.7 3.1 2.0 3.8 1.8 7.8 1.6 0.8 1.4 1.2 
500 µM 1.6 3.3 2.0 4.0 1.6 2.7 1.7 0.7 1.5 1.2 
 
ACV res 
# 846206 # 861747 # 845708 # 854437 # 860929 
24 h p.i. 48 h p.i. 24 h p.i. 48 h p.i. 24 h p.i. 48 h p.i. 24 h p.i. 48 h p.i. 24 h p.i. 48 h p.i. 
n.t. 129.5 97.2 16.9 200.8 111.7 92.3 57.1 75.7 22.8 113.7 
0.8 µM 145.5 104.7 19.2 235.6 141.8 117.9 48.1 84.5 33.9 171.1 
4 µM 162.7 127.8 18.5 218.3 149.2 129.6 44.5 76.4 28.5 166.8 
20 µM 160.4 126.3 17.1 212.7 173.3 159.0 28.6 56.5 21.1 157.2 
100 µM 180.2 152.4 15.6 198.0 122.1 144.3 7.6 23.4 19.9 153.3 
500 µM 107.4 103.8 8.8 81.6 18.8 42.7 44.5 64.3 8.7 24.9 
 
 
Figure 31: Replicon containing rAAV particles for resistance testing of HSV-1. 
Vero cells were seeded and transduced with rAAV2-REP-GLuc using 1500 p/c. After incubation time of 
24 h the cells were treated with indicated concentrations of ACV and infected with 10 different patient 
derived HSV-1 isolates using a 1:10 dilution of propagated viruses. Supernatants were collected after 
24 and 48 h p.i. and GLuc assay was performed. Fold induction of treated compared to non-treated 
cells was calculated and then the fold activity of the non-treated cells was set to 100 % and the 
activities of the ACV treated cells were depicted as % of the non-treated values. (****: p < 0.0001, ns: 
p > 0.05, Two-Way-ANOVA, depicted are means ± SD). 
After an induction time of 24 h, the IC50 of all sensitive strains of HSV-1 towards ACV was 4.6 
µM and increased to 14.6 µM after an induction time of 48 h p.i. Contrary to that, the resistant 
HSV-1 strains showed IC50 values of 633 µM after 24 h and 1197 µM after 48 h. A significant 
differentiation between sensitive and resistant HSV-1 strains could therefore be made earlier 
than with the LE2D8 cell line and even showed a higher sensitivity towards ACV. Interestingly, 
the sensitivity of the assay using the rAAV2-REP-GLuc replicon system decreased after 48 h. It 
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is possible, however, that this effect is caused by prolonged spreading of the virus. The 
increased sensitivity of the system 24 h p.i. was also observed after infection with resistant 
strains. 
In contrast to the LE2D8 cell line, HSV-2 is able to strongly induce the AAV replicon after 
transduction of the recombinant particle. Therefore, we tested the AAV replicon containing 
rAAV particles for the applicability of testing resistance in HSV-2 clinical isolates. The setup of 
the experiment was the same as for testing HSV-1 isolates. Altogether four sensitive and two 
resistant HSV-2 viral isolates that were previously tested could be selected for AAV replicon-
based differentiation based on their resistance to ACV within 48 h. The detailed fold inductions 
of the RLU results obtained for the HSV-2 with 1:10 diluted supernatants are listed in Table 
4.3.2.4.2, the cumulative analysis of the relative values is depicted in Figure 32. 
Table 4.3.2.4.2: Resistance test of clinical HSV-2 isolates with rAAV particles. 
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Figure 32: Replicon containing rAAV particles for resistance testing of HSV-2. 
Vero cells were seeded and transduced with rAAV2-REP-GLuc using 1500 p/c. After an incubation time 
of 24 h, the cells were treated with indicated concentrations of ACV and infected with 6 different 
patient derived HSV-2 isolates using a 1:10 dilution of propagated viruses. Supernatants were collected 
after 48 h. and GLuc assays were performed. Fold induction of treated versus non-treated cells was 
calculated and then the fold activity of the non-treated cells was set to 100 % and the activities of the 
ACV treated cells were depicted as % of the non-treated values. (**: p < 0.01, ns: p > 0.05, Two-Way-
ANOVA, depicted are means ± SD). 
ACV sens # 17-168 # 17-604 # 17-742 # 18-650  ACV res # 18-161 # 18-553 
0.8 µM 183.6 108.7 132.8 98.7  0.8 µM 126.4 130.5 
4 µM 31.9 31.9 42.6 33.9  4 µM 92.1 104.2 
20 µM 15.1 14.4 20.2 5.4  20 µM 62.3 67.6 
100 µM 2.9 2.8 14.4 2.0  100 µM 56.5 31.5 
500 µM 1.3 2.5 12.1 1.0  500 µM 34.4 19.6 
Results 
103 
 
The results show a clear differentiation between sensitive and resistant HSV-2 isolates after 
48 h. The significance was calculated for a very low number of strains and is therefore only an 
indication. The IC50 values of the sensitive strains were between 3.2 and 4 µM in contrast to 
the IC50 values of the resistant strains (130 µM and 53 µM). Therefore, we determined a cut-
off at a concentration of 20 µM ACV for the differentiation between ACV resistant and 
sensitive HSV-2 strains.  
The validity of the AAV replicon-based resistance test for HSV-2 was considerable weaker that 
it was observed for HSV-1. This is maybe due to lower induction levels using HSV-2 and can be 
optimized, for example, by further increasing the replicon load. 
All in all, the AAV replicon response was able to discriminate between infections with ACV-
sensitive and -resistant HSV-1 shown within one or two days and HSV-2 within two days post 
infection. Therefore, the transduction-based assay is now prepared for testing its applicability 
in retrospective and prospective studies in diagnostic settings. 
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4.3.3. Screening for new antivirals by the AAV replicon-based assay  
Our data so far showed that the AAV replicon system is useful for testing the resistance of HSV 
to the known inhibitor ACV. In this setting, the replicon-based assay was robust enough to 
respond reliably to infection with minimally characterized clinical isolates with different 
infectivity. Moreover, the same replicon was inducible with HSV, Ad, and HCMV infections 
upon transduction into the respective permissive cell lines. All in all, these features of the AAV 
replicon suggest that it may be a valuable and unique tool for screening of new antivirals. The 
assay for drug resistance or susceptibility can be carried out in multi-well format. The 
measurement requires one liquid handling step and can be automated. Most importantly, the 
AAV replicon-based assay does not need any genetic modification on the virus or the cell line 
of interest. Consequently, clinical isolates and virus strains with limited laboratory adaptation 
can be subjected to screening approaches. This feature is especially valuable in testing low 
passage, not well-established herpesvirus strains, which undergoes substantial genetic 
changes upon laboratory passages, and genetic manipulation. 
To test this possibility, we set up a pilot study using A549 cells for testing of Ad, as well as Vero 
cells for HSV-1 testing in a 96-well plate format. The before tested ACV was dissolved in water 
and diluted in culture medium before use. As the compound libraries are normally provided 
as highly concentrated stocks dissolved in DMSO, we first tested the effect of DMSO on the 
induction of the AAV replicon.  
For this, Vero, A549 and HFF cells were transduced with 1000 p/c of the replicon containing 
recombinant AAV particle, rAAV2-REP-GLuc, after seeding. Then, infection with HSV-1 at a 
MOI of 0.1 followed after 6 h in parallel with the treatment of the cells with different 
concentrations of DMSO, ranging from 0.1 to 6%. Two days later the induction of GLuc was 
measured in a bioluminescence assay. The results showed that the use of DMSO of up to 1% 
did not influence the results significantly in all cells tested (see Figure 33). 
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Figure 33: DMSO toxicity test of different cell lines. 
HFF, Vero and A549 cells were transduced with rAAV2-REP-GLuc using 1000 p/c. Then the cells were 
infected with HSV-1 at a MOI of 0.1 or kept mock infected and treated additionally with different 
concentrations of DMSO of 0%, 0.1%, 0.5%, 1%, 2%, 4% and 6%. 48 h p.i. Supernatants were collected, 
GLuc induction values were analyzed and values of infected cells were compared to non-infected cells. 
The fold activity of the n.t. cells was set to 100% and activities of ACV treated cells were depicted as % 
of non-treated values. 
As discussed before, there is an urgent need for new antiviral drugs against HSV-1 and against 
human Ad. With regard to this challenge, the next step in this study was to test the 
applicability of the AAV replicon test for drug discovery. For this, a set of heterocyclic small 
molecular kinase inhibitors with known in vitro and in vivo toxicity profiles were provided by 
Origenis GmbH (Martinsried, Germany).  
In order to run the pilot screen, 22 potential inhibitor compounds, deriving from different 
series of compound families, were selected. Additionally, an apoptosis-inducing drug called 
staurosporine [290] was included as inhibitory control as well as a published herpesvirus 
inhibitor. The compounds were labeled “ORI-SIRI-01” to “ORI-SIRI-24” in the first round of 
experiments. In the reproducing second round they were labeled “ORI-SIRI-25” to “ORI-SIRI-
48” in a randomized order to guarantee blind testing. To receive a good overview of the 
inhibition spectrum, both HSV-1 and Ad5 were tested for their inhibition by the different 
compounds. To accomplish this, rAAV1/2-REP-GLuc, a chimeric rAAV particle was produced. 
This particle showed almost as much transduction efficacy as rAAV2 and in addition yielded 
better production titers in our pre-experiments. Experiments to test the rAAV1/2-REP-GLuc 
demonstrated no difference compared to rAAV2-REP-GLuc (data not shown). For testing the 
different kinase-inhibitors, Vero and A549 cells were seeded on 96-well plates at a density of 
104 cells pro well. To receive comparable luciferase induction values with both viruses Vero 
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cells were then transduced with 500 p/c of rAAV1/2-REP-GLuc whereas A549 were transduced 
with a lower number of 10 p/c. The transduced cells were incubated for 6 h in a final volume 
of 100 l/well. The cells were treated with 4 and 40 µM of each compound in presence of 4% 
DMSO, which was applied by multichannel pipetting in 50 l, resulting in a DMSO 
concentration of 1% in total. Known inhibitors in two concentrations were included as positive 
controls in order to have immediate and known controls of the experiment. For Vero cells, 80 
and 2000 µM ACV were added into a volume of 50 l.  For Ad5, 80 and 800 µM of Cidofovir 
(CDV) were also added in a volume of 50 l. These treatments resulted in a final concentration 
of 1 or 10 M of each kinase inhibitors: 20 and 500 M ACV, 20 and 200 M CDV, and 1% 
DMSO in the respective wells. CDV inhibits Ad5 in vitro at an IC50 of 25 µM [291]. In addition, 
to generate DMSO treated cells for determining the infection induced luciferase production 
without any inhibition, normal medium was added to n.t. cells and 4% DMSO. Immediately 
after application of the inhibitors, Vero cells were infected with HSV-1 at a MOI of 0.035 and 
A549 cells with Ad5-WT using a MOI of 10. As established in former experiments, the GLuc 
activity was measured after 48 h p.i. in the supernatants. The induction of the GLuc activity 
was calculated by comparison of the values derived from infected and non-infected values. 
In order to compare the primary and secondary experiment, the compound specific inhibition 
of the GLuc induction was calculated. The GLuc induction after infection in the absence of 
inhibitors were defined as 100% and the induction values were calculated from the compound 
treated cells as % of the non-drug treated cells (Figure 34). 
The results of the internal control with approved drugs showed that CDV treatment of Ad5 
and ACV treatment of HSV-1 leaded to an inhibition of the signal in case of both experiments 
(Table 4.3.3.1). The AAV replicon screening system was capable of detecting the two control 
inhibitors (ORI-SIRI-1, ORI-SIRI-2 in the primary screen and ORI-SIRI-47 and ORI-SIRI-48 in the 
secondary screen) in the reproduced screening with either virus tested. The internal controls 
therefore verified the functionality of the established cell-based assay. 
Since we only tested compounds at a concentration of 1 µM and 10 µM, a scientific statement 
concerning the dose response cannot be made. Nevertheless, results of testing Ad indicated 
a more reliable response comparing the two experiments. Only one compound (ORI-SIRI-20) 
showed a 540% higher induction after treatment with 10 µM compared to treatment with 
1 µM concentration, without reproducibility in the second screen (Table 4.3.3.1). In contrast, 
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for HSV-1 10 different compounds showed an increase in induction (more than 20%) after 
treatment with higher compound concentrations whereas only half of these results were 
reproducible. Generally, the peak-out, defined as showing a 50% higher induction than the 
DMSO control, are not reproducible, since 7 out of 9 compounds showing in either virus a 
peak-out could not be observed in the second experiment. 
Generally, for Ad more inhibitory compounds were found: Three new compounds showed at 
least a 50% inhibition at the higher compound concentration and two compounds even 
inhibited the Ad activity to over 90%. In contrast, HSV-1 inhibition to over 90% could only be 
observed for one compound (ORI-SIRI-17 in primary and ORI-SIRI-46 in secondary screening). 
This compound demonstrated promising results for both viruses. A compound exclusively 
inhibiting HSV-1 could not be found in this application test for inhibitor screening. 
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Figure 34: AAV replicon-based drug susceptibility assay for testing potential HSV-1 and Ad5 
inhibitors. 
Average inhibition by of the corresponding compounds (Cmpd) from the primary and secondary 
experiment are shown (% non-treated). 
A549 cells (A) were transduced with 10 p/c of rAAV1/2-REP-GLuc replicon and infected with Ad5 -WT 
at a MOI of 10 whereas Vero cells (B) were transduced with 500 p/c of rAAV1/2-REP-GLuc and infected 
with HSV-1 at a MOI of 0.035. Addition of 1 and 10 µM of the undisclosed Cmpd followed next to no 
treatment (n.t.) or treatment with 1% DMSO without Cmpd. Supernatants of Vero and A549 cells were 
collected 48 h p.i. and fold induction GLuc were calculated by comparing RLU values of infected and 
non-infected cells. Inhibition of both viruses by each Cmpd was calculated by setting the induction of 
the GLuc expression of the non-drug treated cells as 100% and activities of treated cells were depicted 
as % of non-treated values. 
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Table 4.3.3.1: Comparison of compounds tested twice with the AAV replicon drug susceptibility test. 
    
  
[µM] Cmpd
fold 
induction
Cmpd
fold 
induction
1 % DMSO 311.0 1% DMSO 571.0
20 246.0 7.7
200 1.0 1.0
1 68.1 95.3
10 1.5 1.3
1 76.5 62.4
10 1.9 1.4
1 213.2 551.7
10 103.2 302.2
1 220.2 623.3
10 105.4 515.1
1 296.4 744.6
10 234.5 284.0
1 351.1 592.7
10 263.5 395.5
1 357.7 610.3
10 320.0 477.0
1 330.4 581.7
10 191.7 355.5
1 240.5 622.9
10 123.6 234.6
1 267.4 643.6
10 46.4 22.4
1 317.6 737.2
10 217.5 38.3
1 251.3 639.6
10 240.9 609.6
1 317.4 628.1
10 232.9 437.5
1 343.8 655.6
10 332.9 626.4
1 340.2 640.2
10 273.5 549.9
1 298.4 720.6
10 207.4 534.8
1 178.5 329.2
10 2.6 1.6
1 352.9 737.2
10 285.2 847.9
1 336.1 679.2
10 349.1 659.4
1 344.2 704.8
10 2204.0 697.4
1 289.3 708.5
10 188.9 326.8
1 356.8 730.5
10 320.6 674.6
1 197.3 298.3
10 17.0 29.2
1 358.5 728.6
10 244.6 473.6
ORI-SIRI-37
ORI-SIRI-02 ORI-SIRI-47
ORI-SIRI-03
Ad5-WT
primary screen secondary screen
ORI-SIRI-01 ORI-SIRI-48
ORI-SIRI-29
ORI-SIRI-08 ORI-SIRI-36
ORI-SIRI-09 ORI-SIRI-31
ORI-SIRI-06 ORI-SIRI-34
ORI-SIRI-07 ORI-SIRI-28
ORI-SIRI-04 ORI-SIRI-30
ORI-SIRI-05
ORI-SIRI-12 ORI-SIRI-33
ORI-SIRI-13 ORI-SIRI-25
ORI-SIRI-10 ORI-SIRI-32
ORI-SIRI-11 ORI-SIRI-35
ORI-SIRI-16 ORI-SIRI-44
ORI-SIRI-17 ORI-SIRI-46
ORI-SIRI-14 ORI-SIRI-26
ORI-SIRI-15 ORI-SIRI-27
ORI-SIRI-20 ORI-SIRI-40
ORI-SIRI-21 ORI-SIRI-38
ORI-SIRI-18 ORI-SIRI-45
ORI-SIRI-19 ORI-SIRI-42
ORI-SIRI-24 ORI-SIRI-39
ORI-SIRI-22 ORI-SIRI-43
ORI-SIRI-23 ORI-SIRI-41
CDV CDV
[µM]
[µM] Cmpd
fold 
induction
Cmpd
fold 
induction
1 % DMSO 105.0 1% DMSO 32.0
20 8.5 2.3
500 1.9 1.7
1 11.5 9.9
10 4.7 1.0
1 68.9 22.4
10 6.2 1.0
1 75.8 33.9
10 144.4 56.7
1 89.6 30.6
10 96.1 45.3
1 89.9 27.7
10 79.4 14.3
1 136.0 38.1
10 223.6 47.2
1 137.0 34.7
10 204.2 49.6
1 112.5 41.7
10 104.7 60.4
1 75.4 33.7
10 140.9 35.1
1 79.2 30.2
10 78.3 61.7
1 83.1 34.9
10 116.5 42.5
1 141.0 32.2
10 190.6 32.0
1 77.2 37.4
10 86.3 54.8
1 85.6 39.3
10 69.1 35.8
1 87.9 32.9
10 88.0 35.9
1 82.9 27.7
10 76.6 26.1
1 137.5 23.5
10 6.3 1.3
1 130.2 34.9
10 111.4 22.3
1 143.9 25.4
10 136.2 21.6
1 142.6 25.3
10 131.7 20.7
1 73.9 32.0
10 69.9 33.8
1 75.5 26.0
10 69.7 24.6
1 79.9 35.9
10 198.5 59.0
1 76.3 27.8
10 86.9 32.9
ORI-SIRI-05 ORI-SIRI-37
ORI-SIRI-48
ORI-SIRI-02 ORI-SIRI-47
HSV-1
primary screen secondary screen
ORI-SIRI-01
ORI-SIRI-03 ORI-SIRI-29
ORI-SIRI-08 ORI-SIRI-36
ORI-SIRI-09 ORI-SIRI-31
ORI-SIRI-06 ORI-SIRI-34
ORI-SIRI-07 ORI-SIRI-28
ORI-SIRI-04 ORI-SIRI-30
ORI-SIRI-12 ORI-SIRI-33
ORI-SIRI-13 ORI-SIRI-25
ORI-SIRI-10 ORI-SIRI-32
ORI-SIRI-11 ORI-SIRI-35
ORI-SIRI-16 ORI-SIRI-44
ORI-SIRI-17 ORI-SIRI-46
ORI-SIRI-14 ORI-SIRI-26
ORI-SIRI-15 ORI-SIRI-27
ORI-SIRI-20 ORI-SIRI-40
ORI-SIRI-21 ORI-SIRI-38
ORI-SIRI-18 ORI-SIRI-45
ORI-SIRI-19 ORI-SIRI-42
ORI-SIRI-24 ORI-SIRI-39
ORI-SIRI-22 ORI-SIRI-43
ORI-SIRI-23 ORI-SIRI-41
ACV ACV
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5. Discussion 
There is an increased risk in immune-compromised patients infected with herpesviruses or 
adenoviruses, for development of resistant virus strains especially after long-term therapy 
against nearly all antiviral drugs in clinical use [17]. Most of anti-α-herpesvirus compounds are 
targeting the viral DNA replication, either indirectly by targeting the thymidine kinase (TK) or 
directly by targeting the viral DNA polymerase. The choice of taking an alternative drug is very 
limited and it often goes along with severe side effects. In case of adenoviruses there is only 
one approved drug in clinical use. Especially immune compromised children are of high risk to 
be affected by invasive and disseminated infections by Ad. This is the reason why, on the one 
hand, effective and fast assays are needed to test drug resistance of herpesviruses and, on the 
other hand, new effective drugs with alternative viral targets are urgently required for 
treatment of adeno- and herpesvirus infections. 
In this work, we reported the development of a new AAV-based replicon vector that is suitable 
for detection of DNA virus infections. Using this assay, we established a new phenotypic assay 
for testing HSV resistance and set up a platform, which allows screening for new antiviral 
compounds targeting wild-type adeno- and herpesviruses.  
5.1. Advantages and disadvantages of taking AAV as basis for the 
AAV replicon vector 
5.1.1. Comparison of the AAV replicon to RNA replicon vectors 
The RNA replicase-sensor reporter systems used assaying replication of different RNA viruses, 
can be paralleled with the AAV replicon system which responds to DNA virus infection. 
Phenotypic tests for the evaluation of new drug candidates in a high-throughput format can 
be conducted with either using the RNA replicons for RNA viruses [292] as well as for the AAV 
replicon vector system as we reported here. Replicons are essentially live cell reporter 
systems, which are induced by infectious viral particles. This represents a more attractive 
system in certain applications than genome detection-based technologies like PCR or 
serological-based antigen detection-based assays. Furthermore, in the field of RNA virus 
research, live cell reporter systems, which are dependent on virus replication, play an 
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important role for the viral phenotypical monitoring of host infectious diseases [213]. In case 
of HCV for example, chimeric shuttle replicon vectors carrying all possible single and double 
variants of mutations are used to assess the consequences in response to increasing 
concentrations of antiviral therapy and the level of resistance in comparison to wild-type HCV. 
As a consequence, this knowledge can be used for future genotypic resistance analysis [293]. 
Due to the small genome size of RNA viruses the information of single and multiple mutations 
of RNA viruses leading to drug susceptibility are easily available for the genotypic analysis. 
Concerning resources and time, the phenotypic testing by AAV-based replicon assay may 
become superior to genotyping, due to the larger genome size of the activating DNA viruses. 
One of the major approaches of either positive- or negative-strand RNA replicons which are 
unable to produce infectious progeny, but can be propagated by trans-complementation, is 
the development of vaccines [211]. RNA virus replicons with the gene of interest will be 
abortively replicated and transcribed after delivery inducing an immune response by 
mimicking WT virus replication. In contrast, the AAV replicons, we constructed are not capable 
even of an abortive replication cycle by their own. Therefore, it is very unlikely that using the 
AAV replicon vectors, carrying Rep in addition to the trans gene, will induce better immune 
response as standard recombinant AAV-based recombinant vaccines. 
Alternatively, replicons can provide a trans-complementation for propagation of attenuated 
or replication-incompetent recombinant vaccines [214]. We have tested the trans-
complementation ability of our AAV replicon system and found that the replicon cannot trans-
complement defective Ad genomes. In same settings, we even observed that an inhibitory 
effect at the level of virus rescue from wild-type recombinant genomes, showing that the AAV 
replicon in its present form is not suited for such an application. 
5.1.2. Comparison of the heterologous AAV replicon to the homologous 
DNA virus replicon system 
To our knowledge, until now only one DNA virus replicon was reported (Mohr et al., 2012) 
which is based on a homologous ori and reacted  to murine cytomegalovirus (MCMV) infection 
in trans [214]. Although the MCMV ori based replicon vector also is a DNA virus inducible 
expression system, a number of differences between the AAV based and the MCMV based 
replicon vectors are important to indicate. 
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First, in case of the MCMV based replicon vector, the MCMV oriLyt is the key factor for 
transgene expression. The activation of the replicon oriLyt is very specifically dependent on 
the MCMV DNA replication machinery. No other tested virus within the herpesvirus family 
was able to induce this replicon vector. The here described AAV replicon system utilizes the 
replication system of the AAV and is induced by replication of different helper viruses. 
Therefore, the AAV replicon carries a heterologous origin of replication and, thus, the 
recombination between the replicon and the inducing virus is not possible by homologous 
recombination, which provides a favorable biosafety profile. In addition, the AAV replicon is 
activated by infection with many different helper viruses. The inducibility of the same AAV 
replicon by HSV-1, HSV-2 and HCMV and all Ad serotypes tested so far represents a great 
advantage towards the MCMV replicon vector or potential other replicons constructed in the 
same way, because it allows one standardized setting for testing different viruses. For 
example, as we have shown in the pilot screen for kinase inhibitor-based antivirals (chapter 
4.3.3) both HSV-1 and Ad could be tested in parallel in high throughput. 
Secondly, the inducibility of the MCMV-based replicon vector required chromatin silencing of 
the basal expression of the transgenes. In addition, it was only responsive in an episomal state. 
After integration into the host cell chromosome, the MCMV replicon lost its inducibility by 
MCMV infection. In contrast, the AAV-based replicon was readily inducible upon transient 
transfection and upon rAAV transduction indicating that chromatin silencing does not play a 
major role in its control. However, similar to the MCMV replicon, the extrachromosomal AAV 
replicons showed better induction than the stable cell lines carrying most likely integrated or 
chromatinized replicon copies. One additional remarkable difference between the two DNA 
virus replicon systems is their basal activity in transient settings, which may explain their 
dissimilar inducibility. While in case of the AAV replicon vector, the basal transgene expression 
without infection was very low and often under detection limit, the MCMV replicon vector 
showed very high basal expression levels of the marker gene without induction. This was 
silenced 16 weeks after the establishment of stable transfectants. The episomal and therefore 
circular state of the MCMV replicon vector was very instrumental for a response to MCMV 
infection although it is known that herpesviruses in general are able to replicate via circular 
and linear intermediates [294]. The MCMV replicon vector however failed to respond to WT 
MCMV infection after integration into the host chromosome. The reason for this could not be 
clarified by now. On the contrary, here it has been shown that the AAV replicon vector could 
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efficiently start from circular, linear, and most likely also integrated intermediates as 
described for AAV in the literature [295] [237]. Dependent on the use, the AAV replicon vector 
could be delivered either by transient transfection, stably integrated, or packaged into a 
recombinant AAV vector. Altogether, these features make the AAV replicon the most versatile 
replicon system described so far including the RNA virus replicons as well. 
5.1.3. The versatility of the AAV replicon system 
For establishing the AAV replicon system, it was very convenient to use Ad because we were 
able to compare the results after a wild-type Ad5 virus infection and the viral mutant Ad5-Che 
transduction, lacking essential genes which are only complemented in 293A and 911 cells. 
Because of differences concerning the productive replication ability of the viruses in different 
cell lines, we could test via the usage of transient transfection whether the induction of the 
AAV replicon system was dependent on a full productive cycle of the helper virus. 
Interestingly, there was no signal expression in U2-OS cells after infection with the viral 
mutant because of the lack of viral essential gene complementation in contrast to the wild-
type virus which showed induction of the signal in all cell types tested. Together with the 
results of the qPCR of the GLuc gene, we could therefore assume that the induction of the 
AAV replicon vector is in fact dependent on a full viral replication cycle of the helper virus.  
In the course of exploring the AAV replicon system, we have chosen the chemical transfection 
delivery system FuGENE® HD as transfection reagent showing the highest and most stable 
results. In principle, transient transfection with non-viral delivery systems like the 
nonliposomal FuGENE® HD reagent is suitable for a number of cell lines although relative 
inefficiency and cytotoxicity is an issue [296]. Nevertheless, HSV-1 and HSV-2 inducibility of 
the AAV replicon system could be successfully validated in Vero cells, whereas different 
human Ad serotypes were verified for helper functions in 293A cells. This cell line is derived 
from human embryonic kidney cells. Due to easy culture conditions, good transfection 
efficiencies, and reproducible infection conditions for Ad, HSV-1 and also HSV-2, 293A cells 
were chosen as model cell line for all basic experiments. However, this delivery system 
restricted, for example, the testing of HCMV induction of the AAV replicon in primary HFF cells 
or made the delivery of the AAV replicon system to hepatocarcinoma cell lines for testing its 
HBV inducibility impossible because of the lag time of cell differentiation after transfection 
prior infection. 
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The construction of the stable cell line LE2D8 was also based on 293A cells because of the 
indicated advantages. However, the induction rate of LE2D8 was not as strong as the transient 
system. In general, the stable cell line was very useful for the establishment of different assays 
in the course of this work because it was possible to standardize it for the comparison of 
different studies and the AAV replicon vector was equally distributed while being transduced 
in all cells. However, since it was very time-consuming and extensive work to pick one stable 
cell clone, a translation of the system to different cell lines is not recommended. Nevertheless, 
the transduction of the replicon resulted in better results in all tested cell lines in terms of 
inducibility and also showed similar reproducibility as the stable cell line-based assays. 
Until now, the AAV replicon is the only replicon system, which functions independently of 
transfection or stable cell lines. We tested this possibility in order to circumvent transfection 
inefficiencies shown by some target cells as well as disadvantages of the fixed cell type by the 
stable AAV replicon cell line. The endogenous regions of the AAV replicon vector together with 
the ITRs were used as cis-elements whereas addition of a separate construct coding for rep 
and cap genes provided the structural proteins. These constructs together with the adenovirus 
helper factors delivered in a separate plasmid enabled the production of recombinant AAV 
particles packaging the AAV replicon vector.  
For each target cell type, there are recommended serotypes of AAV and therefore the 
respective rAAV can be chosen for the appropriate application [297]. This feature increased 
the delivery of the recombinant AAV replicon vector into specific cell lines, which were barely 
transfectable before, such as A549 and HFF cells. For choosing the serotype of the rAAV, 
transduction efficacies of different types were tested. Since rAAV2 showed the best results in 
case of the cell lines planned for application, this serotype was further chosen for AAV replicon 
packaging. A549 cell line is a human lung adenocarcinoma cell line which is very susceptible 
for adenovirus infections but hardly transfectable. With the newly established rAAV2-based 
replicon vector the induction rate after human Ad5 wild-type infection was 230-fold higher in 
A549 cells compared to 293A cells treated with the same conditions. 
Furthermore, the transduction of Vero cells with rAAV2-replicon vector and infection with 
HSV-1 leaded to a 2800-fold induction of the marker gene GLuc compared to non-infected 
cells and therefore there was a greater sensitivity compared to the transient or the stable 
system. Moreover, using this delivery system of the AAV replicon vector for Vero cells, the 
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HSV-2 induction became significantly higher, enabling the establishment of a phenotypical 
HSV-2 antiviral resistance test. 
Using the AAV replicon vector packaged into a recombinant AAV particle, we were able to 
transduce HFF cells and therefore testing HCMV as inducer for the AAV replicon system. 
Primary HFF cells are derived from human foreskin and the combination of inefficient 
transfection ability and a slowly replicating virus like HCMV leaded to inappropriate 
experimental conditions. However, transduction of the rAAV2-replicon vector and infection 
with HCMV resulted in 110-fold induction of a marker gene compared to non-infected cells 
after an incubation time of 7 days. Differentiation between HCMV-infected and non-infected 
cells could already be detected after 4 days. 
5.1.4. Comparison to other virus-inducible reporters 
There are several conditional or inducible systems for the transcriptional regulation of 
reporter genes, consisting of a regulatory element, a responsive unit which is linked to a 
transgene and an external inducer. The most prominent inducible transgenic systems are the 
tetracycline-controlled transcriptional activation system (Tet-ON/Tet-OFF) [298] and the 
streptogramin-based gene regulation system (PipOFF/PipON) [299]. In case of the Tet-ON/Tet-
OFF system the external inducer is tetracycline and in case of the PipOFF/PipON system it is 
streptogramin. The AAV replicon system in contrary was induced by an incoming viral 
infection. 
The most important requirement for trigger-inducible transgene expression technologies in 
general is that the system upon induction provides high-level transgene expression, whereas 
under repressed conditions and in the absence of an inducer the expression should be 
suppressed completely or at least elicit only low basal expression. Such technologies are 
especially interesting for precise delivery of protein therapeutics via viral vectors in clinically 
relevant cell phenotypes. In case of small-molecule-inducible systems a high compatibility of 
the transfer system to the specific aimed tissue is extremely important to limit negative effects 
of not affected cells. In principle, the AAV replicon vector would possess the ability for clinical 
applications against herpes-, adeno- and possibly even papillomavirus-infected cells in vivo. 
The latter infection is especially interesting due to the fact that papillomavirus infections can 
cause cervical cancer [300]. Because of these prerequisites it may be possible to insert an 
Discussion 
117 
antiviral compound as transgene in the AAV replicon vector and package it into an AAV 
serotype particle for targeting a specific tissue. After delivery of the AAV replicon vector into 
the targeted tissue cells, the activation of the compound expression would only occur after 
infection of the same cell, leading to an inhibition of the incoming virus. This would prevent 
induction of transgene expression in a non-affected cell. However, before the AAV replicon 
system could be used in this manner, the rep genes in the AAV replicon vector would have to 
be modified in order to prevent integration of the AAV replicon vector into the host cell 
chromosome. Without this safety process an application in vivo is inconceivable.  
5.2. AAV Replicon vector for testing drug resistance 
5.2.1. Advantages and disadvantages of AAV replicon-based test compared 
to classical PRA 
The most important phenotypic test used during the last decades which is standardized by the 
Clinical and Laboratory Standards Institute for the use of susceptibility validations of clinical 
HSV-1 and HSV-2 strains is the plaque reduction assay (PRA) (detailed description in chapter 
1.2.2.8) [123]. There are a number of disadvantages concerning the PRA which led to the 
invention of other tests. But due to the fact that in general phenotypic tests are critical in 
terms of standardization, there are only limited numbers approved by the FDA and the PRA 
remains the ‘gold standard’. The standardized protocol of the PRA includes a lot of different 
technical steps and is therefore very costly in terms of labor. The other very significant 
disadvantage of this phenotypic test is the time which is needed to proof whether a patient-
derived viral isolate is resistant to certain drugs or not. Because of laboratory routine issue, 
the assay takes 5-7 days before a final conclusion about the further therapy decision can be 
made. Furthermore, the manual counting of the plaques needs an experienced person and 
results are highly dependent on the individual opinion of the respective executive technician. 
In contrast, the AAV replicon-based susceptibility assay, established in this study, 
demonstrated a number of advantages over the PRA. First of all, the different working steps 
could be limited to seeding of the cells in a 96-well plate format and direct transduction with 
the recombinant AAV replicon vector. After 6 hours incubation time, the 1:100 diluted pre-
cultured virus as well as different concentrations of the respective antiviral drug to be tested 
were added to the wells without any further treatment and incubated for 24- or respective 48 
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hours. Then 20 µl of the cell supernatants were transferred directly to a white assay plate and 
the GLuc could be measured. To quantitate drug resistance or susceptibility to drugs, the IC50 
values could be calculated based on the inhibition of the virus-dependent inductions of the 
luciferase expression.  
Since the results of the AAV replicon-based resistance tests were measurable via the 
chemiluminescent reagent GLuc, the standardization and comparison between experiments 
can be provided qualitatively.  
In critical cases of HSV-infected patients, therapy decisions have to be made as quick as 
possible [301]. Not only can the treatment of the patient start earlier after the AAV replicon-
based susceptibility assay compared to the PRA but also the economical factor of time is 
reduced to limited technical aspects, reduced working power and time needed for finishing 
the assay. 
Before using the standardized PRA protocol, the patient-derived viral isolate has to be 
propagated in cell culture to produce a standardized viral inocula. For assaying clinical strains 
with the AAV replicon system, the step of pre-culturing of viral material was done as well. In 
this case, patient-derived samples were never tested directly. Since the pre-culturing needs 1-
3 days it would be interesting in the future to test whether this step may be skipped. On the 
other side, standardization of the number of viral particles may be an important requirement 
for quantitative analysis. It was published by van der Beek et al. [130] that without pre-
culturing the cells for a short period of time, viral replication was not detectable. They explain 
this by a possible adoption step of the virus to cell culture conditions which may be a key 
factor. Interestingly, they also tested the influence of pre-culturing on the existing mutations 
by PCR and they did not observe differentiations due to selection pressure after 48 h. 
However, in case of PRA the subpopulation of ACV-resistant viruses has to be at least 20 % to 
give an IC50 of ≥ 2 µg/mL (8.9 µM) as threshold for resistance [289] [115] [302]. In general the 
IC50 of antiviral resistance to ACV or penciclovir has been proposed as > 10-fold higher 
compared to the sensitive control strain [303].  
Using the LE2D8 stable AAV replicon cell line we were able to differentiate between 7 sensitive 
and 7 resistant HSV-1 strains using a 1:10 dilution of the viral pre-culture 48 h post infection. 
The mean IC50 values for HSV-1 ACV sensitive isolates was 25 µM, whereas the IC50s of HSV-1 
resistant strains were not calculable because no sigmoidal curve could be observed after 
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treatment with different doses of ACV. Although the induction levels of the stable cell line 
were generally low, the response of the AAV replicon cell line to the treatment with ACV after 
infection with the clinical isolates enabled a differentiation between sensitive and resistant 
strains. In case of RLU values, the sensitive strains were 4 times less responsive compared to 
resistant strains. Here, the sensitivity of PRA standards could not be provided. Furthermore, 
the induction after HSV-2 infection was in general too low for an establishment of a 
susceptibility assay for this serotype. 
The low sensitivity towards HSV infection could be overcome by a higher induction rate of the 
AAV replicon vector after delivery into cells via transduction. Packaging of the AAV replicon 
vector into a recombinant AAV particle allowed a great increase of sensitivity towards 
susceptibility testing. We calculated an IC50 of 1.87 µM for HSV-1 WT strain and 19.1 µM for 
HSV-2 WT strain 48 hours after infection using the rAAV replicon system. 
With this improvement on hands, significant results were obtained for virus susceptibility 
testing, even after using a higher dilution of the respective pre-cultured virus (1:100). 
Furthermore, significant differentiation between sensitive and resistant strains could be 
observed after a much shorter period of time of only 24 h. In conclusion, the possibility of 
transducing the AAV replicon vector enabled the establishment of a diagnostic test for HSV 
drug resistance, providing answers on antiviral susceptibility within one day after pre-culturing 
the virus. 
PRA for testing the susceptibility of HCMV in general is not performed due to the long pre-
culturing time necessary for this slowly replicating herpesvirus serotype (> 4 weeks) [304]. The 
actual time of the PRA takes 7 to 10 days which results in a test period of approximately 4-6 
weeks [305]. There are proposed cutoffs for the susceptibility to GCV, CDV and FOS (6, 2 and 
400 µM respectively) [306] [307]. However, since the results are dependent on the respective 
laboratory, the IC50 value for resistance can be generally interpreted as ≥ 2-fold compared to 
the reference strain [305]. Therefore, phenotypic testing systems for HCMV are very 
challenging and restricted to specialist diagnostic labs. Using the AAV based replicon, it may 
be possible to establish a test, similar what we have established for HSV here, which would be 
less demanding and therefore easily applicable in standard laboratories. 
Discussion 
120 
5.2.2. Advantages and disadvantages of AAV replicon compared to other 
methods 
Direct analysis of patient-derived viral isolates by PCR-based methods allows fast 
identification of mutations connected to antiviral resistance and is technically easy to perform. 
The distinction whether an analyzed mutation indeed leads to antiviral resistance of the 
respective virus or whether it simply belongs to a natural inter-strain variation has to be pre–
validated by a phenotypic assay. The comparison with mutations described in the literature is 
fundamental for the analysis and interpretation process. 
Genotyping HSV-1 and HSV-2 is concentrating mainly on mutations within the thymidine 
kinase gene (UL23) or the DNA polymerase encoding gene (UL39) [308]. For sequencing of the 
TK gene, patient material can directly be amplified and sequenced whereas analysis of the pol 
gene needs to be performed on previously cultured viral stocks (18). Therefore, the overall 
time for susceptibility testing via sequencing methods still lasts 3-4 days. 
Clearly for HSV tests, the AAV replicon-based system is competitive with the genotypic-based 
methods. It does not require more time and is applicable without further knowledge on 
resistance-associated mutations. 
In general, laboratory testing of HCMV resistance to antiviral drugs is based on genotypic 
diagnostic. Mutations especially in the viral UL97 kinase and the UL54 DNA polymerase gene 
are described [304]. A genotypic test for HCMV lasts 3-4 days, provided sufficient material is 
available. Here, the AAV replicon probably will not be a competitive alternative for 
genotyping, since the in vitro culture of HCMV also is time-consuming. However, the replicon-
based resistance test may allow the generation of a reliable database for resistance-associated 
mutations, allowing HCMV resistance test in a broader range of laboratories. 
There are a number of phenotypic assays to detect HSV which were developed to overcome 
the problems associated with the PRA. Methods which are evaluating the antigen expression 
after virus multiplication in vitro are based on enzyme-linked immunosorbent assays (ELISAs) 
like the sandwich ELISA or the microplate in situ ELISA called MISE [124] [125] [126]. For plaque 
autoradiography in the MISE assay, the activity of viral thymidine of virally infected and drug 
treated cells were measured by the addition of [125I]iododeoxycytidine 72 h post infection 
[125]. Other established methods are based on DNA hybridization assays using radioactivity 
Discussion 
121 
48 h after incubation with different drug concentrations [127] or based on measuring HSV-1 
gC expression in infected cells stained with an appropriate antibody by FACS [128]. The FACS-
based method is very labor-intensive due to several washing steps and the results can be 
observed only 72 h after the pre-cultured virus is recovered. 
A similar method like PRA is the assay with an inducible Vero cell line which responds to HSV 
infection with β-Galactosidase expression. 10-fold dilutions of non-titrated HSV samples are 
used to determine histochemical stained blue plaques after 48 h [129]. Although plaques are 
better visualized, and the assay time is shorter than in case of PRA, the method is still labor-
intensive and has no objective endpoint. 
A recently developed method is a combined assay using cell culture and nucleic assay 
detection and is named DNA reduction assay. Pre-cultured clinical samples are cultured in 
presence of antivirals and after only 24 h the increase of the viral DNA load in the infected 
cells is measured with quantitative real-time PCR whereas the cell count and lysis are 
corrected by beta-globin PCR [130]. This assay is fast, however, very instrumentation-intensive 
and expensive. 
All these tests cannot satisfy the requirements of sensitivity, time consumption, laboratory 
technical efforts, standardization procedure, and cost effectiveness at the same time. This is 
the reason why the PRA assay - or at least variations of the PRA - still belongs to the methods 
of choice in specialized laboratories. Yet, the AAV replicon system, as we show here provided 
an improved alternative by exhibiting a high sensitivity which was comparable to the standard 
PRA test. Additionally, in the AAV replicon-based assay, the time needed for the performance 
of the test was reduced to a minimum due to the decreased technical working steps, which 
also led to reduced costs because less personal expenses have to be calculated. Furthermore, 
the assay can be standardized very well due to gathering quantitative data.  
5.3. AAV replicon vector for testing new inhibitors 
5.3.1. Why new inhibitors are needed 
HSV infections cause clinically mild manifestations with chronically recurrent labial and genital 
herpes. Although these painful lesions are not life-threatening, patients can suffer from stress 
going along each infection which can lead to psychosocial problems [309]. Moreover, 
Discussion 
122 
especially for neonates and immunosuppressed individuals HSV-1 and HSV-2 is a common 
cause for devastating clinical consequences. For instance HSV encephalitis, which is 
responsible for 20% of all cases of sporadic encephalitis [310] typically leads to coma within 6 
days after the first neurological symptom if the disease is not treated in time. The incidence 
of herpes simplex encephalitis is 1 in 250,000 to 500,000 per year with a mortality rate of 
20 - 30% if ACV therapy is started timely at an early stage of encephalitis [311] [312] [313]. 
The number of patients dying although receiving an ACV treatment is very high. Currently, 
new drugs aiming for the helicase-primase complex of HSV are under clinical development as 
well as new vaccines against HSV-2 [101]. Nevertheless, alternative drugs are urgently needed 
that target different sites of the virus than currently used drugs, having additionally a high oral 
bioavailability, an efficient delivery through the blood brain barrier, no, or at least, less toxic 
effects and a high efficacy.  
In case of human Ad infections, 15% of upper- and 5% of lower respiratory tract inflammatory 
diseases in children are accounted to this virus and the course of disease is mainly mild and 
self-limiting in immunocompetent individuals. The situation is different in case of 
immunocompromised patients with an impaired immunological response, such as solid-organ 
transplant or hematopoietic stem cell recipients. In this case, an acute or a persistent infection 
can lead to high morbidity and even mortality. The clinical manifestation is highly dependent 
on the patient age, the virus serotype, the primary disease, and the tissue which is infected by 
Ad. Children have a 2 to 3.5 times higher risk of infections compared to adults [208] [141]. At 
present, there is no approved drug against human Ad infection. Only broad-spectrum antiviral 
agents can be used as an alternative with limited success. Therefore, patients at risk are 
dependent on decreasing the immunosuppression or treatment with adoptive 
immunotherapy using adenovirus-specific T cells. There is an urgent need for new potent anti-
adenoviral drugs, or at least one, to be able to treat the severe cases of infections. New 
antiviral Ad compounds have to meet additionally the challenge that constantly new serotypes 
are recognized that may show difference in drug susceptibility.  
5.3.2. Current testing systems  
Screening of potential new drugs against viruses is a process that can be divided into several 
phases. The most important point is to have an in vitro and in vivo model for testing a large 
number of new target molecules. Fortunately, the HSV-1, HSV-2 and Ads, the mostly used 
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viruses in the course of this work, are in general suitable for in vitro analyses. In case of HSV, 
the in vivo models commonly used to study infections are mice, guinea pigs, rats and rabbits 
[314]. For human Ad there is a new Zealand white rabbit model for corneal infections of Ad-
1, -2, -5, -6, -8 and -37 [315]. Human Ad5 can be tested intranasally or intravenously in 
different mouse models, in the pig and in the Syrian hamster (reviewed in [208]). The latter 
one is the most promising one and was used for testing the new antiviral candidate drug 
Brincidofovir [316] [317].  
For screening of new compounds with antiviral activity, either biochemical or target-based 
assays are used for testing the direct effect on a target protein or a certain function such as 
the enzymatic assay published by McGrath et al. for testing inhibitors of the human Ad 
proteinase [318]. However, for evaluation studies of antiviral activity in the cell, phenotypic 
assays based on cell culture are preferred because a preconceived idea concerning the target 
site, at the stage of high throughput compound library testing is not necessary. 
A widely used assay, which can be used for drug screening towards cell viability, is the 3-
(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method, suitable for a 96-
well format high throughput screening. Compared to the AAV replicon assay there are more 
steps to perform the MTT assay, it cannot be applied in many different cell lines and the 
sensitivity depends highly on different parameters [319] [320]. 
Another method to test the impact of certain compounds on Ad or HSV is the yield reduction 
assay. For HSV-1 for example the enzyme-linked virus inhibitor reporter assay (ELVIRA) is 
published [321] [322]. However, this method is restricted to a certain cell line and furthermore 
the implementation includes more working steps compared to the newly established AAV 
replicon system. Therefore, especially in case of Ad, it is mainly used to ensure already 
selected compounds [323]. The same is true for the plaque reduction assay, which is even 
more time and labor-intensive for Ad and for HSV [324]. Quantification after 
immunofluorescence with antibodies targeting virus specific antigens has the advantage of 
evaluating the antiviral activity of the compound at a defined step of the viral life cycle. 
However, the following quantification of fluorescent cells is again very time consuming and 
not convenient to be performed in high throughput conditions.  
Other test systems used for screening in high throughput format are cell lines expressing a 
marker gene. For HSV-1 a strategy using a modified plaque reduction assay with a transgenic 
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cell line is published. The promoter of the HSV-1 UL39 gene is induced to express β-
galactosidase upon HSV-1 infection [325]. In contrast, the AAV replicon assay is applicable in 
several tested cell lines including primary cells. 
Genetically marked viruses expressing a reporter gene upon viral infections for the evaluation 
of viral infectivity are the most commonly used approaches for high throughput screenings of 
large compound libraries [326] [208]. Ad5-GFP or Ad16-GFP for example have been used for 
high throughput screenings based on labelled genes and modified PRAs [326]. 
The advantage of the AAV replicon system over labelled viruses is the ability to use it for wild-
type viruses and clinically isolated strains. Especially concerning all the different relevant 
serotypes of human Ad, this issue is very relevant because the AAV replicon assay provides a 
direct testing of all in vitro growing Ad without the inconvenient construction of genetically 
labelled BAC-derived serotypes. Until now all alpha- and beta-herpesviruses tested responded 
to the AAV replicon system as well. Most important, viruses known to be resistant to certain 
drugs can be evaluated independent of the mutation leading to this resistance. 
Yet, the newly developed AAV replicon-based screening assay was used to test a compound 
library of 24 candidates for their potential to inhibit Ad5 as well as HSV-1. Compounds that 
inhibited these viruses were analyzed via an absent induction signal of GLuc as transgene of 
the AAV replicon vector, which was transduced in the adopted cell line 4 h before adding the 
possible inhibitors together with the respective virus. The compounds were highly selected 
for their inhibitory effect on certain targets in the cell. Out of 24 small molecules 7 were able 
to inhibit Ad5 and 3 of these compounds were also able to inhibit HSV-1. Out of these 7 Ad 
and 3 HSV-1 inhibitors, one was the known apoptosis inducer staurosporin, and another one 
was a published kinase inhibitor and therefore both were used as internal controls of the assay 
system. For further validations of the compounds, toxicity was tested via an MTT-test in two 
different cell lines (A549 and Vero) using different concentrations (data not shown). The 3 
compounds, inhibiting both viruses (including the two control inhibitors) showed a high 
toxicity profile of less than 80% viability in both cell lines. The two compounds that 
demonstrated 50% inhibition of Ad in contrast did not show any toxicity within those 
concentrations we used in the screening assay. For evaluation, if the inhibitory effect of those 
compounds does not derive from cell toxicity, the MTT test would have to be reproduced and 
other cell lines have to be tested with the replicon system as well. Since this screen was only 
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made with a limited data-set, the AAV replicon system could be further used to establish a 
high throughput screen for testing a greater compound library. Nevertheless, the first 
application of the AAV replicon-based screening system granted a first hint on compound 
groups to be more or less interesting for further studies. 
However, in case of the AAV replicon compound screening it is possible, that the inhibitory 
effect of possible antiviral drugs roots on the inhibition of the AAV replicon vector itself. 
Therefore, it is necessary to further evaluate screened hits with methods for direct analysis of 
the targeted viral inhibition.  
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5.4. Concluding remarks 
In this study a new form of a DNA based replicon vector that is inducible by infection with 
large DNA viruses combining the regulatory elements of the replication controlled late AAV 
gene with the transcription unit of an exchangeable gene of interest was established. The 
novel and major advantages of this new AAV based replicon over similar systems resides in 
the possibility to induce this replicon vector by productive helper viruses without the risk of 
recombinant homologous sequences to these viruses.  
Several delivery systems of the AAV replicon vector were established for varying demands. 
The AAV replicon proved its functionality in context of all tested delivery approaches and 
remained responsive in multiple physical states of its genome demonstrating its superior 
versatility. 
However, the viral delivery system of transducing the AAV replicon by an adeno-association 
virus particle appeared to be superior for most of the applications tested in this study allowing 
fast, easy to apply and quantitative marker of helper virus infections.  
In this study, the construction of the AAV replicon containing recombinant AAV particle was 
the prerequisite for the establishment of two unique approaches towards diagnostic and drug 
development. The phenotypic susceptibility assay for HSV-1 and HSV-2 resistance testing was 
developed and already tested in a small cohort of 16 clinical isolates. The sensitivity of the 
AAV replicon assay was validated by PRA. 
The second major application of the AAV replicon system, was a novel phenotypic screening 
system for the detection of new antivirals. The applicability of the system as sensitive, easy to 
handle and time-saving high-throughput assay was demonstrated in a primary screening test 
of potential inhibitors for human Ad and HSV-1 using conditions adopted for each virus. The 
antiviral effect of 5 compounds inhibiting Ad5 and 1 compound inhibiting HSV-1 could be 
detected as hits towards possible new antivirals against important DNA viruses. We believe 
that in future the AAV replicon can be adapted to detect replication of further viruses, such as 
VZV and HCMV, and other applications such as testing neutralization activity of antisera and 
trans-complementation, which can boost both clinical and basic research on large DNA 
viruses. 
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